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Synthetic cathinones (“bath salts”) are a class of novel psychoactive substances 
abused for their psychostimulant and euphoric effects. However, these drugs have received 
international and national attention due to severe and life threatening adverse effects. In 
order to properly associate pharmacological, impairing, or toxic effects with synthetic 
cathinone use, toxicologists must be able to detect and reliably interpret results. The 
detection of these synthetic phenethylamines relies on validated analytical techniques. 
Quantitative assays determine the concentration of drug present in biological samples at 
the time of analysis, which may be significantly different from the concentration at the 
time of collection or time of death. Drug stability must be understood in order to determine 
the extent to which these changes influence analytical results. This research provides the 
forensic toxicology community with a comprehensive understanding of the stability of 
these compounds in biological matrices.  
A method for the detection of twenty-two synthetic cathinones, isolated from blood 
and urine using liquid chromatography quadrupole/time of flight mass spectrometry (LC-
Q/TOF MS) was developed and validated. This method was used to assess synthetic 
cathinone stability in blood (pH 7) and urine (pH 4 and 8) stored at 32°C, 20°C, 4°C, and 
-20°C for six months. The selected synthetic cathinones were representative of the various 
structural analogs, including unsubstituted secondary amines (methcathinone, 
ethcathinone, buphedrone, and pentedrone); ring substituted secondary amines (3-FMC, 4-




substituted secondary amines (methylone, ethylone, butylone, pentylone, eutylone); and 
tertiary amines (α-PVP, naphyrone, pyrovalerone, MPBP, MDPBP, and MDPV). The 
significance of analyte, storage temperature, storage time, concentration, and matrix pH 
were systematically assessed. 
Stability was influenced by structure, matrix pH, and storage temperature. 
Halogenated cathinones (3-FMC, 4-FMC) were the least stable and the tertiary cathinones 
bearing the methylenedioxy group (MDPBP, MDPV) were the most stable. The analysis 
of authentic urine samples from cathinone users supported these experimental findings. 
Matrix pH and cathinone structure had a more profound influence than prolonged storage.  
In addition to detecting synthetic cathinones from antemortem specimens to support 
experimental stability findings, synthetic cathinones were also identified in a series of fifty 
fatalities to determine postmortem distribution and redistribution. Drugs were identified in 
central and peripheral blood, urine, liver, vitreous humor, and stomach contents. Central to 
peripheral blood (C/P) and liver to peripheral blood (L/P) ratios were determined for seven 
synthetic cathinones to assess postmortem redistribution (PMR). While synthetic 
cathinones appear to exhibit low to moderate PMR, the highest C/P ratios were observed 
for cathinones bearing a secondary amine and a methylenedioxy group.  
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Abuse of novel psychoactive substances (NPS) has escalated worldwide (1-3). 
These drugs provide alternatives to many illicit substances, including stimulants, opioids, 
and hallucinogens. Their appeal can be attributed to their ease of purchase, wide 
availability, low cost, and in some cases, lack of regulatory control (3-7). The research 
presented here pertains to synthetic cathinones, a class of NPS commonly referred to as 
“bath salts”.  
History 
Synthetic cathinones are derived from the natural occurring alkaloid cathinone, 
found in Catha edulils (khat), a shrub originally cultivated on the Horn of Africa and 
Arabian Peninsula (8, 9). Historically, the leaves of the khat plant were chewed for their 
stimulant and euphoric effects. More recently however, powerful synthetic analogs of 
cathinone have become appealing alternatives to methamphetamine and cocaine.  
The first synthetic cathinones, methcathinone and mephedrone, were synthesized 
in the late 1920s to treat depression and serve as appetite suppressants (7, 8). However, due 
to notable abuse and dependence, these drugs were quickly withdrawn from use. Only two 
synthetic cathinones are currently approved for therapeutic use in the United States. These 
include the antidepressant bupropion (Zyban®, Wellbutrin®) and the appetite suppressant 
diethylpropion (Tenuate®). More recently, cathinone derivatives have re-emerged as 
powerful 21st century psychostimulants.  
When they first resurfaced, synthetic cathinones were thought to be a “legal” 




online, labelled with intentionally misleading information such as “not for human 
consumption,” “bath salts”, and “plant food” to circumvent existing legislation (3, 6, 8). 
Typically purchased in pill or powder form, their street names include Atomic, Blaze, 
Cloud 9, Ivory Wave, White Lightening, and Rave (5, 6). Due to a rise in severe adverse 
effects and documented fatalities, many countries, including the United States, enacted 
legislation to deter their use. 
Scheduling  
In the US, drugs are scheduled under the Federal Controlled Substances Act. 
Among the five scheduled categories, a Schedule I drug is a substance with no medical use 
and a high potential for abuse and dependence. Under the Controlled Substances Analogue 
Enforcement Act of 1986, any substance that is structurally similar to a previously 
controlled drug can be classified as such, given that it is sold with the intent for human 
consumption. As a result, many novel psychoactive substances are sold with the 
aforementioned labels. Under the Analogue Act, select synthetic cathinones are already 
scheduled. One of the early synthetic cathinones, methcathinone, was listed as a Schedule 
I drug in 1993. Almost two decades later, methylone, mephedrone, and MDPV were added 
(10). In additional to Federal regulation, thirty states introduced legislation in 2011 to 
prohibit the use and distribution of designer drugs and novel psychoactive substances (11). 
At the state level, “general class bans” have been widely used, because this approach 
prohibits the use of chemically or pharmacologically similar compounds. By 2014, ten 
additional synthetic cathinones, including 4-MEC, α-PVP, butylone, pentedrone, 
pentylone, 4-FMC, 3-FMC, and naphyrone, were Federally controlled and forty-eight 




temporary scheduling was extended in 2016, and as of March 2017 all were permanently 
scheduled. Table 1.1 lists the common names, IUPAC names, and current scheduling 
status of the twenty-two cathinones included in this study. At the time of this report, the 
only cathinones included in this study that are not Federally scheduled are eutylone, 
MDPBP, methedrone, and MPBP. However eutylone and MPBP are positional isomers of 
pentylone and α-PVP, respectively, and could be regulated based on this relationship. 
 
    
4 
Table 1.1. Common name, IUPAC name, and Federal scheduling status for the twenty-two synthetic cathinones included in this 
research. 




3,4-dimethylmethcathinone Schedule I (2017)* 
3-FMC 1-(3-fluorophenyl)-2-(methylamino)-propan-1-
one 
3-fluoromethcathinone Schedule I (2017) 
4-FMC 1-(4-fluorophenyl)-2-(methylamino)-propan-1-
one 
4-fluoromethcathinone, flephedrone Schedule I (2017) 
4-EMC 1-(4-ethylphenyl)-2-methylaminopropan-1-one 4-ethylmethcathinone Schedule I (2017)* 
4-MEC 1-(4-methylphenyl)-2-ethylaminopropan-1-one 4-methylethcathinone Schedule I (2017) 





β-keto-N-methylbenzodioxoyl-butanamine Schedule I (2017) 























4-methylmethcathinone Schedule I (2012) 
   (continued) 
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Common Name IUPAC Name Other Names Federal Scheduling 
Status 














Naphyrone 1-(2-naphthyl)-2-(1-pyrrolidinyl)-pentan-1-one naphthylpyrovalerone Schedule I (2017) 
Pentedrone 2-methylamino-1-phenyl-pentan-1-one α-methyalmino-valerophenone Schedule I (2017) 
Pentylone 1-(1,3-benzodioxol-5-yl)-2-(methylamino)-
pentan-1-one 
β-keto-methylbenzodioxolylpentanamine Schedule I (2017) 
Pyrovalerone 1-(4-methylphenyl)-2-(1-pyrrolidinyl)-pentan-1-
one 
- Schedule V (1988) 
α-PVP 1-phenyl-2-(1-pyrrolidinyl)-pentan-1-one α-pyrrolidinovalerophenone Schedule I (2017) 




     
Chemistry 
Synthetic cathinones can be classified as phenethylamines, similar to amphetamine, 
methamphetamine, and 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”). The 
novel psychoactive substances differ from these well-known substances by the addition of 











Figure 1.1. Chemical structures of methamphetamine and methcathinone which differ 
only by the addition of the β-ketone.  
 
More than 40 different synthetic cathinones have been reported to the National 
Forensic Laboratory Information System (NFLIS) over the past few years, and they can be 
differentiated by substituents to either the α-carbon, the aromatic ring (most often at 
position 3 or 4), or to the nitrogen terminus (8, 13, 14) (Figure 1.2). Substituents on the 
cathinone framework commonly include halogens (R1 and R2), alkyl (R1-R5), methyoxy 
(R2) and methylenedioxy groups (R1 and R2). The addition of a pyrrolidine group on the 
nitrogen (R4 and R5) creates a sub-population of tertiary amines with distinct chemical and 










Figure 1.2. General structure of synthetic cathinones indicating locations of substituents 
(R1-R5).  
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Twenty-two synthetic cathinones were studied in the research presented here. The 
synthetic cathinones chosen are representative of secondary and tertiary amine cathinones 
with and without ring substituents, including halogens, alkyl groups, methyoxy groups, and 
methylenedioxy groups (Figure 1.3, Table 1.2). Figure 1.3 displays synthetic cathinones 
(color-coded) by sub-population. 
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Figure 1.3. Chemical structures of twenty-two synthetic cathinones included in this 
study. Green indicates a secondary amine cathinone bearing no ring substituents; yellow 
indicates a ring-substituted secondary amine cathinone; magenta indicates a 




     
Table 1.2. Substituents at R1-R5 for the twenty-two synthetic cathinones included in this 
study and the nominal molecular weight. 
Name R1 R2 R3 R4 R5 MW 
3,4-DMMC CH3 CH3 CH3 H CH3 191 
3-FMC F CH3 CH3 H CH3 181 
4-EMC H C2H5 CH3 H CH3 191 
4-MEC H CH3 CH3 H C2H5 191 
Buphedrone H H C2H5 H CH3 177 
Butylone 3,4-Methylenedioxy C2H5 H CH3 221 
Ethcathinone H H CH3 H C2H5 177 
Ethylone 3,4-Methylenedioxy CH3 H C2H5 221 
Eutylone 3,4-Methylenedioxy C2H5 H C2H5 235 
Flephedrone (4-
FMC) 
H F CH3 H CH3 181 
MDPBP 3,4-Methylenedioxy C2H5 Pyrrolidinyl 261 
MDPV 3,4-Methylenedioxy C3H7 Pyrrolidinyl 275 
Mephedrone H CH3 CH3 H CH3 177 
Methcathinone H H CH3 H CH3 163 
Methedrone H OCH3 CH3 H CH3 193 
Methylone 3,4-Methylenedioxy CH3 H CH3 207 
MPBP H CH3 C2H5 Pyrrolidinyl 231 
Naphyrone Naphthyl C3H7 Pyrrolidinyl 281 
Pentedrone H H C3H7 H CH3 191 
Pentylone 3,4-Methylenedioxy C3H7 H CH3 235 
α-PVP H H C3H7 Pyrrolidinyl 231 
Pyrovalerone H CH3 C3H7 Pyrrolidinyl 245 
 
The chemical structure of the cathinones greatly influence their pharmacological 
activity. Just like their non-β-ketone counterparts, the presence of the secondary or tertiary 
amine defines their basic nature. While the pKa values are not known for all of the analogs, 
values in the range 7.2 to 8.9 have been reported (15-17). The physico-chemical properties 
of the drug greatly influence its pharmacology. The addition of halogens, pyrrolidine group 
and properties of the alkyl side chain, can influence the lipophilicity of these drugs. A more 
lipophilic drug will readily transverse the blood-brain barrier (BBB), potentially enhancing 
physiological effects in the central nervous system (13, 18). N-alkylation will also maintain 
the desired stimulant effects of phenethylamines (13, 19, 20). Phenethylamines contain a 
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chiral center (α-carbon) producing two enantiomeric forms. The S-(-)-enantiomer has been 
proven to be more potent than the R-(+)-enantiomer in synthetic cathinones, as with 
cathinone and methamphetamine (8, 21-23).  
Cathinones also exist as tautomers in equilibrium. (Figure 1.4). The keto tautomer 
has been shown to be more stable than the enol isomer (24). The enol tautomer, or enamine 
form, may be less stable due to its ability to further tautomerize into an imine. However, 
increased stability may be achieved through intramolecular hydrogen bonds (24, 25). 
During fragmentation, the formation of the enol tautomer is most likely an intermediate 
step for the loss of water (26, 27). Fragmentation of bupropion through collision-induced 
dissociation and electron impact ionization was determined to be the result of the keto 











Keto Tautomer Enol Tautomer
 
Figure 1.4. Keto-enol equilibrium of β-keto amphetamines (shown for mephedrone). 
 
Detection Methods 
In forensic toxicology laboratories, biological evidence suspected of containing an 
unknown drug will be analyzed first by a screening method followed by a confirmatory 
method. Although antibody-based immunoassay (IA) techniques are widely used, they are 
often limited in scope. Chromatographic and mass spectrometry-based screening 
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techniques are often more labor intensive, but can potentially identify a much larger 
number of drugs simultaneously.  
Confirmatory analyses can be completed using an array of different techniques, 
most commonly gas chromatography (GC) or liquid chromatography (LC)-based mass 
spectrometry (MS). These techniques are used for both qualitative and quantitative 
analysis. Although this approach enjoys widespread use, the detection of synthetic 
cathinones is challenging due to the number of different derivatives and the frequency with 
which new derivatives appear in forensic investigations (9, 29).  
Immunoassay Techniques 
Immunoassay screening tests designed for amphetamine and methamphetamine 
have been used in attempt to detect synthetic cathinones. Unfortunately, many studies have 
shown that many of these immunoassays exhibit poor cross-reactivity towards the 
cathinones (14, 30-38). If a positive IA screen was achieved, concentrations exceeded the 
typical average concentration identified in biological samples. For example, in a study 
completed by DeRuiter et. al. using an enzyme multiplied immunoassay technique (EMIT) 
designed for methamphetamine and amphetamine, methcathinone and cathinone 
concentrations greater than 200,000 ng/mL were necessary to produce a positive result, 
compared with 1,000 ng/mL of methamphetamine or amphetamine (23).  
Swortwood et. al. investigated the cross reactivity of eight synthetic cathinones on 
sixteen commercial immunoassay platforms. Target analytes for the sixteen kits included 
amphetamine, methamphetamine, benzylpiperazine, ketamine methyphenidate, 
mephentermine, MDPV, mephedrone, phencyclidine, and cotinine. Only two of the sixteen 
kits resulted in positive results at synthetic cathinone concentrations <1,250 ng/mL; all 
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other kits required concentrations greater than 10,000 ng/mL (36). Synthetic cathinone 
screening methods using biochip array technology have been developed, but these 
techniques are limited to the synthetic cathinones that were popular at the time of 
development (36). These antibody-based assays cannot compete with the rapidly changing 
landscape of novel psychoactive substances. In order to effectively screen for novel 
synthetic cathinones, more specialized chromatographic or mass spectrometry-based 
techniques may be required.  To that end, chromatographic screening techniques for novel 
psychoactive substances, including synthetic cathinones, have been developed for GC and 
LC instrumentation (25, 39-46).  However, chromatographic-based screens require similar 
sample preparation necessary for confirmatory analysis, and are therefore more resource-
intensive than conventional immunoassays. 
Chromatographic Methods 
Drug confirmation in biological evidence requires highly specialized analytical 
instrumentation and methodology. These techniques require sample preparation (to isolate 
analytes of interest), are more costly, and require advanced training to interpret data. Gas 
chromatography-mass spectrometry (GC-MS) is still one of the most widely used 
confirmatory techniques in forensic toxicology laboratories. However, GC-MS analysis is 
limited to molecules that are non-polar, volatile, and thermally stable. Chemical 
derivatization can improve these properties, but further increases sample preparation time.  
Liquid chromatography-mass spectrometry (LC-MS) can be used to analyze a wide 
variety of compounds and is more amenable to polar species. LC methods are also 
advantageous due to their increased selectivity, specificity, and sensitivity compared to 
GC-MS methods (35, 45, 47-49). Increased sensitivity and selectivity can decrease limits 
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of detection (LOD) and quantitation (LOQ). GC-MS methods for cathinones often reported 
LOQs over 20 ng/mL (50-59), whereas LC methods report LOQs <20 ng/mL (33, 44, 47, 
48, 60-67).  
For the detection of synthetic cathinones and other novel psychoactive substances, 
LC separation is most effectively coupled with tandem mass spectrometry (MS/MS) or 
high resolution mass spectrometry (HRMS) using quadrupole/time of flight (Q/TOF), 
Orbitrap™ or QExactive™ detectors. There is widespread use of MS/MS detectors in 
forensic toxicology laboratories and HRMS methods are growing in popularity. HRMS in 
particular has accurate mass resolution, allowing compounds with similar nominal masses 
but different accurate masses (due to elemental composition) to be differentiated. These 
instruments also collect and store data for all ions detected, allowing for retrospective data 
interrogation, which is of particular importance for emerging drugs or drugs that do not 
currently have available reference standards (47, 48, 61, 64, 68).   In drug metabolism 
studies, HRMS may not require the use of reference standards because the structures of 
biotransformed products can be structurally elucidated through the combination of accurate 
mass and detailed mass spectra fragmentation patterns (69, 70).  
Detection Challenges of Synthetic Cathinones 
The proliferation of synthetic cathinones has resulted in the synthesis of multiple 
constitutional isomers. From a chemical standpoint, two, three, or four of these drugs may 
share the same molecular formula, but are structurally different. Two examples are 
ethylone and butylone; both have the chemical formula of C12H15NO3 and differ by the 
location of an ethyl group. In ethylone, the ethyl group is located on the nitrogen, and in 
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butylone it is located at the α-carbon (Figure 1.5). These constitutional isomers pose 













Figure 1.5. Chemical structures of constitutional isomers ethylone and butylone. 
 
In order to differentiate between regioisomers, complete chromatographic 
resolution may be necessary (15, 71-74). Isomeric separation has been achieved for many 
synthetic cathinones; however, the fluorinated cathinones (2-, 3-, and 4-FMC) have 
presented the greatest challenge (71, 75-77). The separation of ethylone and butylone has 
also presented a problem using reversed-phase (RP) liquid chromatography (25). While RP 
chromatography is most common for LC analysis, alternative approaches, including 
hydrophilic interaction liquid chromatography (HILIC), have been implemented (60, 78). 
Separation of cathinones using reversed-phase chromatography can be achieved, but may 
involve moderate to long run times and considerable skill.  
Another challenge is the specificity of cathinone mass spectra produced by GC-MS 
analysis. Isomeric substances can produce very similar mass spectra using electron impact 
(EI) ionization techniques (49, 72, 75, 79, 80). Cathinones fragment readily, often 
producing no molecular ion. EI fragmentation is dominated by the dissociation of the α-β 
carbon bond (27). The major ion produced by this dissociation is an iminium ion, 
comprised of the structural formula CnH2n+2N+, containing a double bond between the 
carbon and nitrogen for aliphatic amine cathinones, and CnH2nH+ for pyrrolidine cathinones 
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(23, 27). The mass to charge ratio (m/z) observed from this dissociation in secondary amine 
cathinones is m/z 44, 58, 72, 86, and 100 derived from the equation 16 + 14n, where n is 
the number of carbons (27). For tertiary amine cathinones the observed m/z from this 
dissociation are m/z 126, 70, 55, 42, and 41 (27). As seen in Figure 1.6, the iminium ion 
(m/z 72) is the base peak for both ethylone and butylone. The formation of m/z 44 by 
ethylone can help differentiate these two constitutional isomers, but these differences are 
visible only in the fine spectra. Softer ionization techniques, including chemical ionization 
(CI) in GC analysis, and electrospray ionization (ESI) in LC analysis, help to preserve the 




     
 
Figure 1.6. In-house GC-EI-MS spectra for ethylone (top) and butylone (bottom) to 
demonstrate the abundant iminium ion (m/z 72) resulting from α-β cleavage that occurs 
during EI fragmentation.   
 
By LC-ESI analysis, synthetic cathinones are fragmented by collision-induced 
dissociation (CID) (81). By studying the methylenedioxy-type cathinones (ethylone, 
butylone) using HRMS, Fornal proposed CID fragmentation pathways for all cathinone 
types (81, 82). While only one characteristic ion, the iminium ion, is produced by GC-EI 
analysis, Fornal concluded that methylenedioxy (MD)-substituted cathinones under ESI 
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CID fragmentation produce four characteristic ions resulting from the loss of a water 
molecule, the loss of a neutral molecule CH4O2 (the methylenedioxy group) to form 
phenyloxazole, the loss of an amine, and the loss of an iminium ion. In non-MD synthetic 
cathinones, water loss was observed in secondary amine cathinones only. The loss of the 
amine, which formed a [M-NR3R4+H]+ cation, was observed by all synthetic cathinones. 
However, the abundance of this ion varied depending on different structural features. If the 
aromatic ring was 4-methyl substituted (e.g. mephedrone, 4-MEC) the abundance of this 
ion increased. In contrast, a decrease was observed in 4-methoxy (4-MeO, methedrone) 
substituted cathinones. 
Just as in GC-EI analysis, α-β cleavage occurred under CID fragmentation 
producing the iminium ion, particularly if the CID voltage was greater than 20 eV (81). 
The iminium cation abundance was higher if the synthetic cathinone was 4-MeO 
substituted or contained both a pyrrolidine and methylenedioxy group.  The alpha-beta 
cleavage could also produce an oxonium cation; however, it was significantly less abundant 
than the iminium ion (81).  
Despite being even-electron molecules, synthetic cathinones, excluding pyrrolidine 
types, form odd-electron radical ions under ESI analysis (83). The most abundant 
fragmentation product for primary amine ketones is the radical cation iminium ion. The 
most common iminium ions are [C9H9N]+. with a m/z of 131.0730, [C10H11NO]+. with a m/z 
of 145.0886, [C10H11NO]+. with a m/z of 161.0835, and [C10H9NO2]+. with a m/z of 
159.1042 (83). Cathinones that are 4-alkyl substituted produced the 131, 145, and 161 
radical cations, and methylenedioxy cathinones produced either the 131 or 145 radical 
cation (83). These reported m/z ratios are important ion transitions to monitor when 
18 
     
producing synthetic cathinone mass spectra under ESI conditions and can help classify 
novel cathinones that have yet to be identified. These characteristic fragments are observed 
in the in-house HRMS mass spectra for ethylone and butylone (Figure 1.7).
 






Figure 1.7. In house MS/MS spectra of ethylone (top) and butylone (bottom) using ESI. Identified ion (circled) discriminate ethylone 
and butylone. 
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Synthetic cathinones are challenging to detect because of multiple constitutional 
isomer pairings. Furthermore, they are thermally unstable, which limits the detection 
ability using GC-MS without derivatization. Studies have shown that cathinone derivatives 
undergo in situ degradation during this common analytical technique (23, 72, 75, 84). This 
was first established by Noggle and DeRuiter in the mid-1990s with methcathinone, 
followed by ethcathinone and dimethcathinone. A second, later-eluting peak with a base 
peak and molecular ion of 2 mass units less (M-2) than the parent was observed. For 
methcathinone, with a molecular ion of m/z 163 and base peak of m/z 58 (formed by the 
imine fragment), the second peak had a molecular ion of m/z 161 and base peak of m/z 56. 
It was concluded that the minor peak was a 2,3-enamine, an oxidative (loss of H2)  
decomposition product formed during GC analysis (23).  
The previous study used secondary amine cathinones to identify the 2,3-enamine 
decomposition product formed during GC analysis. Additional studies further identified at 
which step in GC analysis the degradation may have occurred. Tsujikawa et. al. 
investigated thermal degradation of synthetic cathinones by GC-MS using α-PVP and 
assessed the effect of the injector method, injector temperature, and activity on the liner 
surface (84). The decomposition product was confirmed for α-PVP. After evaluating 
splitless, 1:5 split, and 1:10 split injections, the split injections reduced the amount of 
thermal degradation that occurred. Lower injector temperatures reduced the formation of 
the thermal degradation product. Liner comparisons included a used deactivated liner, a 
new deactivated liner, and a new non-deactivated liner. The formation of the thermal 
degradation product was eliminated by using a new deactivated liner, indicating 
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decomposition was the result of the formation of active sites on the liner. The non-
deactivated liner resulted in the return of the decomposition product (84).  
The influence of injector temperature and age of deactivated liner on the thermal 
degradation of synthetic cathinones was also confirmed by Kerrigan et. al. using 18 
synthetic cathinones comprised of thirteen secondary and five tertiary amines. The M-2 
decomposition product was identified for all 18 cathinones (72).  
Gas chromatography analysis requires high temperatures in order to completely 
vaporize the sample upon injection and maintain a gaseous state throughout separation and 
analysis. These extremely high temperatures may result in in situ thermal degradation of 
synthetic cathinones. In contrast, thermal degradation does not take place during LC 
separation, making it a more suitable technique for cathinones. Both GC and LC 
approaches have been utilized and these are summarized in Tables 1.3 and 1.4. 
Table 1.3. Gas chromatography mass spectrometry methods for the detection of synthetic 
cathinones from biological matrices.  
Cathinone Analytical 
Technique 
Matrix  Reference  
Cathinone 
Methcathinone 
GC-MS U (30) 
Ethylone GC-MS U, Bi (56) 
MDPBP GC-MS B (85) 
MDPV 
Pentedrone 
GC-MS B, U (86) 
MDPV GC-MS B (87) 
MDPV GC-MSC B, U (88) 
MDPV GC-MS U, S (89) 
MDPV GC-MS U (50) 
Mephedrone GC-MS B, U, SC, Bi  (57) 
Mephedrone GC-MS B, U (55) 
Mephedrone GC-MS B, U, SC (54) 
   (continued) 
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Cathinone Analytical 
Technique 
Matrix  Reference  
Mephedrone GC-MS U (90) 
Mephedrone GC-MS P, U (51) 
Mephedrone GC-MS B (91) 






GC-MS U (93) 
Methedrone GC-MS B (94) 
Methylone GC-MS B, U (95) 
Methylone GC-MS B, VH, SC, L (52) 
Methylone GC-MS B, U, L (58) 
α-PVP GC-MS B, SC  (96) 
16 Cathinones GC-MS U (97) 
Matrices include blood (B), urine (U), liver (L), plasma (P), serum (S), stomach contents 
(SC), bile (Bi), and vitreous humor (VH) 
 
Table 1.4. Liquid chromatography mass spectrometry methods for the detection of 




Matrix  Reference  
3,4-DMMC 
α-PVP 
LC-HRMS U (98) 
3,4-DMMC LC-MS B (99) 
3,4-DMMC LC-MS/MS B, U (66) 
3,4-DMMC LC-MS/MS U (100) 
4-MEC 
MDPV 
LC-MS/MS H (101) 




LC-MS/MS B (103) 
4-MEC LC-MS/MS & 
HRMS 
B, P (104) 
   (continued) 
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Cathinone Analytical 
Technique 
Matrix  Reference  
Butylone LC-MS/MS B, L (105) 
MDPBP LC-MS/MS U (106) 
MDPV LC-HRMS U (107) 
MDPV LC-HRMS P (108) 
MDPV LC-MS/MS B (109) 
MDPV LC-MS/MS U (110) 
MDPV LC-MS/MS U (111) 
MDPV LC-MS/MS B (112) 
MDPV LC-MS/MS S (29) 




LC-MS/MS T (60) 
Mephedrone 
MDPV 
LC-MS/MS S (62) 
Mephedrone LC-MS/MS S (114) 
Mephedrone LC-MS/MS B, VH (115) 
Mephedrone LC-MS/MS B, U, SC (116) 
Mephedrone 
MDPV 
LC-MS/MS B, U, S (117) 
Methcathinone 
Mephedrone 
LC-MS/MS U (35) 
Methylone LC-MS/MS B, U, Bi, SC, 
VH 
(118) 




LC-MS B, L, T, SC (63) 
α-PVP LC-HRMS B, U, L, T (67) 
α-PVP LC-MS/MS S (120) 
α-PVP 
OH-α-PVP 
LC-MS/MS B, U, SC, T, L (121) 
α-PVP LC-MS/MS U (122) 
6 cathinones LC-MS/MS OF (33) 
7 cathinones LC-MS/MS  B, P, U, VH (123) 
   (continued) 
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Cathinone Analytical 
Technique 
Matrix  Reference  
7 cathinones  LC-MS/MS B (77) 
8 cathinones LC-HRMS U (61) 
8 cathinones LC-MS/MS B (71) 
9 cathinones LC-MS/MS S (64) 
10 cathinone LC-MS/MS OF (65) 
11 Cathinones LC-MS/MS U (76) 
11 cathinones LC-MS/MS U (25) 
19 Cathinones LC-MS/MS B (45) 
23 cathinones LC-HRMS B (68) 
32 Cathinones  LC-HRMS U (47) 
Matrices include blood (B), urine (U), liver (L), plasma (P), serum (S), oral fluid (OF), 
stomach contents (SC), bile (Bi), vitreous humor (VH), hair (H), and a variety of tissue 
(T) including brain, kidney, spleen. 
 
Pharmacology 
The leaves of the khat plant have been historically chewed for their psychostimulant 
and euphoric effects. The primary psychoactive component in the shrub, cathinone, has 
been chemically modified to produce over 40 synthetic cathinone analytes, each producing 
psychostimulant and euphoric effects. These synthetic analogs have provided an alternative 
option to methamphetamine, MDMA, and cocaine users.  
Through data from emergency department intakes, poison control centers, and self-
reported forums, synthetic cathinone users world-wide are typically males in their mid to 
late 20s (5, 124-131). Common routes of administration include insufflation (snorting), 
inhalation or smoking, oral, rectal, and intravenous (IV) (3, 124, 125, 127, 129, 131-133). 
The route of administration influences the intensity of effects and the onset of action. 
Products containing synthetic cathinones are typically sold as a powder or pill, with 
packages weighing from as low as 25 mg to upward of 1,000 mg (134, 135). When taken 
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orally or by insufflation, reported doses are 5 to 250 mg and 5 to 125 mg, respectively (8, 
132, 134, 136). In contrast, intravenous administration typically involve much lower doses 
(2 to 20 mg), due to the increased bioavailability of the drug (132). Onset of action also 
occurs earlier with IV or insufflation (ranging from 10 to 15 minutes), compared with orally 
administered drug (15 and 45 minutes) (3, 132-134). Desired effects typically last between 
30 minutes to 4 hours depending on route of administration, with adverse effects lasting a 
minimum of eight hours and upwards of two days (3, 8, 132-134, 136). These drugs can be 
administered in small doses over a short period of time (bingeing) to prolong the desired 
effects, resulting in the administration of 500 to 1,000 mg in a single session (8, 137, 138).  
The sought-after effects of cathinones include psychostimulation and euphoria. 
Reported effects include increased alertness, energy, motivation, concentration, libido, 
sociability and talkativeness, and empathy (6, 133, 139). However, numerous adverse 
effects are associated with synthetic cathinones, from a minor headache and nausea to 
hallucinations, delusions, and suicidal thoughts (5, 6, 124, 127, 131, 140). Adverse 
symptoms can be classified as cardiovascular, cognitive, psychiatric, neurological, and 
perceptual (6). A summary of desired and adverse effects associated with cathinone use is 
shown in Table 1.5. 
Table 1.5. Desired and adverse effects associated with synthetic cathinone use.  
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Liver Toxicity  
Rhabdomyolysis  
Organ Failure 
References: (4-6, 8, 9, 124, 127, 131, 133, 139, 141-145) 
Through exposures reported to poison control centers across the United States, the 
most common adverse effects were tachycardia, agitation, hypertension, hallucinations, 
and violent behavior (5, 124, 127). While these studies surveyed and reported symptoms 
associated with synthetic cathinones as a generality, others have documented specific 
cathinone symptoms through web surveys or case studies.  
Surveys of mephedrone users provide information about the most common adverse 
effects associated with the use of this particular cathinone. However, this self-reported data 
is complicated by poly-drug use and the potential for the drug to be misrepresented to the 
user (131). The most common adverse effects associated with mephedrone products were 
headache, nausea, tremors, anxiety, and paranoia (129, 144). Individuals also experienced 
depression, anxiety, irritability, and memory loss (144). Despite these negative effects, 
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users found the mephedrone to be addictive and indicated they would use the drug again 
(4, 129, 131, 144).  
Antemortem case reports in a clinical, rather than forensic setting, are typically the 
result of severe adverse side effects that require emergency services. Although these reports 
are of interest, they can rarely be used to distinguish lethal from non-lethal blood 
concentrations, due to tolerance. Cathinone concentrations in antemortem forensic 
casework is discussed later.  
In a case study presented by Thornton et. al. a patient with prior psychiatric history 
was brought to the emergency department following bizarre behavior, suicidal thoughts, 
and auditory hallucinations one hour after insufflating a white powder. Analysis revealed 
this powder contained MDPV and flephedrone (4-FMC). The patient claimed he had used 
bath salts before and never had this reaction. Blood and urine analysis revealed MDPV and 
its metabolites, flephedrone, and caffeine, ruling out contribution to these symptoms from 
other drugs (146). Truscott et. al. presented a case study involving a patient that had a 
sudden outburst of violence. After admittance to the emergency department, it was 
discovered he suffered from rhabdomyolysis and acute renal failure, which have been 
linked to synthetic cathinone use. MDPV was identified in urine and serum, directly linking 
these symptoms to the use of MDPV (29). In another case, a driver had insufflated α-PVP 
within hours of a vehicular accident. The driver was agitated, but felt full of energy. At the 
time of the accident, he experienced visual hallucinations and a feeling of unconsciousness, 
which caused the accident and the death of two passengers (147). These are a few of the 
numerous published case reports documenting synthetic cathinone involvement in 
emergency room admissions and impaired driving. These cases highlight the unpredictable, 
28 
    
severe, and dangerous adverse effects of synthetic cathinones use resulting from changes 
in the concentration of neurotransmitters.  
Three catecholamine neurotransmitters – dopamine, serotonin, and norepinephrine 
– are linked to various psychological and physiological effects. Understanding a drug’s 
affinity for each neurotransmitter can determine its pharmacological activity. Drugs with a 
high affinity for dopamine, the reward system, have a tendency to be more addictive and 
have a higher risk for dependence. Drugs with a higher affinity for serotonin, linked to 
mood, will more likely produce effects to enhance emotions, sociability, and libido. Drugs 
with a higher affinity for norepinephrine, linked to flight or fight reactions, will stimulate 
the sympathetic nervous system and have stimulant-like effects.  
Pharmacodynamic in vivo and in vitro studies are performed to determine how 
drugs interact with the catecholamines. Pharmacokinetic in vivo and in vitro experiments 
are used to determine how the body eliminates these foreign xenobiotics. In vivo 
experiments for pharmacodynamic studies involve controlled dosing studies, combined 
with behavioral monitoring and neurotransmitter evaluation. Pharmacokinetics are 
typically determined in vivo using animal models. These studies can provide valuable 
information regarding the abuse potential and reinforcing behavior related to these drugs, 
and can also investigate the long-term effects. Given the adverse consequences associated 
with cathinone use, in vitro methods have also been used to examine the 
pharmacodynamics and pharmacokinetics of this drug class.   
Pharmacodynamics 
As with other stimulants, including methamphetamine and amphetamine, synthetic 
cathinones affect the release and reuptake of the catecholamines norepinephrine, 
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dopamine, and serotonin, and the enzymes involved in catecholamine synthesis, including 
tryptophan hydroxylase and tyrosine hydroxylase (21, 137, 148, 149). In vivo and in vitro 
studies have been performed to better understand how synthetic cathinones interact with 
neurotransmitters. Dopamine interaction was first documented using the natural precursor, 
cathinone.  
An early in vitro study done by Kalix using rabbit striatum, confirmed the 
mechanism of action for (-)cathinone was similar to (+)amphetamine. Both of these drugs 
release dopamine from intercellular vesicles. Moreover, there is a direct relationship 
between dopamine release and dose (21). Nearly twenty years later, Gygi et. al. 
investigated the effect of methcathinone on dopamine in vivo using rats. In their first study, 
rats were either administered a single injection of methcathinone or received multiple 
injections over the course of sixteen hours. After a single dose, it was concluded that 
methcathinone decreased the activity of tryptophan hydroxylase. After multiple injections, 
the concentration of dopamine and serotonin had decreased in the striatum, which controls 
many cognitive functions (150). In an additional study, to assess long-term effects of these 
drugs, rats were administered methcathinone over sixteen hours and sacrificed 30 days 
later. The concentration of dopamine, serotonin, and their metabolites significantly 
decreased following the administration of methcathinone, relative to the control group 
(151). These initial studies indicate that cathinones significantly impact neurotransmitter 
concentrations and cause deficits within the brain for weeks after drug cessation. These 
deficits provide an explanation for withdrawal effects, including depression, and the long-
term consequences of cathinone use.  
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Investigations into the pharmacology of synthetic cathinone use reappeared in the 
late 2000s following an increase in synthetic cathinone use worldwide and the 
accompanying severe cardiovascular, neurological, and psychopathological effects. Many 
in vivo studies revolved around mephedrone, one of the earliest synthetic cathinones. One 
study performed by Hadlock et. al. investigated the effects of mephedrone in rats following 
several administrations within an hour to mimic a “binge”. Within one hour of drug 
cessation, there was a significant decrease in dopamine and serotonin transporter function 
and the body temperature of the rats had increased compared to the placebo group. Seven 
days after the last mephedrone dose there was significant decrease in serotonin reuptake 
and concentration, possibly indicating that mephedrone has a long-term effect on serotonin 
transporter function. Mephedrone is also a potent dopamine releaser, evidenced by eager 
self-administration of the drug in animal studies. It should be noted that rats self-
administered mephedrone more times than methamphetamine in a seven-day period, 
highlighting that these novel drugs may be more addictive and have a greater abuse liability 
than methamphetamine or MDMA (138). Additional rat studies involving mephedrone 
revealed that the enantiomers, R-mephedrone and S-mephedrone, do not share the same 
affinity for neurotransmitters. The R enantiomer was found to be a preferential dopamine 
releaser, 50 times greater than the S enantiomer, and the S enantiomer results in a greater 
release of serotonin (22). Synthesizing mephedrone that contains predominantly the R-
enantiomer would greatly increase its abuse potential.  
A limited number of in vivo studies have been performed on other synthetic 
cathinones. Dose dependence on the abuse and reinforcement potential of MDPV and α-
PVP was confirmed through self-readministration and locomotor activity in rats (152, 153). 
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In vivo studies using methylone also revealed a dose dependent effect on locomotor activity 
and that its use can result in long-term changes in cognitive function through persisting 
deficits in neurotransmitter concentrations throughout the brain (18, 154). It should be 
noted that that these drugs inhibit vesicle monoamine transporter (VMAT2), which 
prevents monoamine neurotransmitters from returning to vesicles (155). This decreases 
extracellular storage of neurotransmitters and increases the likelihood of neurotransmitters 
of entering the synapse. 
While in vivo studies investigate a single compound at a time, in vitro studies allow 
for the simultaneous investigation of multiple drugs. Simmler et. al. used HEK 293 cells 
to investigate how ten cathinones (cathinone, methcathinone, mephedrone, flephedrone, 
methylone, ethylone, butylone, pyrovalerone, MDPV, and pyrovalerone) interacted with 
certain neurotransmitters. Their findings revealed there are significant difference between 
the cathinones and monoamine interaction. (149). The various cathinones have different 
affinities for the catecholamines and differ in mechanisms of action. Each cathinone can 
be classified as either a substrate releaser or transport inhibitor. A substrate releaser will 
enter the axon terminal and disrupt the vesicles that store neurotransmitters until they are 
released into the synapse. The excess neurotransmitters will be released into the synaptic 
cleft by reversing the transporter. Substrate releasers ultimately cause a deficit of 
neurotransmitters in the axon and damage transporters (134, 137). A transport inhibitor 
prevents the reuptake of cathinones from the synapse (132, 137, 149). Depending on their 
ability to act as a transport inhibitor, substrate releaser, or a combination of both, synthetic 
cathinones were initially categorized as either A) cocaine-MDMA-mixed cathinones, B) 
methamphetamine-like cathinones, or C) pyrovalerone-like cathinones (149)  (Table 1.6).  
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Cocaine-MDMA-mixed cathinones are non-selective monoamine uptake 
inhibitors; they will inhibit the reuptake of all three neurotransmitters to some degree. This 
category of cathinone includes mephedrone, methylone, ethylone, butylone, and naphyrone 
(149). Naphyrone is a stronger dopamine transporter inhibiter than the other four identified, 
whereas mephedrone and the methylenedioxy-type cathinones have a greater affinity for 
serotonin transporter inhibition. The higher affinity of mephedrone as a serotonin 
transporter inhibitor supports the findings of Hadlock et. al. (138). All, except naphyrone, 
were preferential releasers for serotonin. Mephedrone released both dopamine and 
serotonin.  
Methamphetamine-like cathinones, such as cathinone, methcathinone, and 
flephedrone, are preferential catecholamine transporter inhibitors and dopamine releasers. 
All have a higher affinity for dopamine transporter inhibition over serotonin transporter 
inhibition. The third category, pyrovalerone-like cathinones, including MDPV and 
pyrovalerone, are the most potent and selective dopamine transporter inhibitors with no 
substrate release activity. MDPV and pyrovalerone were 10 times more potent in their 
inhibition of the dopamine transporter than mephedrone (149). Additional in vitro studies 
have supported Simmler’s study regarding the potency of MDPV as a selective dopamine 
transporter inhibitor (148, 156). This strong affinity for dopamine reuptake inhibition 
would increase the abuse and dependence potential of pyrovalerone-like cathinones (152). 
Regardless of potency and affinity for transporter inhibition or neurotransmitter release, all 
cathinones increase the concentration of neurotransmitters in the synapse and have a high 
abuse potential (9, 137, 149).  
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Mephedrone Cathinone MDPV 
Methylone Methcathinone Pyrovalerone 
Ethylone Flephedrone (4-FMC)  
Butylone   
Naphyrone   
 
Studies have also shown that these drugs may have additive or synergistic effects, 
especially when two cathinones having two different mechanisms of action are co-
administered (156-158). Illicit drug preparations, which may contain more than one 
cathinone species, could result in increased toxicity and potential for adverse effects.  
Pharmacokinetics 
In clinical and postmortem biological samples, the identification of the drug may 
rely on the identification of metabolites. For many drugs, the metabolite has a longer 
detection window than the parent molecule, making it easier to identify. Detection time of 
the parent molecule may be shortened due to delayed collection of sample, extensive 
metabolism, and shorter half-life. An example of this phenomenon is cocaine. Cocaine is 
extensively metabolized, with less than 10% of the parent molecule detected unchanged. 
Therefore, the use of cocaine is confirmed through the identification of the primary 
metabolite, benzoylecgonine. Metabolites have the potential to be pharmacologically 
active or toxic and can also interact with other substances in the body. From an analytical 
standpoint, once metabolites are elucidated, they can be incorporated into current detection 
methods. However, one limitation for incorporating metabolites in analytical methods in 
accredited forensic laboratories is the lack of commercially available analytical standard 
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or certified reference material for some substances. This is particularly true for novel 
psychoactive substances, because their development on the illicit drug market far outpaces 
pharmacologic research efforts.  
Numerous in vitro approaches to drug metabolism have been developed, involving 
the use of human liver microsomes (HLMs), primary hepatocytes, liver preparations, 
cytosol, liver S9 fractions, supersomes, and microsomes. Microsomal studies can be used 
to investigate the role of cytochrome P450 (CYP) isozymes. This can be particularly 
important due to genetic variance and the potential for either adverse drug reactions or 
drug-drug interactions. Although HLMs are widely used, hepatocytes and liver slices more 
closely resemble in vivo metabolism (98). Through in vitro studies, identification and 
structural elucidation of metabolites and the involvement of specific enzymes can be 
determined.  In vivo experiments in humans or animal models may help identify the most 
abundant metabolites, but significant differences can be observed between species (159-
161).  Another, less common, method of predicting metabolites is in silico experiments 
using software. In silico models produce all potential metabolites and predict which are 
likely to be the most abundant. The combination of in vivo and in vitro experiments can 
support in silico predictions and provide an accurate pharmacokinetic profile (98).  
The pharmacokinetic profile includes phase I and phase II metabolism. Phase I 
metabolism involves biotransformations that typically increase polarity to facilitate 
elimination or conjugation. These biotransformations often include N-dealkylation, 
reduction, oxidation, and hydroxylation. Phase II metabolism involves primarily 
glucuronidation or sulfation at reactive sites to further increase polarity and excretion. The 
extent of drug metabolism varies significantly for each drug.  In vivo and in vitro 
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experiments can predict how much of the drug will be eliminated unchanged, which can 
help determine which compound should be targeted for identification purposes.  
Synthetic cathinone metabolism has been investigated using in vitro and in vivo 
experiments (89, 90, 97, 98, 100, 107, 122, 160-168). In order to predict and detect 
unknown metabolites, knowledge of the parent drug fragmentation is crucial (89, 90, 107, 
161, 163, 167). GC-MS has been used to identify metabolites through MS/MS spectra and 
fragmentation. Again, derivatization is often required to enhance sensitivity of certain 
function group and elucidate structures (90, 122, 161). High resolution mass spectrometry 
(HRMS) instruments have become invaluable in structural elucidation of metabolites due 
to their mass accuracy and high sensitivity and specificity. Through the use of HRMS and 
GC-MS, the most common metabolic pathways identified for synthetic cathinones involve 
reduction, hydroxylation, N-dealkylation, or a combination thereof. However, 
biotransformation pathways for the most abundant metabolite vary significantly, 
depending on the type, or subgroup of cathinone.  
Substituted Cathinones  
Common metabolic pathways for substituted cathinones include N-dealkylation 
(A), β-keto reduction (B), and hydroxylation to either the aromatic ring substituent or alkyl 
chain (C) (Figure 1.8) (90, 98, 100, 160, 164, 165, 167, 168). The most abundant metabolic 
pathway varied for the substituted cathinones. Regardless of pathway, metabolism of these 
types of cathinones is extensive, with unchanged parent drug accounting for 15% or less 
of the dose (37, 51, 97). Mephedrone has been the most widely studied substituted 
cathinone (90, 100, 165).  
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At least seven metabolites of mephedrone have been identified, including 
hydroxytolyl-mephedrone, nor mephedrone, dihydro mephedrone (mephedrone 
ephedrine), nor-dihydro mephedrone, nor-hydroxytolyl mephedrone, 4-carboxy 
mephedrone, and 4-carboxy-dihydro mephedrone (51, 90, 97, 165, 169). The 4-carboxy-
dihydro mephedrone was only identified in human urine and not produced by rat liver 
microsomes (51, 90). The hydroxytolyl metabolites were further metabolized into phase II 
glucuronides or sulfates (90).  
Other substituted cathinones are metabolized in a similar fashion (98, 100, 160, 
164, 168). Studies on 3-FMC revealed the most abundant metabolite in rat urine was the 
reduced “ephedrine form” of the drug, while the most abundant using HLMs was the N-
dealkylated form (160). A metabolite of 3-FMC was identified where the aromatic ring had 
been hydroxylated to form hydroxyl-3-FMC (164). This transformation has not been 
documented for other substituted cathinones. 3,4-DMMC has an interesting metabolic 
pathway due to the presence of two substituents on the aromatic ring. The methyl groups 
can be hydroxylated to form either 4-hydroxymethyl-3-methylmethcathinone or 3-
hydroxymethyl-4-methylmethcathinone which can be further oxidized to the carboxylic 
acid. However, these were minor products compared to the reduced form (100).  
Cytochrome P450 isoenzymes involved these biotransformations include CYP2D6, 
CYP2B6, CYP2C19, and CYP2E1 (160, 169). CYP2D6 was the most active enzyme in 
the hydroxylation of mephedrone into hydroxytolyl mephedrone. N-dealkylation of 3-FMC 
required CYP2B6 and CYP2D6 with some contribution from CYP2C19 and CYP2E1. 
Based on the structural similarity between the substituted cathinones, other species may 
involve similar isoenzymes. 
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Figure 1.8. Metabolic pathway for substituted and unsubstituted cathinones. 
Biotransformation (bold) and nomenclature identified for each pathway (51, 90, 97, 165, 
169). 
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Methylenedioxy Cathinones 
The methylenedioxy-type cathinones undergo the same biotransformations as their 
substituted counterparts, including reduction (A), N-dealkylation (B), and alkyl chain 
hydroxylation (C)) with the addition of demethylenation (D) (Figure 1.9).  
Demethylenation transforms the methylenedioxy group into two hydroxyl groups forming 
3,4-hydroxy methcathinone, also referred to as catechol methcathinone (144, 162, 167, 
170). Demethylenation is followed by O-methylation using catechol-O-methyltransferase 
(COMT) producing 4-hydroxy-3-methoxymethcathinone (HMMC, 4-OH-3-MeO-MC) or 
3-hydroxy-4-methoxymethcathinone (3-OH-4-MeO-MC) (E) (Figure 1.9) (39, 98, 162, 
167, 170). HMMC is the most abundant metabolite in humans and rats (90, 162). This 
catechol intermediate metabolite and the two methylated metabolites are readily 
conjugated in phase II metabolism processes (170). While most of the metabolism research 
involving methylenedioxy-type cathinones has been completed using methylone, 
comprehensive studies have shown other methylenedioxy analogs follow similar pathways 
(166, 170).  
 The nor- form and the ephedrine (or reduced) form of the substituted cathinones 
are among the most abundant. The methylenedioxy cathinones produce these metabolites, 
but to a lesser extent (170). While the reduced form has been identified through in vitro 
studies, it is not readily identified through in vivo studies (18, 39, 162, 166).  Zaitsu et. al. 
did observe the reduction, but only for ethylone and butylone; methylone did not readily 
metabolize into the ephedrine form (170). Steric hindrance from the methylenedioxy group 
may inhibit the reduction of the beta-keto group.  
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The main isoenzyme involved in biotransformation of methylone is CYP2D6; CYP1A2, 
CYP2B6, and CYP2C19 are involved to a lesser extent (Pedersen, 2013). COMT is 

























































Figure 1.9. Metabolic pathway for methylenedioxy-type cathinones. Biotransformation 
(bold) and nomenclature identified for each pathway (90, 170). 
 
Pyrrolidinophenone Cathinones 
Cathinones containing the pyrrolidinyl group in the absence of the methylenedioxy 
group can be reduced (A) or hydroxylated at either the ring substituent or the alkyl chain 
(B) (Figure 1.10),  with subsequent oxidization to the carboxylic acids. However, the 
pyrrolidine-type cathinones have distinct biotransformations. The pyrrolidinyl group can 
be hydroxylated and then further oxidized to form the 2”-oxo (lactam) metabolite (C & D, 
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CD); it can also open to form an aliphatic aldehyde which can be oxidized to a carboxylic 
acid (E), or it can degrade to form a primary amine (F) (Figure 1.10) (97, 122, 159, 171). 
Alpha-PVP has been the most widely researched pyrrolidinophenone cathinone (98, 122, 
159). The metabolism of MPBP (171), pyrovalerone (172, 173), and naphyrone (166) has 
also been investigated.  
The ephedrine (reduced) form has been identified for all studied pyrrolidinophenone 
cathinones. Hydroxylation has occurred on the alkyl side chain and on the aromatic ring in 
α-PVP and on the naphthyl group in naphyrone (159, 166). Hydroxylation of the aromatic 
ring in α-PVP has not been confirmed in humans (159). 4-Hydroxymethyl metabolites have 
been identified for MPBP and pyrovalerone (171-173). The 2”-oxo metabolite has also 
been identified consistently, however, in one study, the reduced form was more abundant 
(159). In both rat and human studies, glucuronides and sulfates have been identified as 
phase II metabolites (122, 159). Cytochrome P450 isoenzymes involved in the metabolism 
of these cathinones include CYP2C19 and CYP2D6 
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Figure 1.10. Metabolic pathway for pyrrolidine-type cathinones. Biotransformation 




    
Methylenedioxy-Pyrrolidinophenone Cathinones 
The majority of research on metabolism of cathinones contain both the pyrrolidinyl 
and methylenedioxy group has been investigated using MDPV. Metabolic pathways for 
MDPV include reduction to the dihydro (ephedrine) form (A); hydroxylation on the alkyl 
chain (B); oxidation to form the 2”-oxo metabolite (through intermediate hydroxylation) 
(B/C); ring degradation to a primary amine (D); ring opening to carboxylic acid (E); 
demethylenation to form catechol pyrovalerone (F); and O-methylation by COMT to form 
either the 3- or 4-MeO metabolite (G) (Figure 1.11) (89, 107, 161, 163, 167). The most 
abundant metabolite is 4-OH-3-MeO pyrovalerone, similar to the methylenedioxy-type 
cathinones (161, 163).  
Despite the identification of multiple metabolites in vitro and in vivo, it has been 
suggested that as much as 80% of MDPV is excreted unchanged (163).  Unchanged MDPV 
has been identified in vivo along with its phase I and phase II metabolites (89).  Phase II 
metabolism occurs through glucuronidation or sulfation of hydroxyl and carboxylic acids 
(161, 163). Demethylenation, the most common metabolic pathway, reportedly involves 































































Figure 1.11. Metabolic pathway for pyrrolidine-type cathinones bearing the 
methylenedioxy group. Biotransformation (bold) and nomenclature identified for each 
pathway. (107, 161, 163). 
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Through in vitro and in vivo studies, metabolites for the different subgroups of cathinones 
have been proposed and structures elucidated (Table 1.7). When elucidating structures for 
reduced or hydrolyzed metabolites, both diastereomers must be considered (97, 100, 122, 
164). The reduction of the β-ketone or the addition of hydroxyl groups combined with the 
oxidation to a carboxylic acid makes these metabolites more acidic than the parent 
compound. Differences in acid-base properties may hamper isolation and detection of 
parent drug and metabolites. Another complication involves the formation of common 
metabolites, formed by more than one cathinone species (97, 166). This is especially 
apparent with N-dealkylation among the substituted cathinones and the combination of 
demethylenation and N-dealkylation in the methylenedioxy-type.  
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Table 1.7. Proposed metabolites for synthetic cathinones. 




Hydroxytolyl-mephedrone 4-Me hydroxylation  C11H16NO2 194 (90, 165) 
Normephedrone N-demethylation C10H14NO 164 (90, 165) 
Dihydro-mephedrone Reduction C11H18NO 180 (90, 165, 169) 
Nor-dihydro-mephedrone N-dealkylation + Reduction C10H16NO 166 (90, 165) 
4-Carboxy-dihydro 
mephedrone 
Oxidation C11H15NO3 210 (90) 
Nor-hydroxytolyl 
mephedrone 
Hydroxylation + N-dealkylation C10H14NO2 180 (90, 165) 








Hydoxyl-tolyl-MEC 4-Me Hydroxylation C12H18NO2 208 (168) 
4-Carboxy-MEC Hydroxylation + Oxidation C12H16NO3 222 (168) 
Dihydro-4-MEC Reduction C12H20NO 194 (168) 
4-Carboxy-dihydro-4-
MEC 
Hydroxylation + Oxidation and 
Reduction 
C12H18NO3 224 (168) 
Nor-4-MEC N-dealkylation C10H14NO 164 (168) 




Dimethylcathinone  N-dealkylation C11H15NO 178 (98, 100) 
Dihydro-3,4-DMMC Reduction C12H19NO 194 (98, 100) 
     (continued) 
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Cathinone Metabolites Metabolic Pathway Formula MW Reference 
 β-OH-DMC Reduction + N-dealkylation C11H17NO 180 (100) 
 4-MeO-3-MeMC Hydroxylation + Oxidation C12H17NO2 208 (100) 




Dihydro-3-FMC Reduction C10H14FNO 184 (160) 
Nor-3-FMC N-dealkylation C9H10FNO 168 (160, 164) 
Nordihydro-3-FMC Reduction + N-dealkylation C9H12FNO 170 (160) 
Hydroxytolyl-3-FMC Hydroxylation C10H12FNO2 198 (160, 164) 
Dihydro-hydroxytolyl-3-
FMC 








C11H15NO3 210 (90, 162, 170) 
3-OH-4-MeO-MC Demethylenation + O-
methylation 
C11H15NO3 210 (90, 162, 170) 
3,4-
Dihydroxymethcathinone 
Demethylenation C10H13NO3 196 (167) 




Dihydro-α-PVP Reduction C15H23NO 234 (98, 122, 159) 
2”-oxo-α-PVP Oxidation C15H19NO2 246 (98, 122, 159) 
Pyrrodinyl degradation  C11H15NO 178 (98, 122, 159) 
Hydroxy-αPVP Hydroxylation (aliphatic, 
aromatic) 
C15H21NO2 248 (98, 122, 159) 
MPBP 
 
Dihydro-MPBP Reduction C15H23NO 234 (171) 
     (continued) 
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Cathinone Metabolites Metabolic Pathway Formula MW Reference 
C15H21NO 
MW: 232 
2”-oxo-MPBP Demethylenation + 
Hydroxylation 
C15H19NO2 246 (171) 




3-OH-3-MeO-MDPV Demethylenation + O-
methylation 
C16H24NO3 278 (107, 111, 161, 
163, 167) 
4-OH-3-MeO-MDPV Demethylenation + O-
methylation 
C16H24NO3 278 (107, 108, 111, 
161, 163, 167) 
2”-oxo-MDPV Hydroxylation + 
Dehydrogenation 
C16H22NO4 290 (89, 107, 111, 
161, 163) 
3,4-Catechol-pyrovalerone Demethylenation C15H22NO3 264 (107, 108, 111, 
167) 




Naphthyl hydroxylation Hydroxylation C19H23NO2 298 (166) 
Alkyl chain hydroxylation Hydroxylation C19H23NO2 298 (166) 
Dihydro-naphyrone Reduction C19H23NO 284 (166) 
Combination Reduction + Hydroxylation C19H25NO2 300 (166) 
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Prevalence  
Despite the severe adverse side effects that can occur with synthetic cathinone use, 
these drugs are still synthesized and distributed worldwide. Synthetic cathinones are being 
identified across the world in drug seizures and in both antemortem and postmortem 
toxicology casework. National and international controlled substance monitoring systems 
have documented a steady increase in use and derivative identification of these harmful 
drugs.  
The National Forensic Laboratory Information System (NFLIS), sponsored by the 
Drug Enforcement Administration (DEA), compiles data from participating federal, state, 
and local laboratories regarding identifications in drug seizures. This data assists in 
monitoring drug trends across the United States (174-176). In 2009 there were only 34 
reported cases involving five different synthetic cathinones: mephedrone, MDPV, 
methylone, methcathinone, and 4-MEC. By the end of 2010, there was an 18-fold increase 
in case reports, compared with the previous year. By 2015 almost 20,000 cases were 
reported (Table 1.8). Each year, with the exception of 2015, the number of different 
cathinones identified in laboratories has increased. The top three synthetic cathinones 
identified over those six years were a combination of methylone, MDPV, α-PVP, ethylone, 
and mephedrone. In the 2013-2015 NFLIS report there was a notable decrease in the 
number of reported cases involving methylone (72% to 2.3% from 2013 to 2015, 
respectively) and an increase number in the reported ethylone cases (0.1% to 47% in 2013 
to 2015, respectively). This shift could be the result of many factors, including increased 
legislation and monitoring of these substances, as well as precursor availability.   
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Table 1.8. Number of synthetic cathinone seizures and number of different cathinones 








Internationally, the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) has identified over 600 different novel psychoactive substances, with 
synthetic cathinones comprising the second largest group (177). Over 100 different 
synthetic cathinones have been reported, but only of a select few are monitored by 
EMCDDA, including methylone and mephedrone. EMCDDA reports the findings from 
twenty-two European countries and the most commonly identified cathinones in those 
countries are α-PVP, 3-MMC, ethylone, 4-CMC, and pentedrone. The most frequently 
identified cathinone varies from country to country, as it does from state to state within the 
US. Countries and states have performed their own analysis over the years to monitor 
cathinone trends.  
In Italy, a review of 162 drug seizures from 2013-2015 revealed that the majority 
contained cathinones. The top three cathinones identified were 3-MMC, 4-MEC, and 
MDPV, two of which are not on EMCDDA most frequently identified list (178).  A review 
of toxicology casework from January 2010 to December 2012 was conducted in a United 
Kingdom laboratory. Synthetic cathinones were identified in 203 cases, including 
Year Number of Cases  Number of Different 
Cathinones 
2009 34 5 
2010 602 11 
2011 6,542 21 
2012 14,507 33 
2013 16,811 33 
2014 15,523 42 
2015 19,490 35 
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antemortem and postmortem specimens. Mephedrone and MDPV were the most common 
cathinones identified.  Of the novel psychoactive groups investigated, synthetic cathinones 
were not frequently identified in fatalities. However, if a synthetic cathinone was identified 
in a fatality, it was most often a suicide, which supports suicidal thoughts or tendencies as 
an adverse effect as mentioned previously (179).  
Similar studies were performed in the United States. Forrester identified 474 calls 
to Texas Poison Control from 2010-2011 involving synthetic cathinones and that the 
majority of the calls originated from East Texas, close to the Louisiana border (127). In 
2013, Warrick performed an analysis of nine Midwestern states for synthetic cathinone 
cases reported to the National Poison Date System and identified 1,6233 cases. Cases 
identified per state and county varied, with Ohio and Kentucky having the highest number 
of reported cases (124). In 2014, Schneir et. al. performed a study identifying cathinones 
from 35 “bath salt” products purchased either online or storefronts. All packages contained 
warnings such as “do not consume” or “not intended for consumption.” Of the 35 items 
purchased, 32 contained at least one synthetic cathinone, 17 of which contained multiple 
cathinones. These findings confirm the issues associated with ambiguous or intentionally 
misleading packaging, and the potential for additive effects. The most prevalent cathinones 
were MDPV, MDPBP, and methylone (135). An increasing number of seized materials 
containing synthetic cathinones would imply an increased demand for the product. This 
demand is reflected in numerous reports of synthetic cathinones to poison control centers 
and also in antemortem and postmortem toxicology casework.  
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Synthetic Cathinones in Toxicology Casework 
Cathinones have been reported in a variety of antemortem and postmortem 
toxicology investigations (Tables 1.9 & 1.10). The most common antemortem casework 
involving cathinones involve intoxication, driving under the influence of drugs (DUID), 
and motor vehicular accidents. Synthetic cathinones have also been identified in drug 
facilitated sexual assault (DFSA) (93), child endangerment cases (180), and drug 
possession (181). Antemortem cathinone blood concentrations have ranged from 1.2 – 
8,400 ng/mL. Concentrations in urine are much higher, ranging from 34 – 17,420 ng/mL. 
The majority of postmortem investigations involving synthetic cathinones have been 
accidental deaths, most often the result of drug intoxication or motor vehicle accidents. 
Cathinones have been linked to suicides (hanging) and homicides, and have also been 
identified in samples from natural deaths. Postmortem cathinone concentrations in blood 
ranged from 1.1 – 27,000 ng/mL.  
A comparison of antemortem and postmortem toxicology results clearly shows that 
like many other drugs, recreational and fatal drug concentrations clearly overlap. The 
presence of the drug in a postmortem investigation does not necessarily imply that it caused 
or contributed to death. Among twelve fatalities involving α-PVP presented by 
Adamowicz, only one death was directly the result of α-PVP intoxication with a blood 
concentration of 6,200 ng/mL (182).  Human performance and postmortem cases were also 
presented by Marinetti and Antonides. MDPV, pentylone, α-PVP, pyrovalerone, or 
multiple cathinones in combination with each other were identified. Of the twenty-three 
postmortem cases presented, ten were ruled accidental due to multiple drug intoxication. 
Two cases were the direct result of MDPV intoxication. In one case, a meaningful drug 
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concentration could not be determined due to body decomposition, but the other had a 
MDPV blood concentration of 91 ng/mL – considerably less than the case presented by 
Adamowicz (123). These two cases highlight the unpredictable nature of toxicity, due to 
tolerance. Cathinone concentrations in the blood of living subjects have been reported in 
excess of 1,000 ng/mL, however most fall below 500 ng/mL (Table 1.9).  
Many antemortem and postmortem cases were the result of poly-drug use, 
including other illicit drugs and/or prescription drugs. In many instances alcohol (54, 56, 
94, 102, 115, 182, 183), THC, or synthetic cannabinoids (52, 89, 96, 109, 181, 182) were 
also identified. Other illicit substances found were methamphetamine (181), cocaine (54, 
89, 114-116), MDMA (115), and heroin (55). The most commonly identified prescription 
drugs were benzodiazepines (66, 89, 102, 109, 111, 112, 115, 116, 184, 185). In several 
cases, poly-drug use was the result of multiple cathinones (87, 96, 103, 109, 113, 114). The 
presence of other drugs and the combination of multiple cathinones can further complicate 
a toxicologists’ ability to interpret results and evaluate the pharmacological effects of the 
cathinone.  
Understanding how a drug distributes throughout the body and is absorbed into the 
tissue can assist in blood concentration interpretation related to death investigations. There 
have been several postmortem cases that have examined tissue distribution in cathinone-
related fatalities (53, 54, 57-59, 63, 67, 113, 118, 121, 123, 186). As expected, 
concentrations in the urine or stomach contents were higher than concentrations in the 
tissue or blood. Tissue distribution data for a fatal case involving ethylone was presented 
by McIntyre et. al. This study found that urine and gastric contents were 20,000 and 12,000 
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ng/mL, respectively, and blood concentrations for peripheral and central blood were 380 
and 390 ng/mL, respectively (53).  
Liver concentrations also had a tendency to be higher than blood concentrations, 
but lower than urine or gastric concentrations (53, 58, 63, 121, 123). Due to the liver’s 
primary function in the body – the breakdown and removal of substances – it is not 
uncommon to observe higher drug concentrations. Distribution studies also provide insight 
regarding postmortem redistribution, which is discussed later.  
Table 1.9. Antemortem cases involving synthetic cathinones.  
Drug Concentration Investigation Reference(s) 
4-FMC 346 ng/mL (serum) 
257 ng/mL (urine) 
RDU (146) 
4-MEC 46 ng/mL (blood) RDU (181) 
α-PVP 6.4-99 ng/mL (blood) DUID (n=24) (182) 
1.2-56 ng/mL (blood) RDU (n=4) (182) 
63 ng/mL (blood) DUID (187) 
230-360 ng/mL (blood) DUID (n=2) (147) 
70-100 ng/mL (blood) RDU (n=2) (184) 
1-53 ng/mL (serum) RDU (n=9) (120) 
MDPV 306 ng/mL (blood) RDU  (109) 
124 ng/mL (blood) DUID (109) 
75 ng/mL serum) RDU (29) 
<10 – 530 ng/mL (serum) RDU (n=20) (89) 
200-8,400 ng/mL (blood) DUID (n=25)  (112) 
<10-368 ng/mL (blood) DUID/RDU(n=9) (123)  
186 ng/mL (serum) 
136 ng/mL (urine) 
RDU (146) 
24-241 ng/mL (blood) (n=13) 
34-1,386 ng/mL (urine) (n=5) 
RDU (n=13) (5) 
35-55 ng/mL (urine) RDU (n=1, two 
time points) 
(111) 
21.3-146 ng/mL (serum) DUID (n=2) (62) 
140 ng/mL (urine) RDU (110) 
40-3,900 ng/mL (urine) RDU (n=9) (50) 
Mephedrone 80-660 ng/mL (blood) DUID (n=9) (188)  
150 ng/mL (serum) RDU (114)  
   (continued) 
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Drug Concentration Investigation Reference(s) 
 1-51 µg/kg (blood) (n=4) 
560 µg/kg (urine) (n=1) 
DUID (n=4) (169) 
 412 ng/mL (serum) DUID (62) 
Methcathinone 500 ng/mL (serum), 17,420 
ng/mL (urine) 
RDU (189) 
Methylone 6 ng/mL (blood) DUID (187) 
7 ng/mL (blood) DUID  (123) 
Methedrone 0.2-5 µg/g (blood) RDU (94) 
Ethylone  <10 ng/mL (blood) DUID (187) 
Naphyrone 20-30 ng/mL (plasma) RDU (n=1, two 
time points) 
(190) 
RDU: recreational drug use; DUID: driving under the influence of drugs 
 
Table 1.10. Postmortem cases involving synthetic cathinones.  
Drug Concentration Manner of Death Reference(s) 
3,4-DMMC 3,310 ng/mL (blood) Accidental  (99) 
27,000 ng/mL (iliac blood) 
7,600 ng/mL (urine) 
Accidental  (66) 
4-MEC 152 ng/mL (blood),  
122 ng/mL (urine) 
 Accidental (181) 
56 ng/mL (blood),  
14,300 ng/mL (urine) 
Accidental  (181) 
170-1,730 ng/mL (femoral 
blood) 
Accidental  (102) 
1,200 ng/mL (femoral blood) Accidental  (103) 




174 ng/mL (peripheral blood),  
401 ng/mL (urine) 
292 ng/g (brain) 
122 ng/g (kidney) 
190 ng/g (liver) 
606 ng/g (gastric contents) 
Accidental  (67) 
 
901 ng/mL (femoral blood) 
2610 ng/g (liver) 
462 ng/g (kidney) 
120 ng/g (brain) 
 Accidental  (63) 
   (continued) 
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Drug Concentration Manner of Death Reference(s) 
 4,190 ng/g (stomach contents)   
 458 ng/mL (right heart blood) 
442 ng/mL (left heart blood) 
654 ng/mL (femoral vein 
blood) 
11,200 ng/mL (urine) 
1,030 ng/mL (stomach 
contents) 
518 ng/mL (brain)  
681 ng/ml (liver)  
Accidental  (121) 
 486 ng/mL (blood) Accidental  (191) 
Buphedrone 127 ng/mL (blood) Accidental (109) 
3-127 ng/mL (blood) Accidental  (192) 
Ethylone 390 ng/mL (peripheral blood), 
380 ng/mL (central blood),  
20,000 ng/mL (urine) 
1.4 mg/kg (liver) 
580 ng/mL (vitreous) 
12,000 ng/mL (gastric 
contents) 
Accidental  (53) 








670 ng/mL (urine),  
82 ng/mL (serum) 
Accidental  (193) 
 
1,200 ng/mL (cardiac blood) Accidental  (87) 
 
39-130 ng/mL (femoral 
blood),  
760-3,800 ng/mL (urine) 
Accidental  (88) 
 
38 ng/mL (blood) Accidental  (192) 
 
32-576 ng/mL (serum) Accidental  (89) 
 
470 ng/mL (heart blood) 
0.53 mg/kg (liver) 
0.49 mg/kg (kidney) 
580 ng/mL (bile) 
Accidental  (58) 
 30 ng/mL (heart blood) Homicide  (58) 
   (continued) 
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Drug Concentration Manner of Death Reference(s) 
 
10-280 ng/mL (heart blood) 
(n=7) 
31 ng/mL (cavity blood) 
46-640 ng/mL (femoral blood) 
(n=7) 
18-162 ng/mL (peripheral 
blood) (n=4) 
14-940 ng/mL (vitreous) 
(n=13) 
12-6,080 ng/g (liver) (n=8) 
16-896 ng/g (brain) (n=6) 






 440 ng/mL (femoral blood) 
500 ng/mL (heart blood) 
>5,000 ng/mL (urine) 
>2,000 ng/mL (gastric 
contents) 
880 ng/mL (bile) 
980 ng/g (liver) 
120 ng/g (heart) 
Accidental  (113) 
 700 ng/mL (heart blood) 
1,000 ng/mL (peripheral 
blood) 
Accidental  (185) 
 170 ng/mL (blood) 
1,400 ng/mL (urine) 
Accidental  (5) 
 46 ng/mL (blood) 
1,300 ng/mL (urine) 
Accidental  (86) 
 11 ng/mL (heart blood) Not Specified  (64) 
Mephedrone 5,500 ng/mL (blood),  
7,100 ng/mL (vitreous) 
Accidental  (115) 
 




500 ng/mL (blood),  
198,000 ng/mL (urine) 
Accidental  (55) 
 
1,330 ng/m/L (heart blood),  
144,000 ng/mL (urine) 
4,520 ng/mL (gastric content) 
1,290 ng/mL (bile) 
0.79 mg/kg (lung) 
0.89 mg/kg (brain) 
Accidental  (54) 
   (continued) 
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Drug Concentration Manner of Death Reference(s) 
 
5,100 ng/mL (femoral blood),  
186,000 ng/mL (urine),  
1.04 g/L (stomach contents) 
Accidental  (116) 
 
1,200-22,000 ng/mL (blood) Accidental  (92) 
 
130-2,240 ng/mL (femoral 
blood) 
Accidental  (183) 
 14,800 ng/mL (urine) 
500 ng/mL (heart blood) 
1,900 ng/mL (bile) 
38,000 ng/mL (gastric 
contents) 
Accidental  (57) 
 2-3,300 ng/mL (blood) Accidental,  
Suicide  
(130) 
 1,300 ng/mL (femoral blood) Accidental  (103) 
 1,097 ng/mL (peripheral 
blood) 
Not Specified (45) 
Methylone 3,400 ng/mL (iliac blood),  
3,400 ng/mL (central blood) 
4,300 ng/mL (vitreous) 
11 mg/kg (liver) 
1.7 mg (gastric contents) 
Accidental  (52) 
 
560-3,300 ng/mL (peripheral 
blood) (n=3) 
580-1,000 ng/mL (heart 
blood) (n=2) 
0.88 mg/kg (liver) (n=1) 
920-1,400 ng/mL (vitreous) 
(n=2) 
550-230,000 ng/mL (urine) 
(n=2) 
4.5-12 mg/kg (gastric 
contents) (n=2) 
Accidental  (59) 
 
500 ng/mL (peripheral blood),  
39,770 ng/mL (urine) 
6,420 ng/mL (bile) 
1.47 mg/kg (liver) 
0.54 mg/kg (heart) 
1.26 mg/kg (kidney) 
Accidental  (186) 
   (continued) 
58 
     
Drug Concentration Manner of Death Reference(s) 
 729 ng/mL (heart blood) Accidental  (123) 
 
740 ng/mL (central blood) 
670 ng/mL (peripheral blood) 
38,000 ng/mL (urine) 
1.8 mg/kg (liver) 
2.3 mg/kg (kidney) 
2.1 mg/kg (spleen) 
1,800 ng/mL (bile) 
Accidental  (58) 
 110 ng/mL (heart blood) 
200 ng/mL (urine) 
0.55 mg/kg (liver) 
0.26 mg/kg (kidney) 
520 ng/mL (bile) 
Suicide  (58) 
 60 ng/mL (heart blood) 
0.14 mg/kg (liver) 
0.16 mg/kg (kidney) 
420 ng/mL (bile) 
Accidental  (58) 
 1,100 ng/mL (heart blood) 
220 ng/mL (urine) 
1.3 mg/kg (liver) 
0.91 mg/kg (kidney) 
Homicide  (58) 
 3,130 ng/mL (peripheral 
blood) 
6,640 ng/mL (heart blood) 
502,000 ng/mL (urine) 
35,300 ng/mL (bile) 
57,300 ng/mL (gastric 
contents) 





 700 ng/mL (blood) Accidental  (95) 
 272 ng/mL (blood) 
387 ng/g (liver) 
Accidental (194) 
 63 ng/mL (heart blood) Not specified  (64) 
Pentedrone 8,794 ng/mL (femoral blood) 
100,044 ng/g (liver) 
22,102 ng/g (kidney) 
13,248 ng/g (brain) 
500,534 ng/g (stomach 
contents) 
Accidental  (63) 
   (continued) 
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Drug Concentration Manner of Death Reference(s) 
 600 ng/mL (blood) Accidental  (182) 
 160 ng/mL (blood) 
12,000 ng/mL (urine) 
Accidental  (86) 
Pyrovalerone 42 ng/mL (femoral blood),  
59 ng/mL (heart blood) 
24 ng/mL (vitreous)  
124 ng/g (liver) 
48 ng/g (brain) 
70 ng/mL (bile) 
Accidental  (123) 
MDPBP 9,320 ng/mL (blood) Accidental  (85) 
Methedrone 8.4-9.6 µg/g (femoral blood) Accidental  (94) 
Ethcathinone 5-83 ng/mL (blood) Accidental,  
Suicide 
(195) 
Butylone 20,000 ng/mL (femoral blood) 
33 mg/kg (liver) 
Suicide  (105) 
Methcathinone 210 ng/mL (femoral blood) Accidental  (105) 
 
Postmortem Redistribution 
During postmortem toxicology investigations it is common to determine 
quantitative values for drugs in multiple specimens. Concentrations reported in case studies 
significantly increase the knowledge base associated with these emerging drugs. 
Summarized above are reported postmortem cathinone concentrations in blood, urine, and 
various tissues (Table 1.10). When interpreting postmortem results, it is important to 
consider the potential for postmortem redistribution (PMR), or the movement of drugs 
between tissues and fluids after death (196). Postmortem redistribution has been described 
as a “toxicological nightmare” because of the interpretive challenges it presents (197). 
When interpreting antemortem blood and tissue drug concentrations, certain assumptions 
can be made based upon known physico-chemical properties of the drug. However, these 
assumptions do not always hold true for postmortem drug concentrations (198). Factors 
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that effect a drugs’ PMR potential have been thoroughly documented and reviewed, but 
are still not yet thoroughly understood (196, 197, 199-202).  
Postmortem redistribution is often characterized by elevated drug concentrations in 
blood collected from central compartments (e.g. heart blood), relative to those collected 
peripherally (e.g. femoral vein). The movement of drugs between tissues, organs, and body 
fluids after death following the disintegration of chemical and anatomical barriers is quite 
complex (197, 198, 202). Drug movement is driven by the accumulation of drugs in certain 
organs, changes at the cellular level, and exposure to the environment. Physico-chemical 
properties of the drug, including volume of distribution (Vd), lipophilicity, pKa and protein 
binding can influence PMR potential. 
Fundamental drug properties determine where a substance will be absorbed and 
accumulate within the body. These properties include pKa, volume of distribution (Vd), 
and protein binding affinity. In order to be efficiently absorbed through passive diffusion 
and produce a pharmacological effect, a drug must be unionized and ‘free’ or unbound to 
plasma or tissue proteins. Drug pKa and body cavity pH will determine ionization state and 
where a drug will be most efficiently absorbed. pH gradients within the body can lead to 
drug accumulation for charged species, known as “ion trapping”. Plasma protein binding 
affinity (% binding) varies, and drugs which are highly protein bound may distribute less 
readily. Drugs can also bind to proteins within the tissue, which results in drug 
accumulation within the tissue itself. The combination of pKa and protein binding will 
influence a drug’s overall Vd. Drugs with higher Vd will predominately distribute into 
tissue and muscle. Typically, drugs with Vd >3-4 exhibit PMR, however, there are many 
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exceptions (203, 204). Drugs with higher volume of distribution and potential for ion 
trapping within cells can be problematic for postmortem interpretation.  
After death, the body undergoes changes at a cellular level (196, 198, 205). The 
changes arise from the depletion of oxygen leading to the cessation of ATP production. As 
a result, lactic acid builds up, decreasing intracellular pH and sodium concentrations. As 
the ionic potential increases, the overall integrity of the cell structure becomes 
compromised. Cellular edema occurs to dilute the sodium concentration (204, 206). Drugs 
with high pKa values become increasingly ionized in the acidic conditions and remained 
trapped within the cell. As the integrity of organelle membranes decline, particularly that 
of lysosomes, autolytic enzymes are released into cytoplasm and cell lysis begins (204, 
206). As the cell membrane breaks down, ionized drugs that once relied on active diffusion 
to cross into a cell now leach out and through passive diffusion move from areas of high 
concentration to low concentration.  
Concentration changes are most significant around certain organs, specifically the 
gastrointestinal (GI) tract, lungs, and liver. Due to the close proximity of these organs 
within the torso, drug movement between these organs has been well documented (197, 
202, 204, 207). Oral (and intranasal) administration results in high drug concentrations 
within the stomach and GI tract. After death, drug movement can occur from the GI tract 
into the cardiac chambers, aorta, left lung, and left lobe of the liver (204, 207). Aspirated 
stomach contents can also lead to drug movement into the lungs. From the lungs, drugs 
have been shown to transverse the alveoli into the aorta, left cardiac chamber, and to some 
extent, the liver (197, 203, 204, 207). Drug concentrations tend to be higher in the liver due 
to its metabolic and elimination functions. Drugs in the liver redistribute through the 
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hepatic vein into the inferior vena cava or through passive diffusion into surrounding 
organs (198, 204, 207). Much of the drug movement that takes place within the thoracic 
cavity results in artificially elevated concentrations in central blood sources. Subsequent 
central blood analysis can result in concentrations that are not representative of drug 
concentrations at time of death, leading to erroneous conclusions.   
Drug concentrations can also be altered during putrefactive processes and the 
introduction of exterior bacteria. As the body decomposes, internal bacteria that was 
isolated in the GI tract are released and exterior bacteria are introduced. These bacteria 
break down proteins within the blood, releasing protein bound drugs and increasing free 
drug concentration (206). As putrefaction occurs, blood will coagulate and thin out, causing 
changes in blood composition and drug concentration (198, 207). Livor mortis – the 
gravitational pooling of blood in the body – will also effect blood movement and drug 
concentrations (198, 204). With several factors influencing postmortem drug movement 
and producing site-to-site variation, postmortem toxicological analysis is challenging. 
To obtain a representative drug concentration at time of death, multiple specimens 
should be collected, including blood samples from a central source and peripheral source 
(197, 202). Central blood would be an ideal source due to its large volume; however, it 
most susceptible to PMR and contamination from internal injuries. Although limited in 
volume, there are multiple sites from which peripheral blood can be drawn, but the most 
common and preferred location is the femoral vein (197, 207). A peripheral source is less 
likely to be effected by PMR or contamination due to its distance from the central cavity. 
However, there have been some documented cases where peripheral concentrations 
increased postmortem (199, 208). In order to ensure no contamination from other blood 
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sources is present, ideally the vein should be visualized and ligated prior to collection (202, 
207, 209). However, postmortem sample collection is not standardized; this additional step 
is often not completed and peripheral blood sources may vary across jurisdictions. The 
benefit of obtaining specimens from these two independent blood sources is the cardiac to 
peripheral blood (C/P) ratio, which is useful in predicting PMR potential.  
A C/P ratio greater than 1 is often indicative of postmortem redistribution (202, 
210). Early studies documented that basic drugs, such as digoxin and tricyclic 
antidepressants, are more likely to exhibit PMR. In a study done by Dalpe-Scott et. al., C/P 
ratios for 113 drugs were determined to assess PMR potential. Based upon high C/P ratios, 
drugs that were most likely to exhibit PMR were basic with a large volume of distribution. 
However, calculated C/P ratios for a single drug varied (202). Drugs with C/P ratios of 2.4 
or higher were considered to exhibit PMR. These included amitriptyline, propoxyphene, 
doxepin, and chlorpromazine, all with Vd values greater than 6 L/kg. In a more recent 
study, Han et. al. investigated PMR potential for 76 commonly encountered drugs and 
found that many, including amitriptyline, codeine, diazepam, diphenhydramine, ketamine, 
lidocaine, propofol, and zolpidem may exhibit PMR, characterized by C/P ratios of 1.2 or 
higher (210). Zolpidem, with a Vd of 0.6, had a high C/P ratio of 3.74, making it an 
exception to the notion that drugs with low Vd will not exhibit PMR. These studies show 
C/P ratios are a good indicator of whether a drug exhibits PMR and should be considered 
when interpreting drug concentrations. While C/P ratios provide insight about a drug’s 
PMR potential, it is not the only indicator.  
Another approach involves the liver to peripheral blood (L/P) ratio (53, 197, 201, 
211). L/P ratios for drugs that are known to exhibit PMR are reported to exceed 20, whereas 
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drugs that do not are often less than 5, allowing for easy differentiation of drugs that exhibit 
PMR, from those that do not (53, 211). However, caution should be taken when interpreting 
liver concentrations because the liver can also show concentration changes as a result of 
PMR. Pounder et. al. determined that over time the left side of the liver (closest to the 
stomach) can have artificially elevated drug concentrations due to drug presence in the 
stomach. They recommended obtaining liver samples from within the right lobe of the liver 
to avoid contamination from surrounding tissues (197, 209). Although both C/P and L/P 
ratios have been proposed, conclusions should not be drawn from single cases. This is 
evidenced by the wide range of values in multiple studies, and the potential for time-
dependent effects, as well as site-dependent variation (199, 202, 210).  
Time of sample collection after death is an additional factor that complicates 
postmortem toxicology interpretation. The postmortem interval between time of death and 
sampling can impact drug concentration (196, 198, 212). Bacteria present during 
putrefaction can degrade drugs, therefore lowering concentrations. Drug stability also can 
significantly impact concentration at time of analysis (199, 201). As postmortem blood 
becomes more acidic after cell lysis, acid-labile drugs may degrade disproportionately, 
while others are preserved. Conditions and elements the body may be exposed to 
immediately after death can also cause drug concentration to decrease through evaporation 
or degradation (199, 212). Examples include amphetamine and methamphetamine. These 
drugs have been shown to be unstable and degrade in postmortem samples. They also 
exhibit PMR (199, 202, 212, 213). With methamphetamine and amphetamine being closely 
related to synthetic cathinones, information about these drugs can provide insight into the 
postmortem redistribution potential of new designer drugs.  
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Methamphetamine and MDMA are structurally similar to synthetic cathinones, 
with methamphetamine and MDMA being most similar to methcathinone and methylone, 
respectively. MDMA and methamphetamine are basic drugs (pKa 9.9) with relatively large 
volumes of distribution (Vd, 3 to 7 L/kg) (17, 214). Plasma protein binding is 
approximately 65% for MDMA and 10-20% for methamphetamine (17, 214, 215). These 
physico-chemical properties would indicate that both drugs exhibit some degree of PMR, 
with MDMA exhibiting more than methamphetamine due to the high percentage of drug 
released as proteins degrade and bound drugs are released. PMR potential of these drugs 
has been supported by tissue distribution studies (199, 211, 213, 216-218). Barnhart et. al. 
examined PMR potential in 20 cases involving methamphetamine and discovered that in 
every case, the peripheral blood concentration was lower than central blood. In five cases, 
cardiac muscle was available and the concentration of the cardiac muscle was higher than 
both peripheral and central blood, indicating the elevated central blood could be the result 
of redistribution of methamphetamine from the cardiac tissue (213). The average C/P ratio 
for the 20 cases was 2.2. Further investigation of PMR of methamphetamine examined 
results of 18 methamphetamine positive cases containing peripheral blood, central blood, 
vitreous humor, and liver samples (211). Almost all cases had an equal or higher 
concentration in central blood compared to peripheral blood, with the exception of one 
case, where central blood was 0.25 mg/L and peripheral was 0.26 mg/L. This is concordant 
with the previous study. McIntyre et. al. also investigated the relationship of liver and 
vitreous concentration to peripheral blood. Both matrices exhibited higher 
methamphetamine concentrations than peripheral blood. They concluded that 
methamphetamine does exhibit PMR and that vitreous fluid or liver may be a viable sample 
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source if blood is unavailable (211). The average C/P and L/P ratios for these 18 cases were 
1.6 and 5.7, respectively. Based on these two studies with large sample sizes, 
methamphetamine exhibits PMR due to drug diffusion from cardiac tissue to central blood 
sources.  
De Letter et. al. performed comprehensive analysis on numerous samples obtained 
from MDMA positive cases (216-218). They noted higher concentrations of MDMA in 
samples obtained from the central cavity, blood and tissue, rather than peripheral sources. 
The suspected sources that contributed to the elevated concentrations in the central cavity 
were the lungs, stomach contents, and liver. They recommended caution and to avoid 
sampling in areas adjacent to those tissues. C/P and L/P values that could be extrapolated 
from their data ranged from 1.4 to 4.2 and 7.7 to 8.5, respectively (218). C/P and L/P ratios 
for MDMA and methamphetamine are listed in Table 1.11. These high ratios suggest that 
MDMA would exhibit PMR. Given the structural similarity of the synthetic cathinones 
with both MDMA and methamphetamine, it is entirely possible that some drugs within the 
class are susceptible to PMR. 
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Table 1.11. C/P and L/P ratios for amphetamine, methamphetamine, and MDMA.  
Drug Cause of Death Matrix (Concentration) C/P L/P (L/kg or 
mL/g) 
Reference 
Amphetamine  Drug Intoxication: 
Fatal Ingestion 
PB: 0.4 mg/L 
CB: 0.7 mg/L 
L: 0.9 mg/kg 
1.6 2.0 (219) 
Amphetamine 
(n=17) 
Not Specified PB: 0.02 – 218 mg/L 
CB: 0.02 – 0.3 mg/L 
L: 0.1 – 0.9 mg/kg 
0.5 – 2.5,  
Avg: 1.6 
2.8 – 14.9,  
Avg: 8.1 
(211) 
Methamphetamine Drug Intoxication: 
Fatal Ingestion 
PB: 54 mg/L 
CB: 66 mg/L 
L: 91 mg/kg 
1.2 1.7 (219) 
Methamphetamine 
(n=18) 
Not Specified  PB: 0.2 – 1.7 mg/L 
CB: 0.3 – 2.4 mg/L 
L: 0.9 – 12 mg/kg 
0.9 – 2.4,  
Avg: 1.6 





Not Specified PB: 0.14 – 4 µg/mL 
CB: 0.04 – 9 µg/mL 
1.2 – 5.8,  
Avg: 2.2 
N/A (213) 
MDMA Not Specified TB: 0.5 mg/L 
Left arm blood: 0.5 mg/L 
0.9 N/A (220) 
MDMA Hyperpyrexia FB: 2.3 mg/L 
JB: 3.0 mg/L 
1.3 N/A (220) 
MDMA Not Specified Left FB: 7.3 mg/L 





     (continued) 
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Drug Cause of Death Matrix (Concentration) C/P L/P (L/kg or 
mL/g) 
Reference 
      
MDMA Drug Intoxication FB: 1,129 µg/L 
IVCB: 1,801 µg/L 
L: 8,904 µg/kg 
1.6 7.9 (216) 
MDMA Drug Intoxication  HB: 11 mg/L 
FB: 2.8 mg/L 
L: 20 mg/kg 
3.9 7.2 (221) 
MDMA Suicide: Hanging FB: 0.6 mg/L 
L: 1.8 mg/kg 
N/A 3.1 (221) 
MDMA Not Specified FB: 13 µg/mL 
Right atrial blood: 57 
µg/mL 
L: 104 µg/g 
4.2 7.7 (217) 
MDMA Not Specified FB: 3.1 µg/mL 
L: 26 µg/g 
AB: 4.4 µg/mL 
1.4 8.5 (218) 
Aorta blood (AB); Femoral blood (FB); Liver (L); Inferior vena cava blood (IVCB); Heart blood (HB); Central blood (CB); Peripheral 
blood (PB); N/A: not applicable
69 
     
Physico-chemical properties including Vd, pKa and protein binding are unknown 
for many synthetic cathinones. Table 1.12 summarizes the known pKa values for ten 
cathinones (17). Despite their structural similarity they span almost two pH units (pKa, 
7.2 to 8.9). Even less is known concerning the volume of distribution, and protein binding 
has only been documented for a few synthetic cathinones: methylone (30%), mephedrone 
(22%) (18, 222). The absence of this information further complicates the prediction of 
PMR.  













From fatality case studies reporting tissue distribution, C/P and L/P values can be 
calculated for select synthetic cathinones (Table 1.13). Marinetti and Antonides reported 
C/P values in five of their postmortem cases, where four of the cases involved MPDV and 
the fifth involved pyrovalerone. Cause of the death included drug intoxication, suicide by 
hanging, and natural causes. C/P values for MDPV ranged from 1.3 to 1.7, with an average 
of 1.5. The case involving pyrovalerone was accidental, with a C/P value of 1.4 (123). 
Liver concentrations were also reported for many cases. Seven cases included a peripheral 
blood source and liver sample, which allowed for L/P values to be estimated. Six of the 
cases involved MDPV. MDPV L/P ratios ranged from 2.5 to 23, with an average L/P ratio 
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of 9.9. The seventh case involved pyrovalerone, which had an L/P ratio of 2.9. McIntyre 
discussed C/P and L/P ratios in their two cases studies involving methylone and ethylone. 
The C/P and L/P ratios for ethylone were 1.0 and 3.6, respectively (53). The C/P and L/P 
ratios for methylone were 1.0 and 3.2, respectively (52). Based on the C/P ratios from these 
cases, MDPV, methylone, ethylone and pyrovalerone should exhibit minimum post 
mortem redistribution. With the exception of MDPV, the L/P ratios are <5, indicating there 
is minimum potential for PMR.  
Although C/P and L/P ratios were not discussed, additional studies reported central 
blood, peripheral blood, and liver concentrations for α-PVP, methylone, MDPV, and 
pentedrone. (58, 59, 63, 67, 113, 121, 186).  The estimated C/P and L/P ratios from an 
additional study involving MDPV and methylone are in concordance with the 
aforementioned studies (58, 59, 113, 186). The three studies investigating α-PVP related 
fatalities had similar L/P ratios, ranging from 1.0 to 2.9 (63, 67, 121). Only one case 
reported central and peripheral blood concentrations for α-PVP (C/P ratios of 1.4 using 
right heart blood and 1.5 using left heart blood from the same individual) (121). Both C/P 
and L/P ratios indicate that α-PVP, like the other cathinones, had a minimal potential for 
PMR. The last case study involved pentedrone, and only an L/P ratio could be calculated, 
which was 11 (63). This value is between the guidelines for L/P ratio interpretation 
proposed by McIntyre. More importantly, conclusions drawn from a single case report have 
limited value, for the reasons described earlier.  Existing studies indicate that the potential 
for this group of novel psychoactive substances to redistribute is minimal based on C/P 
ratios less than 2 and, on average, low L/P ratios. However, more research is needed.
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Table 1.13. C/P and L/P ratios for synthetic cathinones.  
Cathinone Cause of Death Matrix (Concentration) C/P L/P (L/kg) Reference 
MDPV Drug Intoxication PB: 162 ng/mL 
HB: 280 ng/mL 
L: 3,720 ng/g 
1.7 23 (123) 
Drug Intoxication  PB: 18 ng/mL 
HB: 28 ng/mL  
L: 52 ng/g 
1.6 2.9 (123) 
Drug Intoxication FB: 129 ng/mL 
L: 388 ng/g 
N/A 3.0 (123) 
Suicide  PB: 102 ng/mL 
HB: 133 ng/mL 
L: 256 ng/g 
1.3 2.5 (123) 
Natural PB: 36 ng/mL 
HB: 56 ng/mL 
L: 668 ng/g 
1.6 19 (123) 
Suicide  FB: 640 ng/mL 
L: 6,080 ng/g 
N/A 9.5 (123) 
Drug Intoxication FB: 440 ng/mL 
HB: 500 ng/mL 
L: 980 ng/g 
1.4 2.2 (113) 
Drug Intoxication HB: 0.7 mg/L 
PB: 1.0 mg/mL 
0.7  N/A (185) 
     (continued) 
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Cathinone Cause of Death Matrix (Concentration) C/P L/P (L/kg) Reference 
Pyrovalerone Autoerotic Asphyxia FB: 42 ng/mL 
HB: 59 ng/mL 
L: 124 ng/g 
1.4 3.0 (123) 
α-PVP 
 
Drug Intoxication PB: 174 ng/mL 
L: 190 ng/g 
N/A 1.1  (67) 
α-PVP Poisoning Right HB: 458 ng/mL 
Left HB: 442 ng/mL  
FB: 654 ng/mL 




Drug Intoxication PB: 901 ng/mL 
L: 2,610 ng/g 
N/A 2.9 (63) 
Methylone Drug Intoxication PB: 0.50 mg/L 
L: 1.47 mg/kg 
N/A 2.9 (186) 
 Drug Intoxication PB: 0.84 mg/L 
HB: 1.0 mg/L 
1.2 N/A (59) 
 Drug Intoxication PB: 0.56 mg/L 
HB: 0.58 mg/L 
L: 0.88 mg/kg 
1.0 1.6 (59) 
 Drowning  PB: 3.4 mg/L 
CB: 3.4 mg/L 
L: 11 mg/kg 
1.0 3.2 (52) 
 Drug Intoxication PB: 0.67 mg/L 
CB: 0.74 mg/L 
L: 1.8 mg/kg 
1.1 2.7 (58) 
     (continued) 
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Cathinone Cause of Death Matrix (Concentration) C/P L/P (L/kg) Reference 
 Drug Intoxication PB: 3.13 mg/L 
CB: 6.64 mg/L 
2.1 N/A (118) 
Pentedrone Drug Intoxication PB: 8,794 ng/mL 
L: 100,044 ng/g 
N/A 11 (63) 
Ethylone Drug Intoxication PB: 0.39 mg/L 
CB: 0.38 mg/L 
L: 1.4 mg/kg 
1.0 3.6 (53) 
Butylone Drug Intoxication FB: 20 mg/L 
L: 33 mg/kg 
N/A 1.7 (105) 
N/A: Not applicable 
 
74 
     
Cathinone Stability 
In order to properly interpret toxicological results, the stability of the suspected 
drug should be understood. Qualitative and quantitative analysis of a sample reveals the 
presence and concentration of a drug at the time of analysis, not necessarily at the time of 
interest. This has important consequences for both antemortem and postmortem 
investigations, whereby times of interest may be the time of an alleged sexual assault or 
driving, versus the concentration immediately prior to death. The time between collection 
and analysis can differ by days, weeks, or months and may have significant implications. 
During that time, many factors can cause the concentration of a drug to change 
significantly, or result in a negative or inconclusive finding. These factors include exposure 
to unfavorable (elevated) temperatures, specimen pH or the biological matrix, and the 
chemical properties of the drug. Certain functional groups, those with a tendency to become 
oxidized or reduced, result in a more unstable drug. The stability of common illicit drugs 
is widely understood (223), however this information is relatively limited for novel 
psychoactive substances, including synthetic cathinones. 
Non-biological Stability 
The instability of cathinone, the natural precursor to synthetic cathinones, has been 
documented since the early 1980s. Szendrei was the first to characterize the stimulant 
component in the khat plant, reporting that cathinone was highly unstable in the presence 
of oxygen and in alkaline conditions (224). In 1981, Berrang et. al. determined that 
cathinone would dimerize or racemize unless stabilized by an acid, further indicating that 
cathinone was unstable in basic conditions (225). The instability of cathinone in basic and 
oxygenated conditions had prevented its isolation and identification until the 1980s, despite 
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khat being studied years earlier. In order to isolate and identify cathinone, these two studies 
used fresh plant material that had been freeze dried and frozen until analysis. Thirty years 
later, in 2010, Chappell and Lee reported that cathinone converted to cathine, the less 
psychoactive component, during the drying process. In order to prevent that conversion, 
the harvested plant material should be air-dried or freeze-dried and stored at ambient or 
cold temperatures. Once dried and stored, cathinone was detectable over 10 years in the 
plant material, with a 2-3% loss a year when stored at ambient temperature (226).  
Like their precursor, synthetic cathinones as a hydrochloric salt powder, are also 
highly unstable when exposed to oxygen. This was demonstrated by Tsujikawa et. al. using 
ten cathinone derivatives: α-pyrrolidinoheptanophenone (α-PHPP), α-PVP, α-
pyrrolidinobutiophenone (α-PBP), α-pyrrolidinopropiophenone (α-PPP), 4-fluoro-α-
pyrrolidinovalerophenone (4-F-PVP), 4-methyoxy- α-pyrrolidinopropiophenone (4-MeO-
PVP), pyrovalerone, MDPV, N-ethylpentedrone, and pentedrone. They concluded that 
decomposition of the powder occurred mainly at the surface. Furthermore, using α-PHPP, 
two decomposition products were identified: 2”-oxo- α-PHPP and α-PHPP-N-oxide. From 
the ten synthetic cathinones, conclusions were drawn regarding stability as it related to the 
various functional groups, including alkyl chain length, benzene ring substituents, and 
secondary or tertiary amine. After the powders had been exposed to air for 24 hours, the 
two synthetic cathinones with the lowest residual ratio (<10% remaining) were α-PHPP (a 
tertiary amine cathinone with a seven-carbon alkyl chain, and no benzene ring substituent) 
and pyrovalerone (a tertiary amine cathinone with a five carbon alkyl chain and methyl 
group on the benzene ring). The synthetic cathinone with the least amount of 
decomposition (61% residual ratio) was pentedrone, a N-methylated cathinone with a five-
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carbon alkyl chain and no benzene ring substituent.  The remaining seven synthetic 
cathinones had residual ratios between 20 and 32%. It was concluded that structure was 
related to the stability of these drugs and tertiary amine cathinone appear to be more liable 
when exposed to oxygen (227).  
Tsujikawa et. al. also investigated the stability of synthetic cathinones at various 
pH in aqueous solution. Seven synthetic cathinones were evaluated, including mephedrone, 
4-FMC, 3-FMC, 2-FMC, 4-methyoxymethcathinone (4-MeOMC), ethcathinone, and N,N-
dimethylcathinone (DMC). The synthetic cathinones were stored in aqueous buffers at pH 
4, 7, 10, and 12 at ambient temperature. All seven were highly unstable in basic pH 
solutions (<50% remaining after 12 hours of storage with the exception of 4-MeOMC and 
DMC). The most stable was DMC, with over 90% remaining after 12 hours of storage at 
pH 12 and the least stable was 2-FMC, with less than 10% remaining at pH 7. All had over 
99% remaining in the pH 4 solution. Adding an antioxidant (l-ascorbic acid or sodium 
sulfite) to the pH 12 solution significantly decreased the amount of degradation that 
occurred, indicating the presence of oxygen in the solution contributed to degradation of 
these drugs (228). Maskell et. al. investigated the stability of mephedrone in formalin (5, 
10, and 20%) at various pH (pH 3.5, 7 and 9.5) over 28 days. Mephedrone was highly 
unstable at pH 7 and 9.5, with less than 20% remaining by day 3 in both solutions. Due to 
the unstable nature of mephedrone at basic pH, influence of formalin concentration was 
insignificant. However, at acidic pH, where mephedrone has shown to be stable, the 




     
Biological Stability 
After the identification of cathinone in the 1980s, analysis of cathinone and its 
derivatives in biological fluids did not progress until the early 2000s. Many of the stability 
studies were incorporated into the cathinone method validations using GC or LC. As early 
as 1989, Morad et. al. determined that cathinone was unstable during the extraction process 
of plasma for an HPLC analysis method. To preserve cathinone during the extraction 
process, it was necessary to acidify the solvents prior to evaporation (230). In the early 
2000s, Paul and Cole investigated the stability of methcathinone and cathinone in urine 
during the development of their GC-MS detection procedure. Specimens were stored at 2-
4°C and -18°C for three months. Losses of almost 80% were observed when stored at 2-
4°C for three months, and significant losses were observed by day four. Significant losses 
were observed after two months of storage at -18°C. They also noted that oxidizing agents 
should not be used during the extraction process or cathinones will be oxidized to benzoic 
acid (30). 
Concheiro et. al. developed a LC-HRMS method for the quantification of 24 
synthetic cathinones and four metabolites in urine using a Q-Exactive™ mass 
spectrometer. Unpreserved urine (pH 7.6) was fortified with the 28 analytes at two 
concentrations (3 and 300 ng/mL) and stored at room temperature for 24 hours and 4°C for 
72 hours. Overall, losses were comparable between the low and high concentration at each 
storage temperature and time. All were stable when stored at 4°C for 72 hours, except 
benzedrone (-27% difference). However, instability was observed for over half of the 
analytes after 24 hours of storage at room temperature, with significant losses observed 
over all defined analyte groups. While significant losses were observed in all groups, the 
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majority of pyrrolidinyl-substituted cathinones and metabolites were stable. The authors 
concluded that the presence of the pyrrolidine group and the conversion of the β-ketone to 
a hydroxyl in metabolites increased the stability (48). Conchiero et. al. also published a 
method for the determination of 40 novel psychoactive substances in urine and included 
four new cathinones in addition to the 28 investigated previously. As part of the validation, 
these new drugs were subjected to the same experimental conditions as the original 28. The 
four additional cathinones were all pyrrolidinyl-substituted and no instability was observed 
in any of the conditions (47).   
Al-Saffer et. al. developed a screening method for LC-MS/MS for the detection of 
25 novel psychoactive substances, including 11 synthetic cathinones, in urine. During 
validation, stability of the compounds was assessed over three months of storage at 22°C, 
6°C, and -20°C. Drug-free urine (pH not specified) was fortified at 1,000 ng/mL with all 
25 compounds. Over time, the most extreme losses occurred at 22°C, with 3-FMC 
exhibiting the highest loss and pyrrolidine-type cathinones exhibiting the least (76). At 6 
and -20°C, the pyrrolidine-type cathinones were the most stable, with losses remaining 
within 20% of the original concentration. After extended storage (3 months) at 6°C the 
remaining cathinones had <15% remaining. While frozen storage did not prevent 
degradation, many remain within 20% of the starting concentration. Overall, MDPV was 
consistently the most stable cathinone of the 11 investigated and either buphedrone or 3-
FMC was the least stable. As a group, the synthetic cathinones were generally less stable 
at every condition than the other novel psychoactive substances investigated, except for 4-
hydroxy-N-methyl-N-ethyltrptamine (4-OH-MET), which was less stable than any of the 
cathinones (76).  
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Methods have also been developed for the detection of these drugs in blood. 
Sorenson developed a method for the determination of fifteen cathinones and related 
ephedrines in blood using LC-MS/MS. Of the fifteen drugs investigated, eight were 
cathinone derivatives. During the development, stability was assessed for A) pH of the 
final blood sample extract, B) blood preserved with NaF/potassium oxalate, and C) blood 
preserved with NaF/citrate buffer (71). The blood preserved with NaF/potassium oxalate 
resulted in a final pH of 7.4, whereas the blood preserved with NaF/citrate buffer had a 
final pH of 5.9. The final sample extracts were stored for one week at 20°C. The preserved 
blood was stored at 20°C and 5°C for one week. The results of their study demonstrated 
that the stability of these drugs was pH dependent. Final sample extracts had pH values 
ranging from 2.5 to 8. No significant degradation was observed in extracts with a pH of 4.5 
and lower. Significant degradation was observed at pH values greater than 5.5. The same 
held true for the blood samples; cathinones in the blood preserved with NaF/citrate buffer 
had less degradation occur than the blood preserved with NaF/potassium oxalate at both 
temperatures. After two days of storage, all cathinones had at least a 30% loss in the 
potassium oxalate blood, compared to 10% loss in the citrate buffer blood (71).  
Ammann et. al. investigated processed sample stability, freeze-thaw stability and 
short-term stability over 6 weeks. Using LC-MS/MS, 25 synthetic cathinone and 
ephedrines were evaluated in blood. Blood specimens and extracts were stored at 4°C. The 
extracts for the processed sample stability were stable for over 24 hours. In stored blood, 
all drugs met the acceptance criteria of within 80-120% of controls in the short-term and 
freeze-thaw experiments (77).  
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While the stability of some synthetic cathinones have been reported, findings are 
often incidental, short-term or limited in scope due to the fact that they have been 
incorporated into method development and validation studies. However, Johnson and 
Botch-Jones investigated the stability of MDPV and mephedrone, a tertiary and secondary 
amine cathinone, respectively, using HPLC-QTrap. Urine, blood, and serum were fortified 
with all four drugs at 1,000 ng/mL and stored at 22, 4, and -20°C for two weeks. MDPV 
was within 20% of initial concentration in all matrices at all temperatures over the two 
week period, while mephedrone was only stable at -20°C. At 4°C, mephedrone remained 
within 20% of the initial concentration in plasma and urine, but there was a 30% loss on 
day 7 and over 50% loss after 14 days in blood. At 22°C, mephedrone was unstable in all 
three matrices: in whole blood by day two with approximately 30% loss, in plasma by day 
4 with a 90% loss, and urine at day 7 with an approximate 35% loss. After 14 days 
mephedrone was undetectable in blood and plasma, and had over a 50% loss in urine. The 
pH of the urine was unspecified, however, based on the previous studies these results are 
more comparable to an acidic urine (<pH 6) (117). These results also highlight the 
stabilizing effect of the pyrrolidinyl group on MDPV compared to the secondary amine in 
mephedrone. 
Soh and Elliot investigated the stability of thirteen novel psychoactive substances, 
including one secondary amine cathinone, 4-MEC. The stability of the drugs was 
investigated in blood and plasma stored at 20°C for at least 28 days using HPLC-DAD 
analysis. Included in their investigation was the identification of degradation products 
using LC-MS/MS and UHPLC-Q/TOF-MS. 4-MEC was more stable in plasma compared 
to blood. After seven days of storage, there was a 92% loss in blood compared to 50% in 
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plasma. After 14 days, 4-MEC was undetectable in blood, but remained detectable in 
plasma over the 28 day period. The HPLC-DAD analysis revealed the presence of a peak 
at a difference wavelength (212 nm) compared to 4-MEC (262 nm). LC-MS/MS and 
Q/TOF-MS analysis determined it was most likely dihydro-4-MEC, as a result of the beta-
ketone being reduced to a hydroxyl (104).  
Busardo et. al. investigated the stability of mephedrone in antemortem (AM) and 
postmortem (PM) blood. AM and PM blood were pooled, fortified at 1 mg/mL, and stored 
at 20°C, 4°C, and -20°C. The effect a preservative on mephedrone stability was also 
investigated. PM and AM blood was either unpreserved, preserved with 3% 
ethylenediaminetetraacetic acid (EDTA), or preserved with 1.67%/0.2% sodium 
fluoride/potassium oxalate (NaF/KOx). The final pH of the blood was not stated after the 
addition of the preservative. Samples were stored for six months. Mephedrone was found 
to be most stable when stored at -20°C and least stable at 20°C. The blood with no 
preservative exhibited more degradation than either of the preservatives. Mephedrone in 
the blood preserved with NaF/KOx was the most stable over the six months. Mephedrone 
was detectable for over 87 days in PM blood preserved with NaF/KOx compared to 80 
days when preserved with EDTA. Comparing antemortem to postmortem blood, 
mephedrone was more stable in antemortem blood (91). From their findings, in order to 
prevent mephedrone from degrading in blood, antemortem or postmortem samples should 
be preserved with NaF/KOx and stored at -20°C. The two common additives are contained 
in grey-top evaluated blood tubes.  
While most published studies focus on urine and blood, toxicologists analyze a 
variety of matrices. Miller et. al. investigated the stability of ten synthetic cathinones in 
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oral fluid (OF). OF specimens examined consisted of neat (unpreserved) OF (pH 8), OF-
Quantisal® (pH 6), and OF-Oral-Eze (pH 7). Specimens were stored at room temperature, 
4°C, and -20°C for one month. OF was fortified at 2.5 and 150 ng/mL. Their findings 
revealed that all ten cathinones were most stable in Quantisal and least stable in neat OF 
stored at room temperature and 4°C. All synthetic cathinones were stable in the three OF 
mixtures when stored at -20°C. As with the previous studies, MDPV (a tertiary amine 
cathinone containing the pyrrolidinyl group) was the most stable out of the 10, followed 
by α-PVP. Cathinone, methcathinone, ethcathinone were among the least stable. Despite 
being a tertiary amine cathinone, naphyrone also was considerably unstable, indicating that 
the naphthyl group may influence the stability of this particular cathinone more so than the 
stabilizing pyrrolidinyl group (65). A comprehensive list of stability studies related to non-
biological and biological material can be found in Table 1.14.  
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Table 1.14. Summary of cathinone and synthetic cathinones stability studies in non-biological and biological matrices. 






Cathinone Dried plant Not Specified Not 
Specified 
Unstable in basic conditions 




Not Specified Not 
Specified 
Unstable in basic conditions 
Racemizes and dimerizes 
(225) 
Cathinone Dried plant Room Temperature 10 years Stable when air-dried 
Cathinone conversion to cathine occurs 
in drying process 
(226) 
10 cathinones Hydrochloric salts Room Temperature 24 hours Unstable in air 
Structural dependence  
Identification of 2”-oxo and N-oxide 
for α-PHPP 
(227) 
7 cathinones Aqueous buffers  
(pH 4, 7, 10, 12) 
22°C 48 hours Degradation dependent on pH 
Degradation dependent on chemical 
structure 
Identification of 3 degradation products 
for 4-MMC 
(228) 
Mephedrone Formalin solution  
(5, 10, 20%)  
pH  
(3.5, 7, 9.5) 
Not Specified  28 days Degradation was pH dependent 
Presence of formalin resulted in 
degradation 
More degradation occurred in higher 
concentration of formalin  
(229) 
    (continued) 
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Cathinone Plasma N/A N/A Stable in salt form only 
Dimerizes after solvent is removed 




Urine 2 - 4°C 
-18°C 
3 months Both stable for 3 days at 2-4°C 
Both stable for 2 months at -18°C 
(30) 
32 Cathinones Urine (pH 7.6) Room temperature 
4°C 
72 hours Instability at Room Temp. after 24 
hours 
Stable at 4C for 72 hrs except 
benzedrone, 4-FMC, naphyrone 
Hydroxyl metabolites and pyrrolidinyl 
derivatives most stable 
(47, 48) 
11 cathinones Urine 22°C 
6°C 
-20°C 
3 months Instability occurred at all temperatures 
MDPV consistently most stable 
Buphedrone and 3-FMC least stable 
(76) 
8 cathinones Preserved blood: 
NaF/KOx (pH 7.4) 
NaF/Cit (pH 5.9) 
20°C 
5°C 
7 days More stable at 5°C 
More stable in NaF/KOx 
(71) 
25 cathinones  Blood 4°C 6 weeks All stable (77) 
     (continued) 
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14 days Matrix and storage temperature 
significant  
More stable in urine, followed by 
plasma 
More stable at -20°C 




20 - 23°C 37 days More stable in plasma 
Identification of dihydro-4-MEC 
(104) 







6 months More stable in NaF/KOx 
More stable at -20°C 
AM more stable than PM  
(91) 







One month More stable in Quantisal at room 
temperature and 4°C 





Synthetic Cathinone Degradation 
In addition to providing information regarding the stability of these novel drugs, 
some studies further investigated products that remain after the parent drug degraded. 
While information is limited, degradation products and pathways have been proposed (104, 
227-229). It was shown several decades ago that cathinones can be easily oxidized and lost 
during extraction. The result of this oxidation is dimerization to dimethyldiphenylpyrazine 
or benzoic acid (23, 225). While these may not be directly related to degradation in 
biological matrices, the majority of biological samples are subjected to sample preparation 
and extraction, possibly leading to the formation of these decomposition products.  
Some of the degradation products that form as the result of drug breakdown during 
long term storage overlap with identified metabolites. As a result, degradation product 
determination can be challenging. Most degradation studies have been completed using 
non-biological matrices, including aqueous or formalin solutions, while just a few having 
been involved a biological matrix (104, 228, 229). Dihydro-4-MEC was proposed as a 
degradation product by Soh and Elliott, however, their analysis was completed in plasma 
and blood. Therefore the formation of this product could be the result of metabolism (104). 
However, 4-MEC is known to have more than one metabolite and no other metabolites 
were identified in their sample. It was noted that the decrease of 4-MEC and increase in 
the dihydro- breakdown product was not proportional (104). This lack of relationship could 
indicate that the dihydro breakdown product is minor compared to other, undetected, 
products.  
Another common degradation product and metabolite is the formation of 2”-oxo 
derivatives for cathinones bearing a tertiary amine. The formation of a 2”-oxo species was 
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identified for α-PVP, MDPV, and pyrovalerone (227). This was identified from powders 
exposed to air, therefore the formation of this product was not attributed to metabolism. 
This analysis also revealed the formation of N-oxide degradation product for the tertiary 
amines and N-dealkylation for the secondary amine cathinone, pentedrone (227). The 






















Figure 1.12. Degradation pathway for tertiary amine cathinones (227). 
 
Aqueous solutions and formalin solutions were used to investigate the breakdown 
of mephedrone (228, 229). Tsujikawa et. al. proposed a three-step degradation path for 
mephedrone, beginning with oxidative deamination to form propanedione (Figure 1.13A). 
The propanedione is further oxidized and cleaved to form benzoic acid (Figure 1.13B), 
which then forms benzamide through amidation (Figure 1.13C) (228). Benzamide was the 
most abundant degradant while the others increased then decreased in abundance over the 
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48 hour period. Maskell et. al. reported the formation of a N-alkylated degradation product 
when mephedrone was in formalin solution (229). The degradation products and pathways 
for secondary amine synthetic cathinones are depicted in Figure 1.13 and all identified 
























































Table 1.15. Identified degradation products for select synthetic cathinones. 
Cathinone Degradation Product Reference 













Benzoic Acid (228) 
N-alkylation (229) 
 
Statement of the Problem 
The instability of cathinone was initially documented in the 1980s and the 
investigation of the derivatives’ stability in multiple matrices has received increased 
attention over the last decade due to a rise in cathinone related fatalities. From these studies, 
it can be concluded that synthetic cathinone stability is significantly influenced by pH, 
storage temperature, and chemical structure. However, as Miller et. al. noted, their study 
was limited due to a lack of authentic samples (65). While many of the studies, particularly 
those included in method development, had authentic samples, stability was not 
investigated. Another limitation was storage time. Most studies had a maximum storage 
time of only one month. Only Busardo et. al. stored their mephedrone fortified blood for 
six months.  Due to forensic backlogs, specimens may be stored for several weeks and 
sometimes months. During this time, not only can the concentration of the drug decrease, 
but the pH of the specimen could potentially change. Urinary pH has been shown to 
increase over 2 pH units after room temperature storage for one day. This could be 
problematic for alkaline labile drugs. This rise in pH is thought to be the result of carbon 
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dioxide loss from the breakdown of urea and uric acid (231, 232). Changes in urinary pH 
are minimized at cooler storage temperatures.  
A final factor that can be concluded from these studies is the influence of chemical 
characteristics. It has been suggested that synthetic cathinones containing the pyrrolidinyl 
group are relatively stable under some conditions. However, the majority of studies 
investigated only a limited number of cathinones. To fully understand how structural 
features of the cathinone species influence stability in biological evidence, a 
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CHAPTER II 
IDENTIFICATION AND QUANTIFICATION OF SYNTHETIC CATHINONES 
IN BLOOD AND URINE USING LIQUID CHROMATOGRAPHY-

















This dissertation follows the style and format of The Journal of Analytical Toxicology. 
 
1Glicksberg L., Bryand K., Kerrigan S. (2016). Journal of Chromatography B, 1035, 91-
103. 
Reprinted with permission of publisher.   
125 
   
Abstract 
Synthetic cathinones continue to present a formidable challenge to forensic 
toxicology laboratories despite the fact that they are often encountered in impaired driving 
and death investigations. Due to limitations in immunoassay-based screening technologies, 
many forensic toxicology laboratories must rely on more labor intensive chromatographic-
based screening approaches in order to detect these drugs in biological evidence. Solid 
phase extraction (SPE) and liquid chromatography-quadrupole/time of flight (LC-Q/TOF) 
mass spectrometry were used to identify twenty-two synthetic cathinones in urine and 
blood. Target drugs included methcathinone, ethcathinone, pentedrone, buphedrone, 3-
fluoromethcathinone (3-FMC), 4-fluoromethcathinone (4-FMC), 4-methylethcathinone 
(4-MEC), 4-ethylmethcathinone (4-EMC), mephedrone, methedrone, 3,4-
dimethylmethcathinone (3,4-DMMC), ethylone, butylone, pentylone, eutylone, 
methylone, methylenedioxypyrovalerone (MDPV), 4-methylpyrrolidinobutiophenone 
(MPBP), 3,4-methylenedioxypyrrolidinobutiophenone (MDPBP), α-
pyrrolidinopentiphenone (α-PVP), pyrovalerone, and naphyrone. A total of nine deuterated 
internal standards were employed. Using traditional reversed phase chromatography all 
positional isomers, including 3-FMC and 4-FMC, were separated in 12 mins. The 
procedure was validated in accordance with the Scientific Working Group for Forensic 
Toxicology (SWGTOX) Standard Practices for Method Validation. Extraction efficiencies 
were 84-104% and 81-93% in urine and blood, respectively. Limits of quantitation in both 
matrices were 0.25 – 5 ng/mL. Precision, bias and matrix effect were all within acceptable 
thresholds and the assay was free from more than fifty interferences. The validated method 
was used to identify cathinones in authentic urine case samples (n=20) and these results 
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highlight important considerations for cathinone stability and the subsequent interpretation 
of results.  
 
Keywords:   Cathinone, Designer drug, Liquid chromatography-mass spectrometry, High 
resolution mass spectrometry
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IDENTIFICATION AND QUANTIFICATION OF SYNTHETIC CATHINONES 
IN BLOOD AND URINE USING LIQUID CHROMATOGRAPHY-
QUADRUPOLE/TIME OF FLIGHT (LC-Q/TOF) MASS SPECTROMETRY 
Introduction 
The proliferation of new psychoactive substances (NPSs) continues to present a 
variety of challenges from both a public health and public safety standpoint. Abuse of NPSs 
has increased significantly in recent years and many drugs within this class are now well-
established as recreational drugs. This is certainly true of the synthetic cannabinoids and 
cathinones, both of which have had far-reaching consequences on the field of forensic 
toxicology over the past decade.  
The sought after effects of synthetic cathinones are similar to those of other 
stimulants and may include increased energy, mood enhancement, exhilaration and 
psychoactive effects. Adverse effects include panic attacks, tremors, depression and 
psychosis. Synthetic cathinones are also associated with neurological, cardiovascular and 
psychopathological symptoms such as tachycardia, hallucinations, delusions, violence, 
aggressive tendencies and death (1-3). Due to the severity of these adverse consequences 
and an increase in synthetic cathinone-related emergency room visits and fatal 
intoxications, the Drug Enforcement Administration (DEA) has scheduled more than a 
dozen synthetic cathinones since 2011 (4, 5). Enforcement actions are often confounded 
by the swift appearance of new analogs. For this reason, many states have legislatively 
enforced “general class bans” as part of an ongoing effort to discourage cathinone abuse 
(6). 
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Despite efforts to curb their appeal, synthetic cathinone use is now widespread and 
there are numerous reports of their involvement in criminal and death investigations. The 
proliferation of these new drugs presents a significant challenge to forensic toxicology 
laboratories. The rate at which new drugs are being introduced can significantly outpace 
the ability of many forensic toxicology laboratories to develop and validate methods of 
analysis. Moreover, many of the newer drugs are not readily detected using traditional 
approaches for screening and confirmation and may require more specialized and costly 
instrumental techniques.  
Immunoassay screening has not proven effective for the large number of drugs 
within the synthetic cathinone class. Antibody cross-reactivity using commercial 
amphetamine-based immunoassays are highly variable (7, 8). While biochip array and 
antibody-based assays have been reported for some of the cathinones, the rapid emergence 
of new structural analogs presents a formidable challenge for immunoassay-based 
screening technologies.  
Cathinones are known to undergo a variety of phase I transformations including N-
dealkylation, reduction, hydroxylation, oxidation and demethylenation. Despite a growing 
body of research on cathinone metabolism, commercial metabolite standards are only 
available for a relatively small number of cathinones. For this reason, most toxicology 
methods tend to target the parent drug, and this approach has proven successful due to a 
sufficiently high concentration of parent drug present in biological samples (9, 10) .  
Gas chromatography-mass spectrometry (GC-MS) remains the most widely used 
technique in forensic toxicology in large part due to its robustness, specificity, and low 
capital outlay relative to other hyphenated chromatographic techniques. However, 
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synthetic cathinones may undergo thermal degradation during GC analysis. Noggle and 
DeRuiter (11) were the first to document this phenomenon in 1994 using methcathinone. 
Archer and Tsujikawa (12, 13) observed similar in-situ degradation using 4-FMC and α-
PVP. More recently this phenomenon was demonstrated using eighteen synthetic 
cathinones (14). Unfortunately, these oxidative breakdown products can be difficult to 
separate from their parent drug and share many of the same characteristic ions. 
Furthermore, cathinones undergo extensive fragmentation during electron impact 
ionization (EI) and the strong tendency of these beta-keto amphetamines to undergo alpha 
cleavage can result in mass spectra with a limited number of diagnostic ions (15-18). EI 
spectra are heavily dominated by the immonium ion of relatively low mass, while lower 
intensity acylium and arylium ions tend to lack specificity due to common benzylic 
substituents among the cathinones.  
Liquid chromatography-mass spectrometry (LC-MS) approaches can facilitate a 
larger complement of diagnostic ions because electrospray ionization (ESI) conditions can 
be carefully controlled and optimized to meet analyte-dependent needs. Hyphenated LC 
techniques have been described for many of the synthetic cathinones. However, Ammann 
(19) was the first to report the use of liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) to simultaneously identify a large number of cathinones (twenty-five) in 
blood. More recently, high resolution mass spectrometry (HRMS) has been used to detect 
cathinones in blood (20) and urine (21-23). Although traditional triple quadrupole mass 
spectrometry is considered to offer the greatest sensitivity, HRMS approaches such as 
quadrupole-time of flight and Orbitrap™ offer improved mass accuracy, enhanced 
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selectivity, and the opportunity for retrospective data interrogation, the latter of which is a 
distinct advantage for such a rapidly evolving drug class.  
One of the greatest challenges within the cathinone class are the number of isobaric 
compounds. This is of particular importance when certain positional isomers are scheduled, 
while others are not. Since many of these isomers share the same precursor, product ions 
and fragmentation pathways, mass separation is not always feasible. Hence, significant 
emphasis must be placed on chromatographic separation in order to make a definitive 
identification. While most reported LC methods have separated several isomers, the 
fluorinated derivatives present the greatest challenge (10, 19) and many published reports 
do not include multiple fluorinated isomers in their assays for this reason. Li (24) was the 
first to report the separation of 3- and 4-fluoromethcathinone using hydrophilic interaction 
liquid chromatography (HILIC) tandem mass spectrometry, following unsuccessful use of 
traditional reversed phase approaches.  
In this report we describe the separation of all isomer pairs, including 3-FMC and 
4-FMC using a traditional C18 column and HRMS. We present a validated method for the 
quantitative determination of twenty-two synthetic cathinones in urine and blood using LC-
Q/TOF MS. The method was used to reanalyze authentic urine samples after ten months 
of refrigerated storage. The quantitative assay was developed as part of an on-going study 
to systematically evaluate cathinone stability in biological evidence. For this reason, a total 
of sixteen secondary amines (four unsubstituted and twelve ring-substituted) and six 




   
 




Methcathinone Ethcathinone Buphedrone Pentedrone 
   
 
Secondary Amines with Ring Substituents 
Mephedrone 4-MEC 4-EMC Methedrone 
  
  
Flephedrone (4-FMC) 3-FMC 3,4-DMMC Methylone 
    
Ethylone Butylone Pentylone Eutylone 
  
  
Tertiary Amines (Pyrrolidine-type) 












































































































   
Materials and Methods 
Chemicals and reagents 
Reference standards including 3,4-DMMC, 3-FMC, 4-EMC, 4-FMC, 4-MEC, α-
PVP, buphedrone, butylone, ethcathinone, ethylone, eutylone, MDPBP, MDPV, 
methcathinone, methedrone, methylone, mephedrone, MPBP, naphyrone, pentedrone, 
pentylone, pyrovalerone and internal standards (butylone-D3, ethylone-D3, naphyrone-D3, 
α-PVP-D8, pentylone-D3, eutylone-D5, methylone-D3, mephedrone-D3 and MDPV-D8) 
were purchased from Cerilliant Corp. (Round Rock, TX, USA). Reference materials were 
purchased as methanolic 1.0 mg/mL standards with the exception of deuterated analogs 
(0.1 mg/mL). Pooled drug-free urine purchased from Utak Laboratories (Valencia, CA, 
USA) was preserved with 1% sodium fluoride prior to use. Bovine blood preserved with 
1% sodium fluoride and 0.2% potassium oxalate was purchased from Quad Five (Ryegate, 
Montana, USA). 
Dichloromethane, isopropyl alcohol and glacial acetic acid were obtained from 
Mallinckrodt Chemicals (St. Louis, MO, USA) and methanol (LCMS grade), concentrated 
hydrochloric acid, acetonitrile (LCMS grade) and dibasic sodium phosphate (Na2HPO4, 
ACS grade) were obtained from J.T. Baker (Center Valley, MA, USA). Hexane (Optima®) 
and ethyl acetate (HPLC grade) were obtained from Fisher Scientific (Fair Lawn, NJ, USA) 
and formic acid (>95%) was obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Concentrated ammonium hydroxide was obtained from Macron Fine Chemicals (Center 
Valley, MA, USA) and monobasic sodium phosphate (NaH2PO4, ACS grade) was obtained 
from VWR (Radnor, PA, USA). Deionized water was purified in-house using a Millipore 
Direct-Q® UV Water Purification system (Billerica, MA, USA). PolyChrom Clin II 3 cc 
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(35 mg) solid phase extraction (SPE) columns were obtained from SPEware (Baldwin Park, 
CA, USA).  
Instrumental analysis 
Nitrogen was generated using a Genius 3040 nitrogen generator (Peak Scientific, 
Billerica, MA, USA). SPE was performed using a JT Baker vacuum manifold and extracts 
were evaporated to dryness under nitrogen using a TurboVap LV® concentration 
workstation (Caliper Life Sciences, Hopkinton, MA, USA). An Agilent Technologies 6530 
LC-Q/TOF MS (Agilent Technologies, Santa Clara, CA, USA) equipped with an Agilent 
1290 Infinity autosampler was used to analyze samples. Separation was achieved using an 
Agilent Technologies Series 1200 LC system equipped with an Agilent Poroshell 120 EC-
C18 column (2.1 x 100 mm, 2.7 µm particle size) and an Agilent Poroshell 120 EC-C18 
guard column (2.1 x 5 mm, 2.7 µm particle size) in a thermostatically controlled column 
compartment (35oC).   
The mobile phase consisted of 0.1% formic acid in deionized water (A) and 0.1% 
formic acid in acetonitrile (B). A flow rate of 0.4 mL/min was maintained using the 
gradient elution profile as follows: 96% A and 4% B (0 – 0.5 mins); 10% B (0.5 – 5 mins); 
40% B (5 – 11 mins); 100%B (12 mins). The column was rinsed with 100% B for 1 minute 
before re-equilibration. The total acquisition time was 12 mins and the target compounds 
eluted between 3 and 11 mins.  
The LC-Q/TOF MS was equipped with an ESI source in positive mode with Jet 
Stream technology under the following conditions: drying gas (N2), 13 L/min; drying gas 
temperature, 200oC; nebulizer, 20 psi; sheath gas temperature, 250oC; nitrogen sheath gas 
flow, 12 L/min; capillary voltage, 4000 V; nozzle voltage, 0 V; fragmentor, 150 V; 
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skimmer, 65V. Agilent MassHunter software was used for acquisition, qualitative and 
quantitative analysis.  Following optimization of collision induced dissociation (CID) 
voltages, a minimum of two transition ions were selected with a mass tolerance of 5 ppm 
using targeted MS/MS acquisition. Precursor ion resolution of 7,000 (m/z 164-287) and 
MS/MS resolution of 6,000 was observed at full width half maximum (FWHM). Precursor 
and product ions, collision energies, retention times and the internal standard for each drug 
are summarized in Table 2.1. Precursor ions were selected in the quadrupole using a 1 
Dalton (Da) window. Data was acquired using a mass range of 40-1000 Da, with a MS 
scan rate of 8 spectra/sec and a MS/MS Scan rate of 3 spectra/sec. During the selection of 
product ions, greater emphasis was placed on specificity rather than sensitivity. Non-
specific losses (including water loses) that have been utilized in publications elsewhere 
were not considered acceptable.  
 
Table 2.1.  Transition ions, collision energies (CE), retention time (RT), and internal 










Methcathinone 164.1075 131.0731 (100%) 
105.0703 (25%) 
20 3.394 Mephedrone-D3 
3-FMC 182.0976 149.0634 (100%) 
123.0605 (15%) 
20 3.938 Mephedrone-D3 
4-FMC 182.0976 149.0636 (100%) 
123.0605 (22%) 
20 4.094 Mephedrone-D3 
Methylone 208.0968 160.0757 (100%) 
132.0807 (37%) 
20 4.133 Methylone-D3 
     (continued) 
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Ethcathinone 178.1226 131.0721 (100%) 
117.0586 (34%) 
105.0700 (50%) 
20 4.302 Butylone-D3 
Ethylone 222.1125 174.1222 (100%) 
146.0958 (79%) 
30 5.153 Ethylone-D5 
Methedrone 194.1176 161.0833 (100%) 
146.0598 (41%) 
135.0803 (22%) 
20 5.291 Mephedrone-D3 
Buphedrone 178.1226 131.0731 (100%) 
91.0549 (58%) 
145.0880 (14%) 
20 5.442 Mephedrone-D3 
Butylone 222.1125 174.0914 (100%) 
146.0964 (84%) 
30 6.259 Butylone-D3 
Mephedrone 178.1226 145.0889 (100%) 
119.0853 (14%) 
20 6.444 Mephedrone-D3 
Eutylone 236.1281 188.1069 (100%) 
174.0547 (104%) 
161.0598 (26%)* 
30 6.901 Eutylone-D5 
4-MEC 192.1383 145.0886 (100%) 
159.1041 (33%)* 
131.0738 (30%) 
20 7.185 Mephedrone-D3 
MDPBP 262.1438 161.0597 (100%) 
191.0704 (80%) 
112.1125 (96%) 
20 7.225 Eutylone-D5 
Pentedrone 192.1383 132.0810 (100%) 
91.0546 (68%) 
20 7.505 Mephedrone-D3 
Pentylone 236.1281 188.1070 (100%) 
175.0682 (40%) 
30 7.813 Pentylone-D3 
3,4-DMMC 192.1383 159.1043 (100%) 
144.0802 (24%) 
20 8.055 Methylone-D3 
α-PVP 232.1696 161.0954 (100%) 
91.0549 (367%) 
20 8.159 α-PVP-D8 
     (continued) 
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4-EMC 192.1383 145.0889 (100%) 
105.0701 (10%) 
20 8.232 Mephedrone-D3 
MPBP 232.1696 161.0960 (100%) 
133.1010 (48%) 
112.1120 (61%) 
20 8.410 Naphyrone-D5 
MDPV 276.1594 205.0857 (100%) 
126.1277 (137%) 
175.0756 (116%) 
20 8.444 MDPV-D8 
Pyrovalerone 246.1852 175.1110 (100%) 
126.1280 (63%) 
105.0701 (212%) 
20 9.450 Naphyrone-D5 
Naphyrone 282.1852 211.1122 (100%) 
126.1280 (37%) 
141.0701 (143%) 
20 10.774 Naphyrone-D5 
 
Preparation of standards and reagents 
Working standards containing all twenty-two target compounds were prepared in 
methanol at 0.01, 0.1 and 1.0 µg/mL for the fortification of urine, and 0.02, 0.2, and 2.0 
µg/mL for the fortification of blood. The combined internal standard solution consisted of 
nine isotopically labelled standards in methanol at 0.25 µg/mL and 0.5 µg/mL for urine 
and blood, respectively. Phosphate buffer (pH 6, 0.1M) was prepared from 0.1M solutions 
of mono and dibasic sodium phosphate, and acidic methanol consisted of concentrated 
hydrochloric acid diluted in methanol (2%, v/v).  The elution solvent which was prepared 
daily, consisted of 2% concentrated ammonium hydroxide in 95:5 
dichloromethane/isopropyl alcohol (v/v).  
Urine extraction  
Internal standard solution (0.25 µg/mL) was added to 1.0 mL urine to achieve a 
final concentration of 25 ng/mL. Urine was diluted with 2.0 mL of pH 6.0 phosphate buffer 
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(0.1M) and briefly vortexed. Samples were transferred to PolyChrom Clin II SPE columns 
(3 cc columns, 35 mg) and allowed to flow through under gravity or sufficient vacuum to 
maintain constant flow (approximately 1 mL/min). Columns were rinsed with 1.0 mL 
deionized water followed by 1.0 mL of 1 M acetic acid.  After drying columns for five 
mins on full vacuum, samples were washed successively using hexane (1.0 mL), ethyl 
acetate (1.0 mL) and methanol (1.0 mL). Cathinones were eluted using two 0.5 mL aliquots 
of elution solvent. Acidic methanol (30 L) was added to each extract prior to evaporation 
under nitrogen at 50C. Extracts were reconstituted in 25 L of a 50:50 mixture of Mobile 
Phase A/B and 1 L was injected onto the LC-Q/TOF MS for analysis.  
Blood extraction 
Internal standard solution (0.5 µg/mL) was added to 2.0 mL blood to achieve a final 
concentration of 25 ng/mL. A protein precipitation was performed with the addition of 4.0 
mL of cold acetonitrile while vortex mixing, followed by centrifugation at 4000 rpm for 5 
mins. The supernatant was decanted and diluted with 6.0 mL of pH 6.0 phosphate buffer 
(0.1M) and briefly vortexed. Samples were transferred to SPE columns (3 cc columns, 35 
mg) and extracted in a manner analogous to urine. Extracts were reconstituted in 25 L of 
a 50:50 mixture of Mobile Phase A/B and 1 L was injected onto the LC-Q/TOF MS for 
analysis.  
Assay validation 
Assay performance was evaluated in terms of extraction efficiency, calibration 
model, precision, bias, limit of detection (LOD), limit of quantification (LOQ), matrix 
effects, interference, ion suppression, carryover, processed sample stability, and dilution 
integrity in accordance with published recommendations (25). 
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The extraction efficiency in blood (100 ng/mL) and urine (25 ng/mL) was 
determined by direct comparison of extracted and non-extracted samples. Urine and blood 
containing internal standard (25 ng/mL) was extracted in the presence and absence of the 
target compounds. Samples extracted without target compounds were fortified with 
equivalent drug post-extraction (prior to evaporation and reconstitution). Analytical 
recovery was calculated by comparing the relative peak area (drug/IS) for extracted 
samples (n=4) with the mean relative peak are for the non-extracted samples (n=4). 
Limits of detection and quantitation were established using drug-free blood and 
urine fortified with reference materials. Three sources of drug-free matrix were analyzed 
in duplicate over three independent runs. The LOD was the lowest concentration of drug 
that produced a reportable result (signal to noise ratio of 3:1 or more; retention time ±2% 
of the standard; ion ratios ± 20%). Limit of quantitation was determined 
contemporaneously and was defined as the lowest concentration of drug to produce a 
quantitative value within 20% of the expected value, a S/N ratio of 10:1 or more, retention 
time ±2% of the standard, ion ratios within 20% and acceptable precision and bias.  
Precision and bias were evaluated in urine (10, 100 and 1,000 ng/mL) and blood 
(20, 100, 1,000 ng/mL) using three samples of pooled fortified matrix at three 
concentrations (low, medium, high) over five runs. Within-run precision was calculated for 
each concentration (n=3) over each of the five runs. Between-run precision was calculated 
for each concentration over all five runs (n=15). Bias was evaluated contemporaneously 
with precision using the same concentrations over five days. Tolerance for bias and 
precision was 20%.  
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The calibration model was established in accordance with SWGTOX 
recommendations using a minimum of six non-zero calibrators over five independent runs. 
Calibration models were evaluated visually and analytically using the correlation 
coefficient (R2), standardized residual plots and the F-test to determine the significance of 
the quadratic term (α=0.05). A total of seven non-zero calibrators were used in urine (5, 
10, 50, 100, 250, 500, and 1,000 ng/mL) and eight in blood (5, 10, 50, 100, 250, 500, 750, 
and 1,000 ng/mL).  
Interferences associated with the biological matrix, isotopically labeled internal 
standards, common drugs and structurally related compounds were systematically 
evaluated. Matrix interferences were evaluated using ten drug-free blood and urine samples 
from independent sources in the absence of internal standard. Ion contributions arising 
from the use of stable isotope internal standards were evaluated by fortifying drug-free 
urine and blood with internal standard (25 ng/mL) and monitoring the signal of the target 
analytes. In a similar fashion, ion contributions associated with high concentrations of drug 
(1,000 ng/mL) were evaluated in the absence of internal standard. Drug interferences were 
evaluated using four categories of compounds: common amphetamines, structurally related 
designer drugs, common drugs and other therapeutic drugs of significance. Twenty-two 
common drugs, ten common amphetamine-type drugs and fifteen structurally related 
designer drugs were selected. Diethylpropion (amfepramone, Tenuate®) and bupropion 
(Wellbutrin®, Zyban®) are therapeutically used cathinones. These were included in the 
interference study, together with hydroxybupropion (metabolite) and ropivacaine 
(Naropin®) (due to its mass spectral similarity to MDPV). Putrefactive amines were also 
included for the interference study in blood. Interferences were assessed using negative 
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and positive controls. A 10 to 100-fold excess of interferent (relative to the target drug) 
was employed for interference testing. The negative control consisted of drug-free urine or 
blood fortified with internal standard (25 ng/mL) and 1000 ng/mL of interferent; positive 
controls contained internal standard (25 ng/mL), interferent (1,000 ng/mL) and target 
cathinones at a ten-fold and hundred-fold lower concentration (100 and 10 ng/mL, 
respectively). Interferences associated with more than fifty drugs were evaluated in total 
and these are summarized in Table 2.2.  
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Table 2.2.  Summary of compounds included in the interference study. Compounds were 
separated into five groups: common drugs (n=22), amphetamine-like drugs (n=10), 
designer drugs (n=15), other drugs (n=4), and putrefactive amines (n=4). 
4-bromo-2,5-dimethoxyphenethylamine (2C-B), 2,5-dimethoxy-4-chlorophenethylamine 
(2C-C), 2,5-dimethoxy-4methylphenethylamine (2C-D), 2,5-dimethoxy-4-
ethylphenethylamine (2C-E),  2,5-dimethoxyphenethylamine (2C-H), 2,5-dimethoxy-4-
iodophenethylamine (2C-I), 2,5-dimethoxy4-ethylthiophenethylamine (2C-T-2), 2,5-
dimethoxy-4-isopropylthiophenethylamine (2C-T-4), 2,5-dimethoxy-4-
propylthiophenethylamine (2C-T-7), 4-methylthioamphetamine (4-MTA), 2,5-
dimethoxy-4-bromoamphetamine (DOB), 2,5-dimethoxy-4-chloroamphetamine (DOC), 
2,5-dimethoxy-4-ethylamphetamine (DOET), 2,5-dimethoxy-4-iodoamphetamine (DOI), 
2,5-dimethoxy-4-methylamphetamine (DOM). 
  
































































   
Matrix effects were quantitatively assessed using post-extraction addition at two 
concentrations (20 ng/mL and 200 ng/mL for urine; 50 ng/mL and 500 ng/mL for blood). 
Ten drug-free matrices from independent sources (n=2) were extracted in the absence of 
drug and fortified with drug post-extraction. Ion suppression or enhancement was 
calculated by comparing the mean peak areas of drug in matrix with the drug in mobile 
phase (no matrix).  
Carryover was assessed by analyzing a negative control immediately following the 
injection of a high control (1,000, 2,500, and 5,000 ng/mL). Carryover was present when 
the negative control produced a reportable result (signal to noise ratio of 3:1 or more, 
retention time ±2% and ion ratios within 20% of expected).  The influence of sample 
dilution was evaluated using urine or blood fortified at 1,000 ng/mL. Dilution integrity for 
urine was determined using two- and four-fold dilutions in 0.1M pH 6.0 phosphate buffer 
(to achieve final volume of 1.0 mL) prior to extraction. Dilution integrity for blood using 
two- and four-fold dilutions was determined by direct precipitation of 0.5 mL or 1.0 mL 
blood with 4.0 mL of cold acetonitrile. Quantitative results were evaluated and calculated 
concentrations within 20% of the expected concentration were deemed acceptable.  The 
stability of processed samples was assessed by extracting samples (25 ng/mL and 350 
ng/mL) in triplicate and analyzing the same extracts over a period of up to 48 hours. The 
samples were stored in the refrigerated autosampler tray and were considered stable until 
the quantitative result produced a bias exceeding ± 20%. 
Authentic unpreserved urine samples (n=20) from cathinone users were reanalyzed 
using the LC-Q/TOF method in accordance with an Institutional Review Board (IRB) 
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approved study. Specimens provided by Redwood Toxicology Laboratories (RTL) were 
reanalyzed and compared with the original results.  
Results and Discussion 
Synthetic cathinones can thermally degrade during GC-MS analysis. This oxidative 
degradation is characterized by the loss of two hydrogens to produce a 2,3-enamine or an 
imine (11, 14). As part of the routine ionization optimization process, the possibility of 
thermal degradation was considered. Data was acquired using a non-targeted (full scan) 
method. Precursor ions for known (-2 Da) degradation products were not present for any 
of the drugs, demonstrating that heated conditions inside the ESI source did not result in 
thermal degradation of cathinones.  
An overlaid chromatogram depicts the chromatographic separation of all twenty-
two cathinones, including 3- and 4-FMC (Figure 2.2). Individual extracted ion 
chromatograms and MS/MS spectra, with tentative structures for quantifier and qualifier 
ions, for each cathinone are located in Appendix A. Table 2.3 summarizes structural losses 
that produce product ions. Proposed fragments for common losses in secondary, 
unsubstituted cathinones, secondary, substituted cathinones, secondary, methylenedioxy-
type cathinone, and tertiary (pyrrolidine-type) cathinones bearing the methylenedioxy 
group presented in Figure 2.3. Mass accuracy for a 100 ng/mL control in both matrices 
was within 5 ppm (Table 2.4). Extraction efficiencies were 84-104% in urine at 25 ng/mL 
(n=4) and 81-93% in blood at 100 ng/mL (n=4) (Table 2.5).  
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Figure 2.2.  Chromatographic separation of cathinones, including positional isomers in a 
representative extract (100 ng/mL). Internal standards are excluded for clarity. methcathinone 
(3.295); 3-FMC (3.821); 4-FMC (3.978); methylone (4.036); ethcathinone (4.171); ethylone 
(5.038); methedrone (5.171); buphedrone (5.298); butylone (6.141); mephedrone (6.325); 
eutylone (6.829); 4-MEC (7.071); MDPBP (7.142); pentedrone (7.402); pentylone (7.773); 3,4-
DMMC (7.995); α-PVP (8.031); 4-EMC (8.167); MPBP (8.308); MDPV (8.371); pyrovalerone 
(9.329); naphyrone (10.626). 
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Figure 2.3. Proposed fragmentation pathways for common losses. Common losses 
include CH4O in unsubstituted and substituted cathinones (orange, methcathinone, 3,4-
DMMC), methylenedioxy loss to form phenyloxazole (blue) and loss of R3R4R5NO (red) 
in methylenedioxy-type cathinones, and dissocation of pyrrolidinyl to form 
alkyldioxybenzoyloxonium ion (purple) and immonium ion (green) in tertiary amine 
cathinones.  
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Table 2.3. Proposed fragmentation for quantifier (bold) and qualifier transitions. 
Cathinone 
Precursor Ion  
(m/z) 
Product Ions  
(m/z) 
Loss 
































































   (continued) 
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Cathinone 
Precursor Ion  
(m/z) 
Product Ions  
(m/z) 
Loss 
















































Table 2.4. Accurate mass for 100 ng/mL control in urine and blood.  
   
Blood Urine 
Cathinone Formula Exact Mass [M+H] Accurate Mass Difference (ppm) Accurate Mass  Difference (ppm) 
3,4-DMMC C12H17NO 192.1383 192.1385 1.04 192.1388 2.60 
3-FMC C10H12FNO 182.0976 182.0976 0.00 182.0975 -0.55 
4-EMC C12H17NO 192.1383 192.1383 0.00 192.1385 1.04 
4-FMC C10H12FNO 182.0976 182.0978 1.10 182.0977 0.55 
4-MEC  C12H17NO 192.1383 192.1389 3.12 192.1386 1.56 
α-PVP C15H21NO 232.1696 232.1699 1.29 232.1702 2.58 
Buphedrone C11H15NO 178.1226 178.1231 2.81 178.1228 1.12 
Butylone C12H15NO3 222.1125 222.1135 4.50 222.1128 1.35 
Ethcathinone C11H15NO 178.1226 178.1229 1.68 178.1228 1.12 
Ethylone C12H15NO3 222.1125 222.1132 3.15 222.1128 1.35 
Eutylone C13H17NO3 236.1281 236.1298 2.70 236.1287 2.54 
MDPBP C15H19NO3 262.1438 262.1436 -0.76 262.1443 1.91 
MDPV C16H21NO3 276.1594 276.1592 -0.72 276.1603 3.26 
Mephedrone C11H15NO 178.1226 178.1227 0.56 178.1229 1.68 
Methcathinone C10H13NO 164.1070 164.1069 -0.61 164.1072 1.22 
Methedrone C11H15NO2 194.1176 194.1178 1.03 194.1178 1.03 
Methylone C11H13NO3 208.0968 208.0969 0.48 208.0971 1.44 
MPBP C15H21NO 232.1696 232.1702 2.58 232.1703 3.02 
Naphyrone C19H23NO 282.1852 282.1856 1.42 282.1861 3.19 
Pentedrone C12H17NO 192.1383 192.1384 0.52 192.1388 2.60 
Pentylone C13H17NO3 236.1281 236.1282 0.42 236.1288 2.96 




Table 2.5.  Extraction efficiencies in urine (25 ng/mL) and blood (100 ng/mL) using 
replicate analyses (n=4). 
Cathinone Mean Extraction Efficiency (%) 
Urine Blood 
3,4-DMMC 96 ± 7 83 ± 35 
3-FMC 84 ± 12 81 ± 19 
4-EMC 97 ± 4 87 ± 17 
4-FMC 90 ± 9 86 ± 12 
4-MEC 101 ± 4 85 ± 10 
α-PVP 94 ± 4 84 ± 21 
Buphedrone 95 ± 5 85 ± 11 
Butylone 98 ± 3 87 ± 9 
Ethcathinone 89 ± 4 87 ± 15 
Ethylone 98 ± 3 87 ± 11 
Eutylone 98 ± 3 93 ± 10 
MDPBP 94 ± 3 87 ± 9 
MDPV 95 ± 4 88 ± 20 
Methcathinone 93 ± 10 83 ± 20 
Methedrone 104 ± 6 84 ± 13 
Methylone 99 ± 4 83 ± 20 
Mephedrone 97 ± 7 82 ± 24 
MPBP 93 ± 4 91 ± 7 
Naphyrone 95 ± 4 88 ± 12 
Pentedrone 95 ± 5 88 ± 11 
Pentylone 100 ± 5 88 ± 17 
Pyrovalerone 92 ± 4 90 ± 12 
 
Following visual, analytical, and statistical evaluation of calibration models, a weighted 
(1/x) quadratic model was selected for all analytes in both matrices. The calibration curves 
for the chosen model and the residual plots for a representative drug (MDPV) are depicted 
in Figure 2.4. Residual plots and calibration curves for all twenty-two cathinones in blood 
and urine are located in Appendix B and C, respectively. The coefficients of determination 
(R2) were all above 0.99 or 0.98 for all models. Upon visual assessment using residual 
plots, the data did not appear to be randomly dispersed, indicating a non-linear (quadratic) 
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model should be used. Statistical evaluation further indicated a weighted (1/x) curve was 
optimal.  
 
Figure 2.4. Combined calibration curve of weighted (1/x) quadratic model of MDPV 
over five independent extractions. Calibration curve expressed as relative response and 
relative concentration. Overlaid residual plots for linear unweighted and quadratic 
weighted (1/x) shown below.   
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Limits of detection and quantitation for the twenty-two synthetic cathinones in 
blood ranged from 1-5 ng/mL (n=18), significantly lower than previously published 
literature using HRMS (50-100 ng/mL) (20). Limits of detection in urine ranged from 0.25-
5 ng/mL (n=18). Bias, precision and signal to noise (S/N) ratios at the limits of detection 
and quantitation are summarized in Tables 2.6 and 2.7. Extracted ion chromatograms 
(EICs) for all drugs at the limit of quantitation in urine and blood are shown in Figures 2.5 
and 2.6, respectively.  
Table 2.6.  Limits of detection and quantitation in urine. The mean, standard deviation 







Mean ± SD 
(ng/mL) 
S/N Bias (%) CV (%) 
3,4-DMMC 5 5 5.0 ± 0.3 23:1 -0.7 6.4 
3-FMC 1 2 9.9 ± 0.6 349:1 -0.9 6.4 
4-EMC 2 5 5.1 ± 0.3 43:1 2.3 5.3 
4-FMC 1 1 0.9 ± 0.1 358:1 -8.5 5.9 
4-MEC 1 1 0.9 ± 0.05 1438:1 -8.1 5.3 
α-PVP 2 2 2.0 ± 0.2 103:1 -1.7 9.4 
Buphedrone 2 2 2.0 ± 0.1 159:1 1.4 6.3 
Butylone 1 2 2.0 ± 0.2 44:1 1.6 8.3 
Ethcathinone 1 2 2.0 ± 0.1 578:1 0.0 6.6 
Ethylone 1 5 4.9 ± 0.4 623:1 -0.7 7.1 
Eutylone 5 5 4.9 ± 0.3 338:1 -1.1 5.5 
MDPBP 0.5 5 5.2 ± 0.2 556:1 4.3 4.4 
MDPV 1 2 2.1 ± 0.1 967:1 4.0 6.9 
Mephedrone 2 2 2.1 ± 0.1 95:1 3.5 5.3 
Methcathinone 0.25 0.25 0.24 ± 0.02 241:1 -2.3 9.9 











Mean ± SD 
(ng/mL) 
S/N Bias (%) CV (%) 
Methedrone 1 1 0.9 ± 0.1 102:1 -2.0 14.2 
Methylone 0.25 1 0.9 ± 0.1 1323:1 -0.8 9.4 
MPBP 1 5 4.9 ± 0.4 239:1 -1.0 7.7 
Naphyrone 0.5 0.5 0.27 ± 0.02 666:1 15.3 6.6 
Pentedrone 5 5 5.1 ± 0.3 489:1 1.5 6.4 
Pentylone 1 5 4.7 ± 0.3 125:1 -5.4 5.3 
Pyrovalerone 0.25 0.25 0.27 ± 0.02 235:1 8.7 8.0 
 
Table 2.7.  Limits of detection and quantitation in blood. The mean, standard deviation 







Mean ± SD 
(ng/mL) 
S/N Bias (%) CV (%) 
3,4-DMMC 2 2 1.87 ± 0.13 196:1 -6.4 6.9 
3-FMC 2 2 2.01 ± 0.19 69:1 0.0 9.2 
4-EMC 1 1 1.02 ± 0.06 70:1 1.0 5.9 
4-FMC 5 5 5.07 ± 0.43 128:1 1.5 8.4 
4-MEC 5 5 4.98 ± 0.37 72:1 -0.5 7.4 
α-PVP 2 2 1.85 ± 0.16 16:1 -7.6 8.6 
Buphedrone 5 5 4.94 ± 0.39 117:1 -1.2 7.8 
Butylone 2 2 1.92 ± 0.17 63:1 -4.0 8.8 
Ethcathinone 5 5 4.82 ± 0.39 155:1 -3.6 8.2 
Ethylone 2 2 1.96 ± 0.19 67:1 -3.0 10.0 
Eutylone 5 5 4.80 ± 0.39 46:1 -4.0 8.2 
MDPBP 5 5 4.80 ± 0.25 84:1 -4.0 5.2 
MDPV 2 2 1.86 ± 0.14 55:1 -7.3 7.4 
Mephedrone 2 2 1.99 ± 0.13 181:1 -0.4 6.6 
Methcathinone 2 2 1.91 ±  0.16 155:1 -4.8 8.6 








Mean ± SD 
(ng/mL) 
S/N Bias (%) CV (%) 
Methedrone 2 2 1.90 ± 0.17 104:1 -6.6 8.9 
Methylone 2 2 1.92 ± 0.09 305:1 -4.9 4.5 
MPBP 2 2 1.87 ± 0.16 75:1 -6.5 8.3 
Naphyrone 1 1 1.00 ± 0.07 33:1 0.7 6.9 
Pentedrone 5 5 5.05 ± 0.35 195:1 0.9 6.8 
Pentylone 5 5 4.77 ± 0.42 61:1 -4.6 8.9 












Figure 2.6.  Extracted ion chromatograms in blood at the limit of quantitation. 
 
Precision and bias were evaluated at low, medium, and high concentrations in 
triplicate over five days. Intra-assay CVs were 0.5 – 10.8% (10 ng/mL); 0.2 – 7.3% (100 
ng/mL); 0.2 – 8.6% (800 ng/mL) for urine and 0.2 – 17.0% (20 ng/mL); 0.2 – 8.7% (100 
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ng/mL); 0.8 – 13.8% (800 ng/mL) for blood.  Inter-assay CVs over the same concentration 
ranges were 4.4 - 12.1%, 1.7 - 11.5% and 2.5 - 8.6% in urine (n=15) and 3.3 – 11.7%, 2.7 
– 7.0%, and 3.4 – 10.1% in blood (n=15). Bias and precision at all concentrations tested 




Table 2.8.  Precision and bias (n=15) in urine at low (10 ng/mL), medium (100 ng/mL) and high (800 ng/mL) concentrations. 
Cathinone Intra-assay Precision 
 (n=3, %CV) 
Inter-assay Precision  
(n=15, %CV) 
Bias 



















3,4-DMMC 2.9-6.1 0.3-6.3 0.4-4.9 11.7 8.6 5.5 -1 -3 3 
3-FMC 1.2-10.8 1.1-5.1 0.7-5.3 8.9 4.7 5.9 9 0 2 
4-EMC 1.3-4.1 0.3-2.2 2.7-5.5 6.8 2.2 3.5 8 2 3 
4-FMC 0.5-3.8 1.8-6.9 0.3-3.1 5.6 4.5 9.2 7 1 4 
4-MEC 1.0-8.9 1.0-3.4 0.6-4.1 12.1 11.5 4.3 1 1 4 
α-PVP 1.5-3.9 0.2-3.6 1.6-4.7 6.7 4.2 8.9 9 0 6 
Buphedrone 0.8-5.6 0.9-4.1 0.7-5.3 8.3 2.8 4.7 10 2 6 
Butylone 1.7-7.0 0.2-6.2 1.4-5.0 4.6 4.1 3.5 6 0 4 
Ethcathinone 1.3-4.5 3.4-7.3 0.9-4.1 9.3 6.3 7.5 12 1 8 
Ethylone 0.6-3.4 1.7-4.3 0.2-4.6 6.9 3.0 4.6 7 2 1 
Eutylone 1.8-6.0 1.1-3.1 1.1-4.2 6.7 2.4 5.8 3 2 2 
MDPBP 1.6-7.2 0.6-3.0 0.4-5.3 7.1 4.4 5.7 7 2 1 
MDPV 0.8-6.8 1.5-3.4 1.1-4.6 6.1 5.0 5.1 7 2 1 
Mephedrone 0.5-6.8 0.9-2.1 1.5-5.5 4.8 2.0 3.3 7 2 2 
Methcathinone 0.9-6.4 0.9-3.9 1.4-5.8 7.0 3.0 3.5 8 1 5 
Methedrone 3.6-7.2 0.4-1.4 2.0-8.6 4.7 1.7 6.4 8 1 2 
Methylone 0.8-5.7 0.6-2.3 3.2-7.4 4.4 2.4 2.5 6 1 2 
MPBP 2.4-4.5 2.5-4.2 0.4-4.7 9.4 4.3 3.2 6 2 5 




Cathinone Intra-assay Precision 
 (n=3, %CV) 
Inter-assay Precision  
(n=15, %CV) 
Bias 



















Naphyrone 3.9-7.2 0.5-2.5 0.4-4.2 6.0 1.8 3.3 8 3 3 
Pentedrone 1.0-3.2 1.2-4.6 1.9-7.3 7.8 3.6 4.1 8 1 5 
Pentylone 2.9-8.5 1.3-3.8 1.1-3.9 11.6 3.6 5.8 3 4 3 
Pyrovalerone 1.6-3.9 1.3-2.5 0.7-3.5 8.7 2.3 3.4 7 2 3 
 
Table 2.9.  Precision and bias (n=15) in blood at low (20 ng/mL), medium (100 ng/mL) and high (800 ng/mL) concentrations. 
























3,4-DMMC 2.3-9.5 1.2-7.2 2.1-13.8 6.9 4.9 10.1 -3 1 2 
3-FMC 1.1-17.0 0.3-6.2 1.8-9.8 9.1 5.6 8.1 0 11 4 
4-EMC 1.5-5.8 0.9-7.2 4.6-5.6 4.9 5.0 8.3 -1 -2 -2 
4-FMC 0.8-11.7 1.3-5.8 5.1-8.5 6.0 3.8 7.6 2 11 2 
4-MEC 0.7-5.4 1.3-4.0 2.1-7.3 5.7 3.7 7.7 3 1 2 
α-PVP 3.1-8.8 0.8-8.7 7.0-10.8 7.2 5.4 7.6 -3 4 -4 
Buphedrone 1.3-9.7 0.8-5.5 2.1-8.7 6.8 5.6 7.4 4 9 4 
Butylone 0.9-8.1 2.4-3.8 3.8-5.2 4.6 4.0 5.5 -6 1 -1 
Ethcathinone 1.6-14.0 0.5-7.4 5.5-9.4 8.8 6.0 7.2 6 11 4 




























Ethylone 1.1-7.5 1.5-2.6 1.7-6.3 3.3 4.3 3.6 0 -1 0 
Eutylone 1.3-5.6 2.2-6.0 6.3-10.0 6.6 5.9 5.1 -1 3 1 
MDPBP 1.1-5.5 1.5-5.4 1.0-6.7 5.7 5.1 3.9 9 -2 1 
MDPV 1.2-5.8 0.2-6.1 1.5-6.4 3.6 4.1 4.9 -7 5 3 
Mephedrone 1.3-6.6 1.0-2.2 4.2-4.6 3.6 3.7 6.2 -5 3 1 
Methcathinone 0.6-8.6 0.8-3.9 1.7-5.5 6.2 4.6 8.0 3 6 3 
Methedrone 0.2-10.7 1.1-3.9 2.3-5.7 6.6 2.9 6.3 -2 -6 -4 
Methylone 1.4-5.5 0.5-3.7 2.4-4.8 3.9 3.7 3.4 -6 1 1 
MPBP 0.2-12.6 0.9-6.2 0.8-6.5 11.7 4.9 9.4 3 3 1 
Naphyrone 1.1-9.1 0.7-2.4 1.4-3.0 6.8 2.7 3.8 -1 1 0 
Pentedrone 1.9-11.5 2.0-3.7 2.5-5.9 6.3 4.8 7.2 4 7 6 
Pentylone 0.7-6.2 0.9-6.7 8.4-8.4 6.6 7.0 8.3 -5 -2 1 
Pyrovalerone 0.3-10.6 0.6-4.0 3.7-7.3 5.3 3.9 6.8 7 5 3 
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Interferences from matrix, isotopically labeled internal standards, and other drugs 
were systematically evaluated. Ten drug-free urine matrices from independent sources did 
not reveal interferences and there were no interfering ion contributions associated with the 
deuterated analogs. Furthermore, there were no qualitative interferences from more than 
fifty other compounds, including common drugs, amphetamine-like drugs, designer drugs, 
or therapeutically used cathinones, and putrefactive amines (Table 2.2). Negative and 
positive controls (10 ng/mL and 100 ng/mL) were analyzed in the presence of a 10- and 
100-fold higher concentration of potential interferents (1,000 ng/mL). No qualitative 
interferences were present for any of the compounds tested.  
The potential for ion suppression or enhancement was evaluated using ten 
independently sourced blood and urine samples. Matrix effects were evaluated 
quantitatively using the post-extraction addition technique for all twenty-two analytes and 
nine internal standards. Ionization suppression in urine was -17 to -1% at 20 ng/mL and -
21 to -4% at 200 ng/mL. Corresponding CVs were 2.4-13.7% and 3.5-7.5%, respectively. 
Ionization suppression in blood was -15 to 7% at 50 ng/mL and -3 to 3% at 500 ng/mL. 
Corresponding CVs in blood were 2.5-7.6% and 0.9–3.2%, respectively (Table 2.10). 
Although some ion suppression was evident, matrix effects were well-within tolerable 
limits (±20%) and CVs were <15% (25).  
  
161 
   
Table 2.10.  Matrix effect (%) and associated CVs in urine (20 and 200 ng/mL) and 
blood (50 and 500 ng/mL) (n=10). 

























3,4-DMMC 10.5 6.0 -17 -18 7.0 1.0 5 2 
3-FMC 13.2 3.5 -15 -21 4.0 3.2 -5 0 
4-EMC 9.8 5.2 -14 -5 7.6 1.3 4 1 
4-FMC 7.6 7.5 -2 -16 3.1 0.9 2 2 
4-MEC 4.0 4.9 -10 -16 5.9 1.8 4 -2 
α-PVP 8.0 6.9 -1 -10 4.6 1.6 -9 -1 
Buphedrone 6.9 7.2 -6 -7 5.1 1.7 3 3 
Butylone 4.0 6.9 -10 -18 5.2 1.9 6 3 
Ethcathinone 5.5 8.9 -5 -9 3.9 1.2 -5 -3 
Ethylone 4.7 6.1 -5 -13 4.0 1.5 4 1 
Eutylone 8.7 5.5 -14 -9 4.7 2.2 1 2 
MDPBP 4.9 4.8 -8 -12 3.3 1.5 -2 2 
MDPV 8.6 4.4 -6 -7 5.3 1.5 -11 2 
Methcathinone 9.9 5.8 -13 -14 5.4 1.5 5 2 
Methedrone 7.0 5.7 -12 -9 3.4 1.4 -3 0 
Methylone 5.4 5.7 -6 -4 4.9 1.2 7 2 
Mephedrone 3.8 6.6 -12 -15 4.6 1.2 -2 0 
MPBP 6.6 4.1 -9 -10 2.5 1.0 -8 0 
Naphyrone 2.4 4.8 -8 -11 3.3 1.4 -15 1 
Pentedrone 5.9 5.9 -5 -9 3.7 2.4 -1 0 
Pentylone 13.7 5.7 -8 -11 4.4 1.5 0 3 
Pyrovalerone 3.5 4.6 -4 -10 2.7 0.9 -10 2 
α-PVP-D8 5.4 3.8 -4 -2 3.6 2.6 -8 0 
Butylone-D3 3.6 3.3 -7 -10 4.9 2.6 8 -1 
Ethylone-D5 4.8 2.9 -7 -6 3.7 2.3 4 1 
Eutylone-D5 11.0 3.0 -6 -7 4.8 4.6 2 1 
       (continued) 
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MDPV-D8 8.0 4.3 -22 -6 2.2 2.4 -12 2 
Methylone-D3 5.1 3.2 -16 -6 5.3 3.3 9 -1 
Mephedrone-D3 3.6 2.5 -8 -7 2.8 3.1 4 0 
Naphyrone-D5 2.3 4.2 -14 -10 3.2 1.9 -25 -1 
Pentylone-D3 13.2 3.5 -6 -6 6.2 3.9 -1 1 
 
Dilution integrity was evaluated using two and four-fold dilutions of matrix at 1,000 
ng/mL.  All quantitative measurements were within 20% of the expected value. No 
carryover was present at 1,000 or 2,500 ng/mL for any of the analytes. However, at 5,000 
ng/mL, carryover was observed for naphyrone in both matrices. Finally, processed samples 
were stable for 48 hours at 25 and 350 ng/mL.   
Although not yet widespread in routine forensic toxicology laboratories, interest in 
the use of high resolution mass spectrometry (HRMS) is increasing. HRMS methods for 
the detection of cathinones in blood or urine are still relatively limited and this report offers 
some distinct advantages over previously published work. The quantitative assay was 
suitable for use with both blood and urine, produced significantly lower LODs and LOQs 
in blood (20), separated twenty-two cathinones in a shorter run time (21, 22) and was also 
capable of separating challenging isobaric compounds (3- and 4-FMC) using traditional 
reversed phase chromatography.  
This novel HRMS detection method was further utilized using authentic urine 
samples provided by Redwood Toxicology Laboratory (RTL) (Santa Rosa, CA). Table 
163 
   
2.11 summarizes the original (RTL) results with quantitative analyses following ten 
months of refrigerated storage and Figure 2.7 depicts a representative extract.  
 
 
Table 2.11.  Comparison of quantitative analyses of authentic urine samples (n=20) from 
cathinone users following ten months of refrigerated storage. 





A Ethylone (379 ng/mL) 
Methylone (87 ng/mL) 
Pentedrone (Present) 
Ethylone (257 ng/mL) 




B Ethylone (98 ng/mL) 
Methylone (32 ng/mL) 
Pentedrone (Present) 
Ethylone (69 ng/mL) 




C 4-MEC (present) 4-MEC (113 ng/mL) -- 
D α-PVP (100 ng/mL) 
Methylone (75 ng/mL) 
α-PVP (110 ng/mL) 
Methylone (7 ng/mL) 
α-PVP (110%) 
Methylone (9%) 
E α-PVP (394 ng/mL) α-PVP (310 ng/mL) α-PVP (79%) 
F Ethylone (36 ng/mL) Ethylone (24 ng/mL) Ethylone (67%) 
G 4-FMC and/or metabolite 4-FMC (<LOQ) -- 
H 4-FMC and/or metabolite 4-FMC not detected  -- 
I MDPV (1,301 ng/mL) MDPV (1,095 ng/mL) MDPV (84%) 
J Pentylone (585 ng/mL) Pentylone (433 ng/mL) Pentylone (74%) 
K Methylone (175 ng/mL) Methylone (109 ng/mL) Methylone (62%) 
L α-PVP (105 ng/mL) 
Methylone (108 ng/mL) 
α-PVP (104 ng/mL) 
Methylone (8 ng/mL) 
α-PVP (99%) 
Methylone (7%) 
M Butylone (177 ng/mL) Butylone (12 ng/mL) Butylone (7%) 
N Methylone (1,535 ng/mL) 
Pentedrone (Present) 
Methylone (923 ng/mL) 
Pentedrone (<LOQ) 
Methylone (60%) 
O Ethylone (189 ng/mL) 
Methylone (246 ng/mL) 
Ethylone (152 ng/mL) 
Methylone (190 ng/mL) 
Ethylone (80%) 
Methylone (77%) 
P α-PVP (101 ng/mL) α-PVP (96 ng/mL) α-PVP (95%) 
Q Methylone (84 ng/mL) Methylone (13 ng/mL) Methylone (16%) 
R α-PVP (87 ng/mL) 
Methylone (56 ng/mL) 
α-PVP (93 ng/mL) 
Methylone (10 ng/mL) 
α-PVP (107%) 
Methylone (18%) 
   (continued) 
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S MDPV (271 ng/mL) MDPV (212 ng/mL) MDPV (78%) 
T MDPV (257 ng/mL) MDPV (180 ng/mL) MDPV (70%) 




Figure 2.7.  Extracted ion chromatogram of urine from a cathinone user (Sample D) 
containing 9 ng/mL methylone (4.34 min) and 110 ng/mL α-PVP (8.43 min). 
 
 
These results highlight structurally dependent differences in stability between the 
synthetic cathinones. While tertiary or pyrrolidine-type cathinones exhibited the greatest 
stability, some of the ring-substituted secondary amines were notably unstable. In two 
instances, 4–FMC was either below the LOQ or not detected (Samples G and H). Although 
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results using α-PVP were in excellent agreement (79-110%), methylone was highly 
variable, with 7-77% of the drug remaining after storage. Structure-dependent stability was 
particularly evident in samples D, L and R (which contained both a secondary and tertiary 
amine). In these samples the α-PVP results were within 20% of their original value (99-
110%), while only 7-18% of the methylone remained. These comparisons highlight issues 
associated with cathinone stability, first reported by Morad (26) and later described by Paul 
(27). Instability in biological samples has been noted for a small number of cathinones, but 
has not received widespread attention (13, 21, 28-30). Tsujiikawa (13) was the first to 
suggest that fluorinated cathinones may be particularly unstable and dependent on the 
position of the fluorine on the benzene ring. The influence of chemical structure, matrix, 
temperature, and pH on cathinone stability require additional study and are currently being 
systematically evaluated in our laboratory.  
Conclusions 
High resolution mass spectrometry techniques are gaining momentum in forensic 
toxicology. Accurate mass measurements can improve assay specificity and the ability to 
perform data dependent or targeted acquisition allows for considerable flexibility and 
potential for post analysis data acquisition. In this report, liquid chromatography-
quadrupole/time of flight mass spectrometry was used to identify twenty-two cathinones, 
including regioisomers of flephedrone from urine and blood. The method was validated in 
accordance with published guidelines (25) and provided the necessary sensitivity and 
specificity for use with authentic casework samples.   
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Abstract 
The synthetic cathinones are powerful psychostimulants that have been associated 
with impairment, intoxication and fatal overdose. Forensic laboratories must be able to 
identify these new drugs as part of antemortem and postmortem toxicology investigations. 
Preliminary reports have indicated that some of the synthetic cathinones are unstable in 
biological matrices. It is important to understand drug stability in biological evidence so 
that analytical findings can be interpreted appropriately. The objective of this study was to 
systematically evaluate the concentration, temperature and analyte dependent stability of 
synthetic cathinones in preserved blood using liquid-chromatography/quadrupole-time of 
flight-mass spectrometry (LC/Q-TOF-MS). Cathinone stability was investigated at frozen, 
refrigerated, ambient and elevated temperature (-20°C, 4°C, 20°C and 32°C).  
Although no concentration dependent differences in stability were observed, 
cathinone stability was highly temperature and analyte dependent. Substituents on the 
aromatic ring and nitrogen profoundly influenced stability. Tertiary amines (pyrrolidinyl 
analogs) were significantly more stable than their N-alkylated (secondary amine) 
counterparts. Furthermore, the methylenedioxy group also exerted a significant stabilizing 
effect, for both secondary and tertiary amines. The unsubstituted and ring substituted 
secondary amines were the least stable, most notably 3-fluoromethcathinone (3-FMC). 
Under some conditions, significant losses were observed within hours of storage. Half-
lives ranged from a little as 8 hours (3-FMC) to 21 days (3,4-methylenedioxy-α-
pyrrolidinobutiophenone, MDPBP) at elevated temperature (32°C). In contrast, half-lives 
ranged from 0.4 to >10 months when refrigerated and demonstrated even greater stability 
when frozen.  
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Biological evidence may be subjected to a variety of environmental conditions prior 
to, and during transport to the laboratory. These findings highlight the need to consider the 
potential for both temperature and analyte dependent differences. Due to the inherent 
instability of certain drugs within the class, quantitative drug findings in toxicological 
investigations must be interpreted with caution, and within the context of specimen storage 
and integrity.  
 
Keywords: Synthetic cathinones, Stability, LC/Q-TOF-MS, Blood 
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STABILITY OF SYNTHETIC CATHINONES IN BLOOD 
Introduction 
The synthetic cathinones are powerful amphetamine-like psychostimulants that 
have increased in popularity in the United States since 2009 (1). According to the Drug 
Enforcement Administration, cathinones were reported in 48 of the 50 states in 2015, with 
the highest number of reports occurring in the South and Midwest regions. In 2010 the 
most common cathinones in the US were mephedrone, methylenedioxypyrovalerone 
(MDPV) and methylone (2). From 2013-2015 however, methylone, α-
pyrrolidinopentiophenone (α-PVP) and ethylone accounted for 91% of all reports. In 
addition to increased drug seizures, illicit drug manufacturers produce new cathinones as 
part of their ongoing attempt to circumvent drug laws and evade judicial consequences. 
This is evidenced by the fact that the number of synthetic cathinones encountered in the 
National Forensic Laboratory Information System increased from five in 2009 to thirty-
five in 2015. The sought-after effects of these drugs include increased energy, empathy, 
openness and libido. However, cardiac, psychiatric and neurological effects are common 
among users that require medical intervention. Over the past decade the federal government 
has taken numerous steps to ban specific synthetic cathinones and the majority of states 
have enacted legislation, often in the form of general class bans, in an effort to curb their 
appeal. 
These compounds present a challenge to the forensic toxicology community due to 
the number of structurally related analogs and regioisomers that currently exist. The 
cathinones are β-keto amphetamines (2-aminopropiophenones) that can be categorized into 
N-alkylamines (secondary amines) and pyrrolidines (tertiary amines). The chemical 
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properties of these arylaminoketones are dominated by two functional groups: the ketone 
and the amine. The cathinones are either ring substituted (R1 and R2), formed by the 
variation of the α-carbon substituent (R3), or N-alkylated (R4 and R5) (Figure 3.1). At the 
inception of this study, a total of twenty-two synthetic cathinones were commercially 
available and the individual structures of these compounds are shown in Figure 3.2.  
 
Figure 3.1. General cathinone structure. 
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Figure 3.2. Structures of synthetic cathinones included in this study.  
 
Drug stability must be carefully considered when interpreting toxicological results 
(3). Pre-analytical conditions, including specimen transport, storage and handling may 
cause the drug concentration to change. The stability and intrinsic chemical properties of 
many illicit and pharmaceutical drugs are widely known and understood, but this 
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information is relatively limited for the synthetic cathinones. An increased understanding 
of cathinone stability is needed due to the prevalence of these drugs in criminal and death 
investigations (4-9). Forensic toxicology laboratories go to considerable lengths to ensure 
the precision and accuracy of their quantitative results. However, in order to reliably 
interpret those results, drug stability and pre-analytical changes in drug concentration 
should be carefully considered.  
While the proliferation of cathinone compounds over the past decade has renewed 
interest in the stability of synthetic cathinones, the instability of cathinone (its natural 
precursor) has been understood for decades. Cathinone was first identified in the 1970s as 
the principle pharmacologically active compound in “khat”. Although its degradation 
product (cathine) had been identified years earlier, the delay in the identification of 
cathinone was largely due to its instability in the plant material (10-13). Cathinone was 
also reported to be unstable in basic conditions (11, 14).  More recently, Tsujikawa, et al. 
investigated the stability of five synthetic cathinones in aqueous solutions over a range of 
pH. They concluded that drug stability increased with decreasing pH and that the rate of 
decomposition was likely dependent on the chemical structure (14). Following 
decomposition four degradation products were identified, one resulting from acetylation. 
The remaining three were produced following oxidative deamination of mephedrone 
(Figure 3.3) (14). Through analysis of synthetic cathinone powders exposed to air, 
Tsujikawa, et. al., identified two additional breakdown products for pyrrolidine-type 
cathinones: N-oxide and 2”-oxo (Figure 3.3) (13). Cathinone instability was also observed 
during gas chromatography-mass spectrometry (GC-MS) analysis. Under some conditions 
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cathinones can thermally degrade, resulting in the formation of oxidative breakdown 
products (15-17).  
There are a relatively small number of studies that have addressed synthetic 
cathinone stability in blood or plasma. Morad et. al. was the first to report that cathinone 
was unstable in plasma in 1989 (18). More recently, issues associated with quantitative 
reproducibility and stability of the newer designer cathinones have emerged. Marinetti and 
Antonides described the lack of reproducibility of methylone and methedrone in 
toxicological samples in a series of published case reports (19). Soon thereafter, Johnson 
and Botch-Jones investigated the stability of MDPV and mephedrone at 1,000 ng/mL in 
blood, plasma and urine over 14 days of storage (20). Mephedrone was considerably less 
stable than MDPV, demonstrating complete loss (100%) after 7 days of storage at room 
temperature in blood. Both drugs were stable under frozen storage conditions for the entire 
two-week period. Based on the considerable difference between mephedrone and MDPV, 
the authors emphasized the need for additional research and the need to consider chemical 
instability when interpreting results.  
Li et. al. investigated the stability of eleven synthetic cathinones in equine plasma 
over various time intervals. Samples were stored at 25°C for 24 hours, 4°C for 7 days, -
20°C for 4 weeks, and -70°C for 24 weeks (6 months). The authors concluded that the 
eleven cathinones were stable for 30 days at -20°C, and 6 months in -70°C. Most were 
stable at room temperature for 24 hours, with the exception of 4-fluoromethcathinone (4-
FMC), 3-fluoromethcathinone (3-FMC), and 3-methyoxymethcathinone (21). Busardò 
investigated the stability of mephedrone in antemortem and postmortem blood over six 
months, concluding that preserved blood should be stored at -20oC to prevent significant 
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loss (23). Mephedrone was undetectable after 30 days at 20°C, 90 days at 4°C and stable 
at -20°C for the duration of the 6-month study.  Soh and Elliott also described the stability 
of 4-methylethcathinone (4-MEC) in blood and plasma at ambient temperature (22). 4-
MEC, originally fortified at 2,000 ng/mL was undetectable within 14 days, although 
plasma was reported to have greater stability. The degradation of 4-MEC in blood produced 
an unknown peak, which was identified as a degradation product, dihydro-4-MEC resulting 
from keto-reduction (Figure 3.3).
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Figure 3.3. Proposed degradation pathway for synthetic cathinones (13, 14, 22). 
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In this report we describe the systematic evaluation of twenty-two synthetic 
cathinones in preserved blood to evaluate concentration, analyte and temperature 
dependent differences in stability. Over a period of six months, stability was evaluated at 
four temperatures, selected to represent frozen (-20°C) and refrigerated (4°C) long- and 
short-term storage temperatures at the laboratory; exposure to ambient (20°C) or room 
temperature during routine processing and handling; and finally, potential exposure to 
elevated temperatures, which might be experienced during shipping and transport to the 
laboratory (32°C). Tentative identification of breakdown products was also investigated 
where possible. 
Materials and Methods 
Chemicals and reagents  
Methcathinone, 3-FMC, 4-FMC (flephedrone), methylone, ethcathinone, ethylone, 
methedrone, buphedrone, butylone, mephedrone, eutylone, 4-MEC, MDPBP, pentedrone, 
pentylone, 3,4-dimethylmethcathinone (3,4-DMMC), α-PVP, 4-ethylmethcathinone (4-
EMC), 4-methyl-α-pyrrolidinobutiophenone (MPBP), MDPV, pyrovalerone, and 
naphyrone were purchased from Cerilliant Corporation (Round Rock, TX, USA) in 1.0 
mg/mL methanolic solutions. Internal standards methylone-D3, ethylone-D5, buytlone-
D3, mephedrone-D3, eutylone-D5, pentylone-D3, alpha-PVP-D8, MDPV-D8, and 
naphyrone-D5 were also purchased from Cerilliant Corporation in 0.1 mg/mL methanolic 
solutions. Bovine blood containing 1% (w/v) sodium fluoride and 0.2% (w/v) potassium 
oxalate was purchased from Quad Five (Ryegate, Montana, USA). Commercial evacuated 
glass tubes without additional preservative (BD Vacutainer™ red-top tubes, 10 mL, 16 x 
100 mm) were purchased from VWR (Radnor, PA, USA).  
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Dichloromethane, isopropyl alcohol, and glacial acetic acid were purchased from 
Mallinckrodt Chemicals (St. Louis, MO, USA). LC-MS grade methanol, concentrated 
hydrochloric acid, LC-MS grade acetonitrile, and dibasic sodium phosphate were 
purchased from J.T. Baker (Center Valley, MA, USA). Optima® Hexane and HPLC grade 
ethyl acetate were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Formic acid 
(>99%) was purchased from Sigma-Aldrich (St. Louis, MO, USA) and monobasic sodium 
phosphate was purchased from VWR (Radnor, PA, USA). Deionized water was purified 
in-house using a Millipore Direct-Q® UV Water Purification system (Billerica, MA, 
USA). PolyChrom ClinII 3 cc (35 mg) solid phase extraction (SPE) columns were 
purchased from SPEware (Baldwin Park, CA, USA). Phosphate buffer (pH 6, 0.1 M) was 
prepared from 0.1 M solutions of mono and dibasic sodium phosphate, and acidic methanol 
consisted of concentrated hydrochloric acid diluted in methanol (2%, v/v). The elution 
solvent (prepared daily) consisted of 2% concentrated ammonium hydroxide in 95:5 
dichloromethane/isopropyl alcohol (v/v). 
Instrumental analysis 
An Agilent Technologies 6530 LC-Q/TOF-MS (Santa Clara, CA, USA) equipped 
with an Agilent 1290 Infinity autosampler and a Series 1200 LC system was used for 
analysis. The LC system was equipped with an Agilent Poroshell 120 EC-C18 column (2.1 
x 100 mm, 2.7 µm particle size) and a Poroshell 120 EC-C18 guard column (2.1 x 5 mm, 
2.7 µm particle size) located in a thermostatically controlled column compartment (35°C). 
Nitrogen was generated using a Genius 3040 Nitrogen Generator (Peak Scientific, 
Billerica, MA, USA). Solid Phase Extraction (SPE) was performed using a JT Baker 
vacuum manifold and extracts were evaporated to dryness under nitrogen using a 
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TurboVap LV® concentration workstation (Caliper Life Sciences, Hopkinton, MA, USA). 
Mobile Phase A consisted of 0.1% formic acid in deionized water and Mobile Phase B 
consisted of 0.1% formic acid in acetonitrile. The LC-Q/TOF procedure used for the 
quantification of cathinones in blood was previously published and validated in accordance 
with generally accepted guidelines (24, 25).  
Preparation and sampling of blood 
Preserved drug-free blood (1 L, pH 7.35-7.45) was fortified with twenty-two 
synthetic cathinones to achieve a final concentration of 100 ng/mL and 1,000 ng/mL. Blood 
was immediately aliquoted into glass Vacutainer™ tubes and stored at the appropriate 
temperature for the duration of the study (-20°C, 4°C, 20°C and 32°C). The experimental 
design is summarized in Figure 3.4.  
 
Figure 3.4. Experimental design. 
 
Aliquots at each concentration were immediately removed and analyzed to establish T0 
(0% loss).  At each sampling interval a single Vacutainer™ tube was removed from each 
temperature and aliquots (n=2) were removed and analyzed using the validated procedure. 
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After aliquots were removed, Vacutainer™ tubes were returned to the appropriate storage 
temperature. Sampling frequency was variable throughout the study. During the initial 48 
hours, quantitative analysis was performed every 2-6 hours. Sampling remained frequent 
(4 assays/week) throughout the initial month, decreasing thereafter. Calibrators (10, 25, 
100, 250, 350, 500 ng/mL) and controls (0, 100 ng/mL) were included in each run. Where 
appropriate, analysis of variance (ANOVA) was used to determine statistical significance 
(α=0.05). The drug was considered unstable when the concentration decreased by more 
than 20% of the original (T0) concentration. 
Isolation of cathinones from blood 
Internal standard solution (0.5 µg/mL) was added to 2.0 mL blood to achieve a final 
concentration of 25 ng/mL. A protein precipitation was performed using 4 mL of cold 
acetonitrile. The samples were then centrifuged at 4,000 RPM for 5 minutes. The organic 
layer was decanted and diluted with 6 mL of pH 6 phosphate buffer (0.1 M) and briefly 
vortexed. Samples were transferred to PolyChrom ClinII SPE columns and allowed to flow 
through under gravity. Columns were rinsed with 1 mL deionized water followed by 1 mL 
of 1 M acetic acid. Columns were dried under full vacuum for 5 minutes and washed 
successively, with 1 mL of hexane, ethyl acetate, methanol, and dichloromethane. 
Synthetic cathinones were eluted using two 0.5 mL aliquots of elution solvent (2% conc. 
ammonium hydroxide in 95:5 dichloromethane: isopropyl alcohol). Acidic methanol (30 
µL) was added to each extract prior to evaporation under nitrogen at 50°C. Extracts were 
reconstituted in 25 µL of 50:50 mixture of Mobile Phase A:B and 1 µL was injected onto 
the LC-Q/TOF-MS for analysis. Extraction efficiencies using this previously published 
procedure were 81-93% and limits of quantitation (LOQ) were 1-5 ng/mL (24). 
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Degradation product identification 
Structural elucidation of degradation products was attempted using modified 
acquisition parameters. Targeted analysis was replaced with auto (full scan acquisition), 
insert mass range etc. Chromatographic and ionization conditions were unchanged. In order 
to improve the quality of MS/MS spectra, a preferred list (m/z) was used, based on 
predicted transformations (oxidative deamination, benzoic acid, amidation, N-oxide, 2”-
oxo, and keto-reduction) (Table 3.1). Agilent Technologies Qualitative Analysis B.07.00 
was used to identify potential synthetic cathinone breakdown products in blood. When 
possible, breakdown products were monitored over the six months to determine 





Table 3.1. Molecular formula and accurate mass for predicted synthetic cathinone degradation products.  
 Synthetic Cathinone Precursor (Parent)  Reduction  Oxidative Deamination Benzoic Acid Amidation 
Secondary Amines Formula M+H Formula M+H Formula M+H Formula M+H Formula M+H 
Methcathinone C10H13NO 164.1069 C10H15NO 166.1226 C9H8O2 149.0597 C7H6O2 123.0441 C8H9NO 136.0757 
Ethcathinone C11H15NO 178.1226 C11H17NO 180.1383 C9H8O2 149.0597 C7H6O2 123.0441 C8H9NO 136.0757 
Buphedrone C11H15NO 178.1226 C11H17NO 180.1383 C9H8O2 149.0597 C7H6O2 123.0441 C8H9NO 136.0757 
Pentedrone C12H17NO 192.1383 C12H19NO 194.1539 C9H8O2 149.0597 C7H6O2 123.0441 C8H9NO 136.0757 
3-FMC C10H12FNO 182.0976 C10H14FNO 184.1132 C9H7FO2 167.0503 C7H5FO2 141.0346 C8H8FNO 154.0663 
4-FMC C10H12FNO 182.0976 C10H14FNO 184.1132 C9H7FO2 167.0503 C7H5FO2 141.0346 C8H8FNO 154.0663 
Methedrone C11H15NO2 194.1176 C11H17NO2 196.1332 C10H10O3 179.0703 C8H8O3 153.0546 C9H11NO2 166.0863 
Mephedrone C11H15NO 178.1226 C11H17NO 180.1383 C10H10O2 163.0754 C8H8O2 137.0597 C9H11NO 150.0913 
4-MEC C12H17NO 192.1383 C12H18NO 194.1539 C10H10O2 163.0753 C8H8O2 137.0597 C9H11NO 150.0913 
3,4-DMMC C12H17NO 192.1383 C12H19NO 194.1539 C11H12O2 177.091 C9H10O2 151.0735 C10H13NO 164.1069 
4-EMC C12H17NO 192.1383 C12H19NO 194.1539 C11H12O2 177.091 C9H10O2 151.0735 C10H13NO 164.1069 
Methylone C11H13NO3 208.0968 C11H15NO3 210.1123 C10H8O4 193.0495 C8H6O4 167.0339 C9H9NO3 180.0655 
Ethylone C12H15NO3 222.1125 C12H17NO3 224.1281 C10H8O4 193.0495 C8H6O4 167.0339 C9H9NO3 180.0655 
Butylone C12H15NO3 222.1125 C12H17NO3 224.1281 C10H8O4 193.0495 C8H6O4 167.0339 C9H9NO3 180.0655 
Pentylone C13H17NO3 236.1281 C13H19NO3 238.1438 C12H12O4 221.0808 C8H6O4 167.0339 C9H9NO3 180.0655 
Eutylone C13H17NO3 236.1281 C13H19NO3 238.1348 C11H10O4 207.0652 C8H6O4 167.0339 C9H9NO3 180.0655 
Tertiary Amines Precursor (Parent)  Reduction  N-oxide 2"-oxo   
Formula M+H Formula M+H Formula M+H Formula M+H   
α-PVP C15H21NO 232.1694 C15H23NO 234.1852 C15H21NO2 248.1645 C15H19NO2 246.1489   
MPBP C15H21NO 232.1694 C15H23NO 234.1852 C15H21NO2 248.1645 C15H19NO2 246.1489   
Pyrovalerone C16H23NO 246.1852 C16H25NO 248.2008 C16H23NO2 262.1802 C16H21NO2 260.1645   
Naphyrone C19H23NO 282.1852 C19H25NO 284.2008 C19H23NO2 298.1802 C19H21NO2 296.1645   
MDPBP C15H21NO3 262.1438 C15H21NO3 264.1594 C15H19NO4 278.1387 C15H17NO4 276.1230   




One-way ANOVA was used to statistically evaluate concentration, temperature, 
and analyte dependence. Concentration dependence was assessed by comparing the 
percentage of drug remaining (% target) at 100 ng/mL and 1,000 ng/mL to normalize the 
data. Absolute concentrations (ng/mL) were used to evaluate temperature and analyte 
dependence. To properly evaluate analyte dependence, ANOVA was used to examine 
variances within a population prior to comparisons between populations to ensure show 
that differences within a group were not significant (F < FCV or F-crit). No significance 
testing was performed when drug concentrations were within 20% of the initial (T0) 
concentration for the entire duration of the study. Representative statistical values will be 
stated within the Results and Discussion; a complete list of statistical analysis can be found 
in Appendix D. Half-lives (T1/2) for each drug were determined by estimating rate 
constants (k), assuming first order decay, based upon duplicate measurements at each time 
interval (T1/2=Ln2/k). Rate plots were only generated if a significant decrease in 
concentration (>20%) was evident over three consecutive measurements. Due to the large 
number of drugs, graphical representations of the data were color-coded to facilitate 
interpretation. Cathinones (2o amines) without aromatic substituents (R1 and R2 = H) were 
identified in green, 2o amines with aromatic substituents (R1 or R2 ≠ H) were yellow, 
cathinones with methylenedioxy (MD) groups were indicated with a magenta line (for both 




Results and Discussion 
Half-life estimation 
To estimate half-lives, rate plots were generated and are summarized in Figure 3.5. 
 
Figure 3.5. Rate plots and estimation of T1/2 in blood. 
 
In whole blood, half-lives were estimated for all drugs at elevated and ambient 
temperatures. In contrast, with the exception of 3-FMC, all drugs were stable for the entire 
six-month period when frozen. Cathinone half-lives in blood ranged from 8 hours (3-FMC) 
to 21 days (MDPBP) at elevated (32°C) temperature and 22 hours to almost three months 
at ambient (20°C) temperature. At refrigerated and frozen temperatures, synthetic 
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cathinones were considerably more stable and half-lives were measured for some but not 
all of the drugs (Table 3.2). These findings highlight the significant temperature and 
analyte dependent differences in stability, which are discussed in more detail below.  










3-FMC 2.6 m 13 d 22 h 8 h 
3,4-DMMC - 3.4 m 4.0 d 22 h 
4-EMC - 2.7 m 3.4 d 21 h 
4-FMC - 1.5 m 2.8 d 16 h 
4-MEC - 4.1 m 4.1 d 13 h 
Buphedrone - 4.0 m 3.4 d 14 h 
Ethcathinone - 2.9 m 4.5 d 8 h 
Mephedrone - 3.3 m 4.6 d 29 h 
Methcathinone - 1.9 m 4.2 d 17 h 
Methedrone - 5.9 m 7.3 d 28 h 
Pentedrone - 3.0 m 4.3 d 20 h 
Secondary Amines - Methylenedioxy-Substituted 
Butylone - - 21 d 4.1 d 
Ethylone - - 18 d 2.8 d 
Eutylone - - 31 d 4.8 d 
Methylone - 9.6 m 8.6 d 1.4 d 
Pentylone - - 16 d 2.1 d 
Tertiary Amines 
MPBP - 15 m 1.7 m 8.2 d 
Naphyrone - 10 m 11 d 1.4 d 
α-PVP - - 20 d 2.4 d 
Pyrovalerone - - 28 d 3.3 d 
Tertiary Amines - Methylenedioxy-Substituted 
MDPBP - - 2.7 m 21 d 





No concentration dependent differences in stability were observed for any of the 
drugs. Figure 3.6 depicts representative stability data for refrigerated blood at both 
concentrations tested (100 and 1,000 ng/mL). One-way ANOVA analysis confirmed lack 
of significance for unstable drugs (methcathinone, 32°C, F(1,58)=0.004, p=0.95) and 
stable drugs (pyrovalerone, 32°C, F(1,54)=0.392, p=0.534) alike. Due to the absence of 
concentration dependent stability for any of the cathinones, all subsequent statistical 
evaluations of temperature and analyte dependence were routinely undertaken at 1,000 
ng/mL unless otherwise stated. 
 




In order to evaluate the significance of analyte-dependence, ANOVA was used to 
examine the variances within and between populations.  For example, before determining 
the significance of the MD group, it was necessary to show that differences within the 
group were not significant. The plots presented in Figure 3.7 help visualize within and 
between sub-population significance. Due to notable differences in stability for some of the 
fluorinated cathinones (clearly illustrated in Figure 3.7 at 20 and -20°C) 3- and 4-FMC 





Figure 3.7. Box plots depicting within and between sub-populations of synthetic 
cathinones. Sub-populations include secondary amine, unsubstituted (green); secondary 
amine, ring substituted (yellow); secondary amine, MD (magenta); tertiary amine, non-
MD (purple); tertiary amine, MD (magenta/purple). Mean (‘X’) and median (line) 




Among the secondary amines, there were no significant differences in stability 
between unsubstituted and ring substituted cathinones at elevated and ambient 
temperatures in blood. This was attributed to their very rapid degradation under these 
conditions.  No significant differences were observed in refrigerated or frozen blood when 
3-FMC and 4-FMC were excluded. Addition of the MD group had a significant stabilizing 
effect. The MD-substituted secondary amines (ethylone, butylone, pentylone, methylone, 
eutylone) were considerably more stable than their unsubstituted counterparts 
(methcathinone, ethcathinone, buphedrone, pentedrone). The stabilizing effect of the MD 
group was also evident for the tertiary amines (pyrrolidines). MD-substituted pyrrolidines 
(MDPBP, MDPV) were generally observed to be more stable that their non-MD substituted 
counterparts (α-PVP, MPBP, pyrovalerone, naphyrone), although in all but a few instances, 
the differences were not statistically significant. Comparisons between these groups were 
not always possible due to within group variability among the pyrrolidinyl analogs, notably 
naphyrone (the least stable of the tertiary amines). The stabilizing effect of the MD group 
was evident throughout, most notably between the MD-substituted tertiary amines and the 
unsubstituted secondary amines (F(5,125)=4.7, p<0.0001) and the substituted secondary 
amines (F(8,252)=3.1, p=0.002) in refrigerated blood.  
The nitrogen substituent exerted an even greater stabilizing influence. Tertiary 
amines were consistently more stable than their secondary amine counterparts. This 
stabilizing effect was even evident when comparing the most stable MD-substituted 
secondary amines with their pyrrolidinyl counterparts. Additionally, MD-substituted 
tertiary amines were more stable than MD-substituted secondary amines at refrigerated 
temperature (F(6,165)=2.9, p<0.01).  
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Cathinone stability was highly analyte dependent. Pyrrolidinyl-type cathinones 
with tertiary amines were notably more stable than their secondary amine counterparts. The 
inability of the tertiary amines to undergo oxidative deamination is a likely explanation. 
Although significant differences between unsubstituted and ring substituted secondary 
amines were not observed, substitution with a MD group had a notable stabilizing effect 
for all drugs. Among the twenty-two drugs tested, MD-substituted pyrrolidinyl cathinones 
were the most stable (i.e. MDPBP, MDPV), followed by tertiary amines (α-PVP, MPBP, 
pyrovalerone, naphyrone) and MD-substituted secondary amines (ethylone, butylone, 
pentylone, methylone, eutylone). Unsubstituted (methcathinone, ethcathinone, 
buphedrone, pentedrone) and ring-substituted cathinones (mephedrone, 4-MEC, 4-EMC, 
methedrone, 3,4-DMMC, 3-FMC, 4-FMC) were considerably less stable, with 3-FMC 
exhibiting the greatest instability.   
Temperature dependence  




Figure 3.8. Cathinone stability in blood (1,000 ng/mL) at elevated, ambient, refrigerated, and frozen temperatures. 
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Temperature dependent differences were significant (p<0.001) for all twenty-two 
cathinones at both 100 ng/mL and 1,000 ng/mL. For the most unstable drug (3-FMC) half-
lives ranged from 8 hours at elevated temperature to almost three months when frozen. 
These results highlight how low storage temperatures can significantly reduce degradation, 
even for the most unstable cathinone species. The dramatic influence of temperature on 
half-life (Table 3.1) is shown graphically in Figure 3.9.  
 
Figure 3.9. Temperature dependent stability of cathinones in blood. Unlabeled data 




Table 3.3 summarizes the number of days to significant (20%) or complete (100%) 
loss of drug in blood originally fortified at 100 ng/mL. This data not only highlights the 
importance of storage temperature on cathinone stability, but also the analyte dependent 
variables discussed earlier. With the exception of 3-FMC, all of the cathinones were 
relatively stable or exhibited only moderate losses (<40%) in blood after 30 days of 
refrigerated storage and significant losses were not observed until 2.5 months of frozen 
storage.  At elevated temperature (32oC), significant losses were observed for unsubstituted 
and ring substituted cathinones within 24 hours, compared with days or weeks for the 
pyrrolidines. Unless specifically packaged to protect from heat, it is not uncommon for 
specimens to be exposed to elevated temperatures during shipping and transport to the 
laboratory, particularly during summer months. At ambient temperature (20°C), all twenty-
two were unstable by day 27, with the exception of MDPBP and MDPV (MD-substituted 
tertiary amines), which were unstable by day 55. In contrast the secondary amines with and 
without ring substituents experienced significant losses (>20%) within one to eight days. 
The ranges presented in Table II by chemical structure summarize days until significant 
(>20%) loss and 100% loss in blood (originally fortified at 100 ng/mL). This data also 
highlights that despite significant changes in concentration that might take place for some 
drugs under certain conditions, all the cathinones included in the study were detectable in 
blood for extended periods of time when refrigerated or frozen. It should be noted however 
that actual detection times are influenced by many factors, including dose of the drug 



































3-FMC 1 2 5.5h 2 1 7 4 88 14 -- 
3,4-DMMC 5 5 1 4 4 76 19 -- 101 -- 
4-EMC 2 5 1 4 4 24 55 -- 130 -- 
4-FMC 1 1 1 3 2 24 19 166 76 -- 
4-MEC 1 1 2 7 8 34 41 -- -- -- 
Buphedrone 2 2 2 7 7 31 41 -- 146 -- 
Ethcathinone 1 2 1.5 4 3 27 27 -- 88 -- 
Mephedrone 2 2 2 11 4 27 55 -- 130 -- 
Methcathinone 0.25 0.25 1.5 4 3 19 19 184 76 -- 
Methedrone 1 1 2 7 8 55 101 -- -- -- 
Pentedrone 5 5 1 4 4 24 41 -- 130 -- 
Range 0.25 - 5 0.25 - 5 5.5h - 2d 2 - 11 1 - 8 7 - 76 4 - 101 88 - >6m 14 - >6m >6m 
Secondary Amines - Methylenedioxy-Substituted 
Butylone 1 2 4 27 19 166 -- -- -- -- 
Ethylone 1 5 4 24 19 146 -- -- -- -- 
Eutylone 5 5 4 41 27 -- -- -- -- -- 
Methylone 0.25 1 2 19 11 101 101 -- -- -- 
Pentylone 1 5 4 24 19 146 -- -- -- -- 
Range 0.25 - 5 1 - 5 2 - 4 19 - 41 11 - 27 101 - >6m 101 - >6m >6m >6m >6m 
         (continued) 


































MPBP 1 5 7 59 24 -- -- -- -- -- 
Naphyrone 0.5 0.5 3 14 14 59 130 -- 146 -- 
α-PVP 2 2 4 27 14 146 130 -- 101 -- 
Pyrovalerone 0.25 0.25 3 24 19 166 130 -- 184 -- 
Range 0.25 - 2 0.25 - 5 3 - 7 14 - 59 14 - 24 59 - >6m 130 - >6m >6m 101 - >6m >6m 
Tertiary Amines - Methylenedioxy-Substituted 
MDPBP 0.5 5 14 115 55 -- -- -- -- -- 
MDPV 1 2 9 41 55 -- -- -- -- -- 




Synthetic cathinone degradation products 
Synthetic cathinone degradation product identification was extremely challenging 
due to twenty-two cathinones in a single sample, each potentially having multiple 
degradation products and intermediate species. This significantly hindered identification 
efforts. Furthermore, cathinones bearing a secondary amine may degrade into acidic 
products (figure and ref), which are not expected to extract from blood using the mixed-
mode (cation exchange) SPE. While degradation product identification for the secondary 
amine cathinones was limited, the N-oxide degradation product was identified for all 
tertiary amines, except MPBP due to suspected interference from pyrovalerone. The 2”-
oxo degradation product was also identified, albeit in very low abundance. Representative 
MS/MS spectra of N-oxide and 2”-oxo degradation products are shown for MDPV in 
Figure 3.10. 
While MDPV, MDPV-N-oxide, and 2”-oxo-MDPV share many fragments, the 
MS/MS spectra for N-oxide and 2”-oxo had characteristic m/z of 86.0596 and 84.0803, 
respectively. The two ions correspond to the dissociation of γ-lactam (2”-oxo, C4H6NO) 
and N-oxidized pyrrolidine group (C4H8NO) from the phenethylamine pharmacophore. 
These characteristic ions were observed in all degradation product spectra for tertiary 
amine cathinones (Appendix E). The mass accuracy of precursor and fragment m/z were 
<14 ppm (Table 3.4). Although mass accuracies of 5 ppm or less are ideal, biological 







Figure 3.10. LC-Q/TOF MS MS/MS spectra for 2”-oxo-MDPV (top), MDPV (middle), 
and MDPV-N-oxide (bottom).  
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Table 3.4. Mass accuracy for N-oxide fragments for tertiary amine cathinones.  
Fragment Theoretical Mass Experimental Difference (PPM) 
α-PVP 
C15H21NO2 248.1645 248.1621 -9.7 
C8H16N 126.1283 126.1268 -11.9 
C8H7O 119.0491 119.0478 -10.9 
C7H14N 112.1121 112.1115 -5.4 
C4H8NO 86.0600 86.0598 -2.3 
MDPBP 
C15H20NO4 278.1387 278.1379 -2.9 
C8H5O3 149.0239 149.0221 -12.1 
C7H14N 112.1121 112.1114 -6.2 
C4H8NO 86.0600 86.0600 0.0 
C4H8N 70.0651 70.0645 -8.6 
MDPV 
C16H22NO4 292.1543 292.1531 -4.1 
C10H9O3 177.0546 177.0540 -3.4 
C8H5O3 149.0233 149.0222 -7.4 
C8H16N 126.1283 126.1268 -11.9 
C4H8NO 86.0600 86.0596 -4.6 
C4H8N 70.0651 70.0650 -1.4 
Pyrovalerone 
C16H24NO2 262.1802 262.1771 -11.8 
C8H16N 126.1283 126.1266 -13.5 
C8H7O 119.0491 119.0485 -5.0 
C7H14N 112.1121 112.1108 -11.6 
C4H8NO 86.0600 86.0598 -2.3 
Naphyrone 
C19H24NO2 298.1802 298.1831 9.7 
C11H7O 155.0491 155.0479 -7.7 
C8H16N 126.1283 126.1267 -12.7 





Cathinone use is an ongoing drug problem, evidenced by increased drug seizures, 
adverse effects and fatalities. Cathinone stability was investigated to determine 
concentration, temperature and analyte dependence. Although no concentration 
dependence was observed, cathinone stability was greatly influenced by temperature and 
analyte-dependent variables. Figure 3.11 summarizes overall analyte-dependent 
differences in stability among the twenty-two cathinones evaluated. Nitrogen substituents 
and MD ring-substitutions had the greatest impact. With the exception of 3-FMC, ring 
substituents had limited influence on stability among the secondary amines; differences in 
stability between ring substituted secondary amines were of sufficient magnitude to 




Figure 3.11. Influence of chemical structure on synthetic cathinone stability. 
 
Although a highly systematic approach was taken in this study to address 
concentration, analyte and temperature dependent effects, the results are in good agreement 
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with previously published studies. Johnson and Botch-Jones’ study of MDPV and 
mephedrone noted considerable differences in stability between the tertiary and secondary 
amine and also recommended frozen storage to minimize losses (20). The study of 
mephedrone in antemortem and postmortem blood reported by Busardò concluded that 
mephedrone was undetectable after 30 days at 20°C (23). These results are in close 
agreement with our results, which showed that mephedrone was undetectable by 27 days.  
Drug instability and the magnitude of the loss was heavily influenced by 
temperature and chemical characteristics. Therefore, concentrations at the time of testing 
may not always reflect those at the time of interest e.g., time of death or time of driving. 
Although drugs may still be detectable, significant losses are possible. Given that 
biological evidence is sometimes exposed to unfavorable conditions in both postmortem 
and antemortem toxicology investigations during routine shipping and transport to the 
laboratory, toxicological findings should be interpreted cautiously and within the full 
context of evidence disposition. These finding are of value in forensic toxicology 
investigations involving these twenty-two cathinones. However, a greater understanding 
of analyte dependent variables (specifically functional groups that have stabilizing effects) 
has a much broader impact, because it may allow us predict the stability of future synthetic 
cathinones, as these designer drugs continue to evolve. 
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In this report, we evaluate the concentration, pH, temperature, and analyte 
dependent effects on cathinone stability in preserved human urine. A total of twenty-two 
synthetic cathinones were evaluated at 100 ng/mL and 1,000 ng/mL in pH 4 and pH 8 urine 
over six months. Specimens were stored at -20, 4, 20 and 32°C. The stability of synthetic 
cathinones was highly dependent upon urine pH and storage temperature. Cathinones were 
considerably more stable in acidic urine (pH 4) at low temperature. In alkaline urine (pH 
8) at 32°C, significant losses (>20%) were observed within hours for the majority of drugs. 
In contrast, all drugs were stable in frozen and refrigerated urine at pH 4 for the duration 
of the study. These results highlight the importance of sample storage and the potential for 
pre-analytical changes in concentration during routine shipping and handling of specimens. 
Significant structural influence was also observed. Cathinones bearing a tertiary amine 
(pyrrolidine group) were significantly more stable than their secondary amine counterparts. 
The methylenedioxy group also exerted a significant stabilizing effect on both the tertiary 
and secondary amines. In the absence of the methylenedioxy group, no significant 
differences in stability were observed between the unsubstituted and ring substituted 
secondary amines. Half-lives at ambient temperature in pH 8 urine ranged from 9 hours (3-
fluoromethcathinone, 3-FMC) to 4.3 months (methylenedioxypyrovalerone, (MDPV) and 
3,4-methylenedioxy-α-pyrrolidinobutiophenone, MDPBP), demonstrating the importance 
of analyte dependence, and the dual stabilizing effect of both the pyrrolidine and 
methylenedioxy groups. Biological evidence may be subjected to a variety of 
environmental conditions prior to, and during transport to the forensic laboratory. These 
findings demonstrate the inherent instability of certain cathinone species in biological 
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evidence under some conditions. Moreover, this study highlights the need for quantitative 
drug findings in toxicological investigations to be interpreted cautiously, and within the 
context of specimen storage and integrity. 
 
Keywords:   Designer drugs, Cathinones, Stability, Urine
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STABILITY OF SYNTHETIC CATHINONES IN URINE 
Introduction 
The ongoing proliferation of designer drugs and novel psychoactive substances 
(NPSs) continues to present a variety of public health and safety challenges (1, 2). 
Synthetic cathinones are an important class of designer drugs, capable of producing 
euphoric, empathogenic and central nervous system stimulant effects similar to 
methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) (3, 4). 
Their harmful and addictive effects, resulting in acute toxicity and death, have led to 
increased vigilance as they relate to forensic toxicology investigations.  
Synthetic cathinones and other NPSs are constantly evolving, as part of a strategic 
effort to circumvent and undermine drug legislation. According to the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA), a total of six hundred and 
twenty new substances are currently being monitored (2). Synthetic cathinones were the 
most frequently seized NPSs in 2015, accounting for one third of the total number of 
seizures. The emergence of new drugs each year, including cathinones, presents a 
formidable challenge to the forensic toxicology community. In Europe, the EMCDDA 
reported fourteen new cathinones in 2016 and in the United States, the Drug Enforcement 
Administration’s National Forensic Laboratory Information System (NFLIS) reported a 
total of thirty five synthetic cathinones in 2015 (1, 2). Substitutions on the aromatic ring, 
side chain and nitrogen influence the pharmacological and physicochemical properties of 
the drug. Although many of the drugs share similar functionality, the proliferation and 
variety of cathinone analogs makes it an ongoing challenge to keep pace with the 
chemistry, toxicology and stability of these arylaminoketones. 
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Drug stability and in particular, pre-analytical changes in drug concentration, must 
be considered when interpreting toxicological results (5). The stability and properties of 
common illicit drugs are widely understood, but relatively little is known regarding the 
synthetic cathinones. However, there is real need to investigate their stability in biological 
evidence, due to their increasing prevalence in ante-mortem and post-mortem 
investigations (6-15). Reports of synthetic cathinone stability in biological evidence are 
still relatively limited and have been described for a relatively small number of cathinones. 
We recently described a systematic approach to determine cathinone stability in blood 
using twenty-two cathinones (16). In this report, we describe a similar approach to evaluate 
the concentration, analyte, matrix, and temperature dependent stability of cathinones in 
urine. 
 To date, there have been a limited number of reports that describe cathinone 
stability in urine (17-20). Paul and Cole (17) were the first in the early 2000s to investigate 
the stability of methcathinone and cathinone in urine over three months at -18°C and 4°C. 
Both drugs were stable for two months when frozen, and for three days when refrigerated. 
As much as 79% was lost within three months at 4°C.  Al-Saffar (19) and Johnson (18) 
were among the first to draw attention to the analyte dependent differences in cathinone 
stability. MDPV and mephedrone were evaluated in urine at -20°C, 4°C, and 22°C over 14 
days at 1,000 ng/mL. MDPV was stable in all matrices at all temperatures. In contrast, 
mephedrone was considerably less stable, demonstrating significant losses within 7 days 
at room temperature (18). Al-Saffar (19) evaluated the stability of ten cathinones in urine 
(1,000 ng/mL) over 3 months at 22, 6 and -20oC. Significant losses were observed within 
one day at room temperature for methcathinone, buphedrone, mephedrone, 3-FMC, 4-
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fluoromethcathinone (flephedrone, 4-FMC), and pentylone. Although MDPV, naphyrone, 
butylone and methedrone exhibited greater stability, all but MDPV were undetectable 
within three months at room temperature. Concheiro (20) reported losses as high as 68% 
for some cathinones in urine when stored at room temperature for 24 hours. Urinary pH 
and preservatives were not specified in any of the published studies to date.  
Tsujikawa (21) investigated the stability of five synthetic cathinones in aqueous 
buffers at various pHs (4, 7, 10 and 12). They noted the influence of chemical structure and 
pH on rates of decomposition. Cathinone stability was highly pH dependent, demonstrating 
significant alkaline lability. Maskell  (22) investigated the stability of three secondary 
amines, including mephedrone, in various formalin concentration solutions (5, 10, and 
20%) at three pHs (3.5, 7, and 9.5). pH-Dependent degradation was independent of 
formalin concentration, with mephedrone having significant degradation within 1-3 days 
of storage at pH 9.5 and 7 in all formalin solutions. At a pH of 3.5 however, mephedrone 
was considerably more stable. The findings of Tsujikawa and Maskell are particularly 
significant for biological specimens such as urine, because the pH range can be quite 
variable.  Although normal urinary pH is typically 4-8, it is influenced by diet, renal 
function, disease state, metabolic acidosis, diabetic ketoacidosis and other factors. Storage 
time and temperature can also play a role (23). Although preliminary studies suggest 
analyte, temperature and pH dependent effects, a comprehensive approach is needed. Such 
an approach may provide insight into new cathinones, yet to emerge.  In this report we 
describe a systematic approach to evaluate the concentration, analyte, pH, and temperature-
dependent stability of cathinones in urine, including a variety of substituted and 
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unsubstituted secondary and tertiary (pyrrolidine) analogs over a period of six months 
(Figure 4.1). 
 
Figure 4.1. Cathinone structures, indicating secondary and tertiary amines, unsubstituted, 
ring-substituted and methylenedioxy (MD)-substituted drugs. 
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Materials and Methods 
Chemicals and reagents  
Methcathinone, 3-FMC, 4-FMC, methylone, ethcathinone, ethylone, methedrone, 
buphedrone, butylone, mephedrone, eutylone, 4-methylethcathinone (4-MEC), 3,4-
methylenedioxy-α-pyrrolidinobutiophenone (MDPBP), pentedrone, pentylone, 3,4-
dimethylmethcathinone (3,4-DMMC), α-pyrrolidinopentiophenone (α-PVP), 4-
ethylmethcathinone (4-EMC), 4-methyl-α-pyrrolidinobutiophenone (MPBP), 
methylenedioxypyrovalerone (MDPV), pyrovalerone, and naphyrone were purchased from 
Cerilliant Corporation (Round Rock, TX, USA) in 1.0 mg/mL methanolic solutions. 
Internal standards methylone-D3, ethylone-D5, butylone-D3, mephedrone-D3, eutylone-
D5, pentylone-D3, alpha-PVP-D8, MDPV-D8, and naphyrone-D5 were also purchased 
from Cerilliant Corporation in 0.1 mg/mL methanolic solutions. The internal standard 
working solution consisted of all nine deuterated internal standards at a concentration of 
0.25 ng/µL in methanol. Pooled drug-free urine, preserved with 1% sodium fluoride, was 
purchased from Utak Laboratories (Valencia, CA, USA).  
LC-MS grade dichloromethane and isopropyl alcohol, and ACS grade glacial acetic 
acid were purchased from Mallinckrodt Chemicals (St. Louis, MO, USA). LC-MS grade 
methanol, concentrated hydrochloric acid, concentrated ammonium hydroxide, LCMS 
grade acetonitrile, and dibasic sodium phosphate were purchased from J.T. Baker (Center 
Valley, MA, USA). Optima® Hexane and HPLC grade ethyl acetate were purchased from 
Fisher Scientific (Fair Lawn, NJ, USA). LC-MS grade formic acid was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Monobasic sodium phosphate was purchased from 
VWR (Radnor, PA, USA). Deionized water was purified in-house using a Millipore Direct-
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Q® UV Water Purification system (Billerica, MA, USA). PolyChrom ClinII 3 cc (35 mg) 
solid phase extraction (SPE) columns were purchased from SPEware (Baldwin Park, CA, 
USA). Non-sterile polypropylene urine specimen cups (100 mL) were purchased from 
Starplex Scientific Corp. (Cleveland, TN).  
Instrumentation  
Sample analysis was performed using an Agilent Technologies 6530 LC-Q/TOF-
MS (Santa Clara, CA, USA) equipped with an Agilent 1290 Infinity autosampler and a 
Series 1200 LC system. The LC system was equipped with a Poroshell 120 EC-C18 column 
(2.1 x 100 mm, 2.7 µm particle size) and an Agilent Poroshell 120 EC-C18 guard column 
(2.1 x 5 mm, 2.7 µm particle size) located in a thermostatically controlled column 
compartment (35°C). The mobile phase consisted of 0.1% formic acid in deionized water 
(A) and 0.1% formic acid in acetonitrile (B). A flow rate of 0.4 mL/min was maintained 
using a gradient elution profile as follows: 96% A and 4% B (0 to 0.5 mins); 10% B (0.5 
to 5 mins); 40% B (5 to 11 mins); 100% B (12 mins). The LC-Q/TOF MS was equipped 
with an electrospray ionization (ESI) source (positive mode) was operated under the 
following conditions: drying gas (N2), 13 L/min; drying gas temperature, 200oC; nebulizer, 
20 psi; sheath gas temperature, 250oC; nitrogen sheath gas flow, 12 L/min; capillary 
voltage, 4000 V; nozzle voltage, 0 V; fragmentor, 150 V; skimmer, 65V. Agilent 
MassHunter software was used for acquisition, qualitative, and quantitative analysis. 
Nitrogen was generated using a Genius 3040 Nitrogen Generator (Peak Scientific, 
Billerica, MA, USA). Solid Phase Extraction (SPE) was performed using a JT Baker 
vacuum manifold and extracts were evaporated to dryness under nitrogen using a 
TurboVap LV® concentration workstation (Caliper Life Sciences, Hopkinton, MA, USA). 
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The LC-Q/TOF procedure was described previously (24, 25) and was validated in 
accordance with previously published guidelines (24, 25).  
Sample preparation 
Preserved, drug-free urine (1 L) was adjusted to pH 8.0 and pH 4.0 using 
concentrated ammonium hydroxide and concentrated hydrochloric acid, respectively. 
Urine was fortified with twenty-two synthetic cathinones to achieve a final concentration 
of 100 ng/mL and 1,000 ng/mL. Cathinone-positive urine, which was prepared in bulk, was 
then aliquoted into non-sterile polypropylene specimen cups to allow for sampling 
throughout the duration of the six month study. The experimental design is summarized in 
Figure 2. Exposure to light was not evaulated. Specimens stored at elevated and frozen 
temperatures were stored predominantly in the dark, while ambient and refrigerated 
samples were periodically exposed to light. All urine samples were subjected to light 
during initial preparation, routine sampling, and analysis. Aliquots of urine at each 
concentration (100 and 1,000 ng/mL) and each pH were immediately analyzed to establish 
T0 (0% loss). Samples were analyzed in duplicate using the validated procedure described 
previously (24). Sampling frequency varied throughout the study to allow for sufficient 
data collection during periods where significant concentration changes were taking place. 
Sampling occured every 2-4 hours during the intial 72 hours and remained frequent (4 
assays/week) during the first month of storage. Sampling generally decreased to bimonthly 
and then to monthly over the remaining months. Calibrators (10, 25, 100, 250, 350, and 
500 ng/mL) and controls (0, 100 ng/mL) included in each batch were prepared daily using 
independently fortified standards. Appropriate dilutions (up to four-fold) were applied 
initially at the high concentration (1,000 ng/mL) to ensure quantitative results were within 
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the calibration range of the assay. The drug was considered unstable when the 
concentration decreased by more than 20% of the original (T0) concentration. Statistical 
tests, including analysis of variance (ANOVA), were used to determine statistical 
significance (p=0.05).  
Isolation of cathinones from urine 
Internal standard solution (100 µL) was added to 1 mL urine to achieve a final 
concentration of 25 ng/mL. The urine was diluted with 2 mL of pH 6 phosphate buffer (0.1 
M) and briefly vortexed. Samples were transferred to PolyChrom ClinII SPE columns and 
allowed to flow through under gravity. Columns were rinsed with 1 mL deionized water 
followed by 1 mL of 1 M acetic acid. Columns were dried under vacuum for 5 minutes and 
washed, successively, with 1 mL of hexane, ethyl acetate, and methanol. Synthetic 
cathinones were eluted using two 0.5 mL aliquots of elution solvent (2% conc. ammonium 
hydroxide in 95:5 dichloromethane: isopropyl alcohol). Acidic methanol (30 µL) was 
added to each extract prior to evaporation under nitrogen at 50°C. Extracts were 
reconstituted in 25 µL of 50:50 mixture of mobile phase A:B and 1 µL was injected onto 
the LC-Q/TOF-MS for analysis.  
Results 
The purpose of the study was to systematically evaluate the concentration, pH, 
temperature, and analyte dependent stability of synthetic cathinones. Each variable is 
considered below. Due to the large number of drugs, graphical representations of the data 
were color-coded to facilitate interpretation. Cathinones (secondary amines) without 
aromatic substituents are depicted in green; secondary amines with aromatic substituents 
are yellow, and tertiary amines (pyrrolidine-type) cathinones are purple. Finally, 
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cathinones with a methylenedioxy (MD) group are shown with a magenta line (for both 
secondary and tertiary amines). 
Concentration dependence 
Concentration dependence was assessed by comparing the percentage of drug 
remaining (% target) at 100 ng/mL and 1,000 ng/mL, in order to normalize the data. One-
way ANOVA was used to compare the mean (% target at each sampling interval) at each 
temperature and pH in urine. Statistical significance was evaluated for each drug under all 
eight conditions (Figure 4.2). Figure 4.3 depicts the changes in concentration over time in 
pH 4 urine at ambient temperature. No concentration dependent differences in stability 
were observed for any of the conditions (p=0.05). Therefore, all subsequent statistical 
evaluations of temperature, pH, matrix, and analyte dependence were undertaken at 1,000 
ng/mL. 
 
Figure 4.2. Summary of experimental design, indicating the sixteen conditions under 





Figure 4.3. Degradation of synthetic cathinones (100 and 1,000 ng/mL) at 20oC. 
Cathinone structure throughout can be differentiated as follows: unsubstituted secondary 
amines (green), ring-substituted secondary amines (yellow), tertiary amines (purple) and 
methylenedioxy (MD)-substituted cathinones (magenta line).  
 
Half-life determination 
Assuming first-order decay, rate constants (k) and half-lives (T1/2) were estimated 
for each drug based upon duplicate measurements at each time interval (T1/2=Ln2/k). Rate 
plots were only generated if a significant decrease in concentration (>20%) was evident 




Figure 4.4. Decomposition of cathinones at pH 4 (elevated and ambient temperature) and 
pH 8 (all temperatures). 
 
The synthetic cathinones were significantly more stable in acidic urine, therefore half-life 
estimation was only possible for some cathinones at ambient and elevated temperatures. 
Half-lives in acidic urine ranged from 10.4 days to 13.2 months, and 1.8 to 14.2 months at 
elevated and ambient temperature, respectively (Table 4.1). At pH 4, all cathinones were 
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stable over the six month period at refrigerated and frozen temperatures, precluding half-
life determination.  
Table 4.1. Half-lives of cathinones in urine (pH 4 and 8) in hours (h), days (d) and 
months (m) at  elevated, ambient, refrigerated and frozen temperature. 








pH 4 pH 8 pH 4 pH 8 pH 4 pH 8 pH 4 pH 8 
3,4-DMMC -- 5.3 m -- 21 d 14 m 1.7 d  2.0 m 11 h 
4-EMC -- 4.4 m -- 17 d 11 m 1.3 d 1.3 m 9 h 
3-FMC -- 1.3 m -- 4.5 d 1.8 m 9 h  10 d 2 h 
4-FMC -- 2.7 m -- 8.8 d 5.8 m 20 h  1.1 m 5 h 
Buphedrone -- 5.6 m -- 1 m -- 2.3 d 1.8 m 20 h 
Butylone -- -- -- 3.8 m -- 8 d 7.4 m 2.1 d 
Ethcathinone -- 4.5 m -- 14 d 8.2 m 23 h  1.4 m 8 h 
Ethylone -- 13 m -- 1.8 m -- 3.2 d 2.5 m 19 h 
Eutylone -- -- -- 6.2 m -- 11 d 13 m 3 d 
MDPBP -- -- -- -- -- 4.3 m -- 3.6 m 
MDPV -- -- -- -- -- 4.3 m -- 1.7 m 
4-MEC -- 5.5 m -- 25 d 9.7 m 1.3 d 1.6 m 9 h 
Mephedrone -- 4.7 m -- 25 d 14 m 1.5 d 1.5 m 10 h 
Methcathinone -- 2.9 m -- 9.3 d 6.6 m 18 h  1.2 m 5 h 
Methedrone -- 7.6 m -- 1.7 m -- 3.7 d 2.3 m 19 h 
Methylone -- 8.7 m -- 1.4 m -- 3 d 1.9 m 1 d 
MPBP -- -- -- 15 m -- 1.4 m -- 1.6 m 
Naphyrone -- -- -- 3.9 m -- 11 d -- 4.8 d 
Pentedrone -- 4.3 m -- 19 d 13 m 1.4 d 1.8 m 10 h 
Pentylone -- 15 m -- 2.6 m -- 5 d 5.2 m 1.4 d 
α-PVP -- -- -- 7.1 m -- 1.3 m -- 18 d 
Pyrovalerone -- -- -- 11 m -- 1.0 m -- 1.2 m 
 
In contrast, half-lives were estimated for all cathinones in alkaline urine at ambient 
and elevated temperature. The half-lives for all twenty-two cathinones ranged from 2 hours 
(3-FMC) to 3.6 months (MDPBP), and 9 hours (3-FMC) to 4.3 months (MDPBP and 
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MDPV) at elevated and ambient temperatures, respectively. At refrigerated and frozen 
temperatures, cathinones were considerably more stable. Half-lives in pH 8 urine were 
estimated for all but two cathinones (MDPV and MDPBP) at refrigerated temperature, and 
all but eight drugs (α-PVP, butylone, eutylone, MDPBP, MDPV, MPBP, naphyrone and 
pyrovalerone) at frozen temperature. When specimens were refrigerated, half-lives ranged 
from 4.5 days to 11 months, and when frozen, ranged from 1.3 to 15 months. Half-life 
estimates for these drug clearly demonstrate the significance of storage temperature, matrix 
pH and analyte dependent variables.  
Analyte dependence 
Analyte dependent differences in stability were readily observed from graphical 
representations of the data (Figure 4.5 & 4.6). Statistical comparisons were also made, 
wherever possible. The twenty-two cathinones (Figure 4.1) selected in the study included 
secondary and tertiary amines, with and without ring substituents, which allowed for the 
comparison of cathinone stability within a sub-population and between populations using 
one-way ANOVA. Statistical comparisons between structural groups were only made if 
the differences in stability within the group were not significant. 3-FMC was excluded from 
all statistical tests presented because it degraded much more extensively than its ring-
substituted counterparts. As would be expected, analyte dependent differences in stability 
were more readily identified under unfavorable conditions (elevated pH and temperature). 
Statistical comparisons between groups were not made when overall stability was 
observed, which included the majority of conditions at pH 4 (Figure 4.5). As a result, 
conclusions pertaining to analyte dependent differences in stability are predominantly 
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drawn from results obtained in alkaline urine. A summary of statistical analysis for 





Figure 4.5. Box plots depicting within and between sub-populations of synthetic 
cathinones. Sub-populations include secondary amine, unsubstituted (green); secondary 
amine, ring substituted (yellow); secondary amine, MD (magenta); tertiary amine, non-
MD (purple); tertiary amine, MD (magenta/purple). Mean (‘X’) and median (line) 




Figure 4.6. Box plots depicting within and between sub-populations of synthetic 
cathinones. Sub-populations include secondary amine, unsubstituted (green); secondary 
amine, ring substituted (yellow); secondary amine, MD (magenta); tertiary amine, non-
MD (purple); tertiary amine, MD (magenta/purple). Mean (‘X’) and median (line) 
concentration for each drug over the six month study also identified.  
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In pH 8 urine, no significant differences in stability were observed within the 
unsubstituted secondary amines (methcathinone, buphedrone, ethcathinone, pentedrone), 
substituted secondary amines (mephedrone, 4-MEC, 4-EMC, methedrone, 3,4-DMMC, 4-
FMC) or  MD-substituted secondary amines (ethylone, butylone, pentylone, methylone, 
eutylone). Collectively however, significant differences were observed within all of the 
secondary amines. Tertiary amines produced similar results. Differences within the groups 
were highly significant for secondary (F(14,354=7.71, p<0.0001, 4oC) and tertiary amines 
(F(5,116)=8.22, p<0.0001 at 4oC), suggesting that cathinone stability is influenced by more 
than just the amine moiety.  
The methylenedioxy group exerted a significant stabilizing effect on both the 
secondary and tertiary amines (Figure 4.5 & 4.6). In refrigerated pH 4 urine, MD-
substituted secondary amines were significantly more stable than their unsubstituted 
(F(8,210)=11.67, p<0.0001) or substituted counterparts (F(11,273)=8.74, p<0.0001). MD-
substituted pyrrolidinyl analogs were also more stable than their non-MD substituted 
counterparts, further highlighting the stabilizing effect of the methylenedioxy group, 
independent of the amine.  
Cathinones bearing a tertiary amine were generally more stable than the secondary 
amines (Figure 4.5 & 4.6). It was not possible to evaluate these differences statistically 
however, because of significant within group differences arising from ring substituents. 
Cathinones bearing a the tertiary amine and a methylenedioxy substituent were more stable 
than their secondary amine methylenedioxy-type counterparts (F(6,147)=10.03, p<0.0001, 
4°C), making the MD-type pyrrolidines (MDPBP and MDPV) the most stable of the 
twenty-two drugs evaluated. The half-life estimation further highlights the stability of the 
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pyrrolidines, with half-lives on the order of days to months under many of the conditions 
tested, compared with hours to days for the secondary amines (Table 4.2, Figure 4.7 & 
4.8). An understanding of the analyte dependent differences in stability, particularly the 
stabilizing effect of both the pyrrolidine and methylenedioxy groups, is particularly useful 
as laboratories encounter new and emerging cathinone derivatives in the future.  
Table 4.2. Influence of chemical structure on cathinone half-life in hours (h), days (d) 
and months (m) at elevated, ambient, refrigerated and frozen temperature. 
Urine (pH 8) 
Amine Structure 32°C 20°C 4°C -20°C 
Tertiary MD-substituted 2 – 4 m 4 m - - 
Tertiary - 5 – 46 d 0.4 - 1.4 m ≥4 m - 
Secondary MD-substituted 19 – 72 h 3 – 11 d 1.4 – 6 m ≥8 m 
Secondary - 2 – 20 h 0.4 – 4 d 4 – 25 d ≥2 m 
Urine (pH 4) 
Amine Structure 32°C 20°C 4°C -20°C 
Tertiary MD-substituted - - - - 
Tertiary - - - - - 
Secondary MD-substituted ≥2 m - - - 







Figure 4.7. Analyte dependent stability of cathinones (tertiary amine to secondary amine) 
in acidic urine (pH 4). Unlabeled data indicates a half-life of >365 days or no 





Figure 4.8. Analyte dependent stability of cathinones (tertiary amine to secondary amine) 
in alkaline urine (pH 8). Unlabeled data indicates a half-life of >365 days or no 
measureable half-life due to stability.  
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Matrix pH and temperature dependence 
Not surprisingly, stability was significantly influenced by storage temperature, 
regardless of urine pH. All cathinones, from the least stable (3-FMC, F(3,101)=9.83, 
p<0.0001) to most stable (MDPV, F(3,98)=18.76, p<0.00001, pH 8; MDPBP, 
F(3,78)=38.87, p<0.0001, pH 8) were optimally preserved at decreased temperatures. 
Stability was also significantly dependent upon matrix pH, even for the most stable 
cathinones like MDPV (F(1,53)=26.63, p<0.0001, 4oC) and MDPBP (F(1,41)=23.56, 
p<0.0001, 4oC. Cathinones were significantly more stable in acidic urine, illustrated in 
Figure 4.5 & 4.6 and 4.9. Over the six month period, all twenty-two drugs were stable in 
pH 4 urine when refrigerated or frozen. Changes in pH during the course of the study were 
moderate (less than 0.5 pH units) for urine stored at frozen, refrigerated, and ambient 
temperatures over six months. Urine stored at elevated temperature was subject to a greater 
increase in pH (less than 2 pH units), consistent with previously published reports (23, 26). 
Due to the analyte dependent differences discussed earlier, the influence of temperature 









Unsubstituted & substituted secondary amines 
All secondary amines (without the methylenedioxy group) proved to be stable in 
acidic urine at elevated temperature for approximately 30 days, with the exception of 3-
FMC (Figure 4.9). Methcathinone and 4-FMC were unstable at elevated temperature after 
28 days. At ambient temperature, all were stable for at least two months (with the exception 
of 3-FMC), and when refrigerated or frozen  no instability was observed over the six month 
period.   
In contrast, instability was observed in alkaline urine at all temperatures within 
hours of storage at elevated and ambient temperatures, and within days at refrigerated and 
frozen temperatures (Table 4.3). This highlights the significant pH and temperature 
dependent stability of these drugs. For almost all secondary amines, instability occurred 
within 5 hours of storage at pH 8 at 32oC, emphasizing the need to minimize exposure to 
elevated temperatures during shipping and transport. Losses of 100% were observed in pH 
8 urine within days of exposure to elevated temperature (32°C) (Table 4.4). In contrast, 
although significant losses were observed in pH 8 urine within days or weeks when frozen 
(Table 4.3), all drugs were detectable over the six month period (Table 4.4).  
Methylenedioxy-type 
With the exception of elevated temperature, all five methylenedioxy-type 
secondary amines were stable in pH 4 urine for the duration of the study (Table 4.3). In 
pH 8 urine, instability was observed under all conditions, with the exception of eutylone at 
-20°C. However, even under unfavorable alkaline conditions, the stabilizing effect of the 
methylenedioxy group was evident relative to other secondary amines. This is readily 
observed in refrigerated and frozen urine at pH 8 (Figure 4.9). At elevated temperature at 
236 
  
pH 8, all were unstable within one day, compared with 0.9 to greater than 6 months when 
frozen (Table 4.3). In addition to the dramatic effect of temperature, matrix pH also played 
a key role. Methylenedioxy-substituted secondary amines were stable for 5 to 21 days in 
pH 8 urine, compared with over 6 months of storage in pH 4 urine.  
Pyrrolidine-type 
The tertiary amines were the most stable group under all conditions tested (Figure 
4.9). Degradation however, was still greatly influenced by temperature and pH. When 
refrigerated, non-MD substituted pyrrolidines were stable for 18 to 91 days at pH 8, 
compared with greater than 6 months at pH 4. At alkaline pH, this same group was stable 
for 1 to 3 days at elevated temperature, compared with 0.9 to over 6 months of storage 
when frozen. When refrigerated or frozen, MDPBP and MDPV were the only drugs to 
remain stable in urine for the duration of the study, regardless of pH. This again highlights 
the dual stabilizing effect of the tertiary amine and the methylenedioxy group. 
Overall 
The influence of storage temperature and matrix pH was highly significant. This is 
reflected in the extreme differences in the number of days to significant loss (20%) and 
complete loss (100%) depicted in Tables 4.3 and 4.4. Based on these findings, positive 
cathinone toxicology results should be interpreted accordingly. Although the laboratory 
can ensure that biological samples are stored appropriately upon receipt, exposure to 
elevated temperatures during transport and individual specimen pH are factors largely 
beyond their control. Not only can these factors decrease drug concentrations, it could 




Table 4.3. Time to significant (20%) loss of drug at 1,000 ng/mL. Time is expressed in hours (h), days (d) and months (m). Data is 
also summarized by amine type and aromatic ring substitution. The limit of detection (LOD) is shown in parentheses. 
Cathinone (LOD) Elevated Ambient Refrigerated Frozen 
 pH 8 pH 4 pH 8 pH 4 pH 8 pH 4 pH 8 pH 4 
Secondary Amine, Unsubstituted 
Buphedrone (2 ng/mL) 6 h  63 d <1 d 91 d 3 d -- 5 d -- 
Ethcathinone (1 ng/mL) 5 h  38 d <1 d 63 d 2 d -- 12 d -- 
Methcathinone (0.25 ng/mL) 4 h 28 d 6 h  63 d 1 d -- 12 d -- 
Pentedrone (5 ng/mL) 5 h  42 d <1 d 115 d 3 d -- 12 d -- 
Secondary Amine, Substituted 
3,4-DMMC (5 ng/mL) 5 h 42 d 1 d 172 d 5 d -- 28 d -- 
3-FMC (1 ng/mL) 2 h  9 d 4 h 21 d <1 d -- 5 d -- 
4-EMC (2 ng/mL) 5 h  38 d 1 d 91 d 5 d -- 11 d -- 
4-FMC (1 ng/mL) 4 h 28 d 6 h  63 d 1 d -- 9 d -- 
4-MEC (1 ng/mL) 5 h  42 d <1 d 91 d 3 d -- 9 d -- 
Mephedrone (2 ng/mL) 5 h  38 d <1 d 91 d 3 d -- 12 d -- 
Methedrone (1 ng/mL) 8 h  68 d 1 d -- 8 d -- 16 d -- 
Secondary Amine, Methylenedioxy-Type 
Butylone (1 ng/mL) 1 d 143 d 3 d -- 18 d -- 38 d -- 
Ethylone (1 ng/mL) 8 h  78 d 1 d -- 9 d -- 28 d -- 
Eutylone (5 ng/mL) 1 d 172 d 4 d -- 21 d -- -- -- 
Methylone (0.25 ng/mL) 6 h 63 d 1 d -- 5 d -- 38 d -- 




Cathinone (LOD) Elevated Ambient Refrigerated Frozen 
 pH 8 pH 4 pH 8 pH 4 pH 8 pH 4 pH 8 pH 4 
Pentylone (1 ng/mL) <1 d 115 d 2 d -- 7 d -- 38 d -- 
Tertiary Amine (Pyrrolidine-Type) 
α-PVP (2 ng/mL) 3 d -- 3 d -- 18 d -- -- -- 
MDPBP* (0.5 ng/mL) 1 d 143 d 4 d -- 143 d -- -- -- 
MDPV* (1 ng/mL) 18 d -- 28 d -- -- -- -- -- 
MPBP (1 ng/mL) 1 d -- 7 d -- 91 d -- -- -- 
Naphyrone (0.5 ng/mL) 1 d 172 d 4 d -- 18 d -- 38 -- 
Pyrovalerone (0.25 ng/mL) <2 d -- 6 d -- 91 d -- -- -- 
Amine Structure Time to Significant Loss 
Tertiary MD 1 – 18 d 4.7- >6 m 4-28 d >6 m >6 m >6 m >6 m >6 m 
Tertiary - 1 – 3 d 5.7- >6 m 3-7 d >6 m 18-91 d >6 m 0.9- >6 m >6 m 
Secondary MD 6 h – 1 d 2.1- 4.7 m 1-4 d >6 m 5–21 d >6 m 0.9- >6 m >6 m 





Table 4.4.  Time to complete (100%) loss of drug at 1,000 ng/mL.  Time is expressed in hours (h), days (d) and months (m).  Data is 
also summarized by amine type and aromatic ring substitution. The limit of detection (LOD) is shown in parentheses. 
Cathinone (LOD) Elevated Ambient Refrigerated Frozen 
 pH 8 pH 4 pH 8 pH 4 pH 8 pH 4 pH 8 pH 4 
Secondary Amine, Unsubstituted 
Buphedrone (2 ng/mL) 5 d -- 14 d -- -- -- -- -- 
Ethcathinone (1 ng/mL) 3 d -- 9 d -- 143 d -- -- -- 
Methcathinone (0.25 ng/mL) <2 d 143 d 5 d -- 56 d -- -- -- 
Pentedrone (5 ng/mL) 4 d -- 11 d -- 143 d -- -- -- 
Secondary Amine, Substituted 
3,4-DMMC (5 ng/mL) 4 d -- 16 d -- -- -- -- -- 
3-FMC (1 ng/mL) <1 d 143 d 3 d -- 42 d -- -- -- 
4-EMC (2 ng/mL) 3 d 172 d 11 d -- 143 d -- -- -- 
4-FMC (1 ng/mL) <3 d 143 d 7 d -- 56 d -- -- -- 
4-MEC (1 ng/mL) 3 d -- 11 d -- 172 d -- -- -- 
Mephedrone (2 ng/mL) 4 d -- 12 d -- -- -- -- -- 
Methedrone (1 ng/mL) 7 d -- 38 d -- -- -- -- -- 
Secondary Amine, Methylenedioxy-Type 
Butylone (1 ng/mL) 18 d -- 63 d -- -- -- -- -- 
Ethylone (1 ng/mL) 7 d -- 24 d -- -- -- -- -- 
Eutylone (5 ng/mL) 21 d -- 91 d -- -- -- -- -- 
Methylone (0.25 ng/mL) 7 d -- 24 d -- -- -- -- -- 




Cathinone (LOD) Elevated Ambient Refrigerated Frozen 
 pH 8 pH 4 pH 8 pH 4 pH 8 pH 4 pH 8 pH 4 
Pentylone (1 ng/mL) 11 d -- 38 d -- -- -- -- -- 
Tertiary Amine (Pyrrolidine-Type) 
α-PVP (2 ng/mL) 172 d -- -- -- -- -- -- -- 
MDPBP* (0.5 ng/mL) -- -- -- -- -- -- -- -- 
MDPV* (1 ng/mL) -- -- -- -- -- -- -- -- 
MPBP (1 ng/mL) 172 d -- -- -- -- -- -- -- 
Naphyrone (0.5 ng/mL) 78 d -- 78 d -- -- -- -- -- 
Pyrovalerone (0.25 ng/mL) -- -- -- -- -- -- -- -- 
Amine Structure Days to Complete Loss 
Tertiary MD >6 m >6 m >6 m >6 m >6 m >6 m >6 m >6 m 
Tertiary - 2.6 - >6 m >6 m 2.6 - >6 m >6 m >6 m >6 m >6 m >6 m 
Secondary MD 7 – 21 d >6 m 24 – 91 d >6 m >6 m >6 m >6 m >6 m 
Secondary - <2 – 7 d 4.8 - >6 m 3 – 38 d >6 m 1.4 - >6 m >6 m >6 m >6 m 
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Discussion 
This six month systematic stability study shows that cathinone stability is highly 
analyte, pH and temperature dependent. These findings are consistent with our previously 
reported results in whole blood (16). To reduce pre-analytical losses, biological samples 
should be protected from heat wherever possible. Specimen pH, which is not typically 
measured during routine human performance or postmortem toxicology investigations, 
might also be considered. Finally, analyte dependent differences in stability are influenced 
by multiple factors. The increased stability of the pyrrolidine analogs might be explained 
by their inability to undergo oxidative deamination. However, methylenedioxy substitution 
and ring position also plays an important role. Of the twenty-two drugs included in the 
study, 3-FMC was the least stable in urine, while MDPV and MDPBP (MD-type 
pyrrolidines) were the most stable.  
Our findings are in consistent with previous published studies. Tsujikawa (21) 
assessed the stability of methcathinone, mephedrone, 3-FMC, 4-FMC, and ethcathinone in 
various aqueous buffer systems. They also observed increased stability with decreasing 
pH, in addition to structural influences. Although direct comparisons cannot be made 
between estimated half-lives in their study (pH 4, 7, 10, and 12) and ours (pH 4 and 8), the 
overall trends are in good agreement. Johnson and Botch-Jones’ (18) study resulted in 
minimal loss of mephedrone in urine over two weeks, but significant losses in blood (pH 
of 7). While they did not specify the urinary pH or the use of preservative in their matrix, 
it is likely that it may have been more acidic, based on the findings of this research.  Al-
Saffar (19) evaluated eleven cathinones in urine after one day, one week, and three months 
of storage at -20, 6, and 22°C. Although the urinary pH was not specified and the sampling 
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frequency was limited, they concluded that MDPV and 3-FMC were the most and least 
stable drugs, respectively, within their scope of testing. The comprehensive study presented 
here supports previously published literature and offers greater insight into analyte 
dependent variables.  
Commercial drug-free urine was used for this study, rather than authentic urine 
from cathinone users. Although this might be considered a limitation, it was necessary in 
order to include a sufficient number of structural analogs for statistical analysis, and to 
accommodate a sufficient quantity of urine for the experimental design. Drug stability was 
not evaluated in unpreserved urine. Although antioxidants such as ascorbic acid and 
sodium sulfite may inhibit the oxidative degradation of synthetic cathinones (21), these are 
not typically encountered during routine urine collections. Sodium fluoride (1%), which 
was utilized in this study, is the most common urinary additive for preservation purposes. 
Finally, increases in urinary pH that take place during storage are largely attributed to the 
chemical breakdown of nitrogenous analytes (23, 26). It should be noted that this natural 
phenomenon creates a less favorable environment for cathinone species, increasing their 
rate of decay and ultimately detection time.   
Conclusion 
Cathinone stability in preserved human urine can be summarized as follows: 
 Cathinone stability is pH, temperature and analyte dependent.  
 Cathinones are alkaline-labile drugs. Degradation rates increase with increasing 
pH and temperature. 
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 With the exception of 3-FMC, no significant differences in stability were 
observed between ring substituted and unsubstituted secondary amine 
cathinones. 
 The position of the ring substitution can influence stability (e.g., 3- and 4-
FMC).  
 Although cathinones bearing a tertiary amine (pyrrolidines) are generally more 
stable than their secondary amine counterparts, stability is influenced by more 
than just the nitrogen.  
 The methylenedioxy group exerts significant stabilizing effect on both the 
secondary and tertiary amine cathinones.  
 The most stable cathinones contain both the tertiary amine (pyrrolidine) and the 
methylenedioxy group.  
Acknowledgements 
This project was supported by Award No. 2013-R2-CX-K006 awarded by the 
National Institute of Justice, Office of Justice Programs, U.S. Department of Justice. The 
opinions, findings, and conclusions or recommendations expressed in this publication are 
those of the author(s) and do not necessarily reflect those of the Department of Justice.  
244 
   
References 
1. U.S. Drug Enforcement Administration: Diversion Control Devision (2016) 
Synthetic Cannabinoids and Synthetic Cathinones Reported in NFLIS, 2013-
2015. Springfield, VA: U..S. Drug Enforcement Administration. 
2. European Monitoring Centre for Drugs and Drug Addiction. (2017) European 
Drug Report 2017: Trends and Developments. Available at 
http://www.emcdda.europa.eu/. 
3. Coppola, M.; Mondola, R. (2012) Synthetic cathinones: chemistry, pharmacology 
and toxicology of a new class of designer drugs of abuse marketed as “bath salts” 
or “plant food”. Toxicology Letters, 211, 144-149. 
4. Katz, D.P.; Bhattacharya, D.; Bhattacharya, S.; Deruiter, J.; Clark, C.R.; 
Suppiramanian, V.; et al. (2014) Synthetic cathinones: “A khat and mouse game”. 
Toxicology Letters, 229, 349-356. 
5. Kerrigan, S. (2013) Sampling, Storage and Stability, in: A. Negrusz, G. Cooper 
(Eds.), Clarke's Analytical Forensic Toxicology 2 Ed, Pharmaceutical Press, 
London, England,  pp 335-347. 
6. Belhadj-Tahar, H.; Sadeg, N. (2005) Methcathinone: a new postindustrial drug. 
Forensic Science International, 153, 99-101. 
7. Gil, D.; Adamowicz, P.; Skulska, A.; Tokarczyk, B.; Stanaszek, R. (2013) 
Analysis of 4-MEC in biological and non-biological material—three case reports. 
Forensic Science International, 228,  e11-e15. 
245 
   
8. Potocka-Banaś, B.; Janus, T.; Majdanik, S.; Banaś, T.;  Dembińska, T.; Borowiak, 
K. (2017) Fatal intoxication with α-PVP, a synthetic cathinone derivative. Journal 
of Forensic Science, 62, 553-556. 
9. McIntyre, I.M.; Hamm, C.E.; Sherrard, J.L.; Gary, R.D.; Burton, C.G.; Mena, O. 
(2014) Acute 3,4-methylenedioxy-N-ethylcathinone (Ethylone) intoxication and 
related fatality: a case report with postmortem concentrations. Journal of 
Analytical Toxicology, 39, 225-228. 
10. McIntyre, I.M.; Hamm, C.E.; Aldridge, L.; Nelson, C.L. (2013) Acute methylone 
intoxication in an accidental drowning - a case report. Forensic Science 
International, 231, e1-e3. 
11. Murray, B.L.; Murphy, C.M.; Beuhler, M.C. (2012) Death following recreational 
use of designer drug “bath salts” containing 3, 4-methylenedioxypyrovalerone 
(MDPV). Journal of Medical Toxicology, 8, 69-75. 
12. Wright, T.H.; Cline‐Parhamovich, K.; Lajoie, D.; Parsons, L.; Dunn, M.; Ferslew, 
K.E. (2013) Deaths involving methylenedioxypyrovalerone (MDPV) in upper east 
Tennessee. Journal of Forensic Science, 58, 1558-1562. 
13. Pearson, J.M.; Hargraves, T.L.; Hair, L.S.; Massucci, C.J.; Frazee, C.C.; Garg, U.; 
et al. (2012) Three fatal intoxications due to methylone. Journal of Analytical 
Toxicology, 36, 444-451. 
14. Gerace, E.; Petrarulo, M.; Bison, F.; Salomone, A.; Vincenti, M. (2014) 
Toxicological findings in a fatal multidrug intoxication involving mephedrone. 
Forensic Science International, 243, 68-73. 
246 
   
15. Lusthof, K.J.; Oosting, R.; Maes, A.; Verschraagen, M.; Dijkhuizen, A.; Sprong, 
A.G.A. (2011) A case of extreme agitation and death after the use of mephedrone 
in The Netherlands. Forensic Science International, 206, e93-e95. 
16. Glicksberg, L.;  Kerrigan, S. (2017) Stability of synthetic cathinones in blood. 
Journal of Analytical Toxicology, https://doi.org/10.1093/jat/bkx071. 
17. Paul, B.D.; Cole, K.A. (2001) Cathinone (khat) and methcathinone (CAT) in 
urine specimens: a gas chromatographic-mass spectrometric detection procedure. 
Journal of Analytical Toxicology, 25, 525-530. 
18. Johnson, R.D.; Botch-Jones, S.R. (2013) The stability of four designer drugs: 
MDPV, mephedrone, BZP and TFMPP in three biological matrices under various 
storage conditions. Journal of Analytical Toxicology, 37, 51-55. 
19. Al-Saffar, Y.; Stephanson, N.N.; Beck, O. (2013) Multicomponent LC–MS/MS 
screening method for detection of new psychoactive drugs, legal highs, in urine—
experience from the Swedish population. Journal of Chromatography B, 930, 
112-120. 
20. Concheiro, M.; Anizan, S.; Ellefsen, K.; Huestis, M.A. (2013) Simultaneous 
quantification of 28 synthetic cathinones and metabolites in urine by liquid 
chromatography-high resolution mass spectrometry. Analytical and Bioanalytical 
Chemistry, 405, 9437-9448. 
21. Tsujikawa, K.; Mikuma, T.; Kuwayama, K.; Miyaguchi, H.; Kanamori, T.;  Iwata, 
Y.T.; et al. (2012) Degradation pathways of 4-methylmethcathinone in alkaline 
solution and stability of methcathinone analogs in various pH solutions. Forensic 
Science International, 220, 103-110. 
247 
   
22. Maskell, P.D.; De Paoli, G.; Seneviratne, C.; Pounder, D.J. (2011) Mephedrone 
(4-methylmethcathinone)-related deaths. Journal of Analytical Toxicology, 35, 
188-191. 
23. Cook, J.D.; Strauss, K.A.; Caplan, Y.H.; LoDico, C.P.; Bush, D.M. (2007) Urine 
pH: the effects of time and temperature after collection. Journal of Analytical 
Toxicology, 31, 486-496. 
24. Glicksberg, L.; Bryand, K.; Kerrigan, S. (2016) Identification and quantification 
of synthetic cathinones in blood and urine using liquid chromatography-
quadrupole/time of flight (LC-Q/TOF) mass spectrometry. Journal of 
Chromatography B, 1035, 91-103. 
25. Scientific Working Group for Forensic Toxicology (SWGTOX). (2013) Standard 
Practices for Method Validation in Forensic Toxicology. Journal of Analytical 
Toxicology, 37, 452-474. 
26. Fura, A; Harper, T.W.; Zhang, H.; Fung, L.;  Shyu, W.C. (2003) Shift in pH of 
biological fulids during storage and processing: effect on bio analysis. Journal of 
Pharmaceutical and Biomedical Analysis, 32, 513-522. 
 
248 
   
CHAPTER V 




















This dissertation follows the style and format of The Journal of Analytical Toxicology.   
1Glicksberg L., Rana S., Kerrigan S. (2017).  
Submitted to Forensic Science International. 
249 
   
Abstract 
Synthetic cathinones are encountered in a variety of antemortem and postmortem 
forensic toxicology investigations. Earlier experimental studies using fortified urine have 
evaluated analyte, temperature and pH-dependent variables associated with their stability. 
The purpose of this study was to compare experimental findings with those obtained using 
authentic urine from cathinone users.  
In this report we compare cathinone concentrations in 180 authentic unpreserved 
urine specimens, following specified periods of refrigerated storage. These findings are 
compared with previously published experimental data using fortified drug-free urine. 
Liquid chromatography quadrupole time-of-flight mass spectrometry (LC-Q/TOF-MS) 
was used to target twenty-two cathinones. Quantitative results were compared in urine 
specimens (pH 4.5–10) following 5 to 17 months of storage.  
The 180 specimens resulted in 156 quantitative findings involving α-PVP, 
ethylone, methylone, MDPV and pentylone. Initial drug concentrations ranged from 25 
ng/mL to over 100,000 ng/mL. Upon reanalysis, the percentage of drug remaining (0 – 
119%) was correlated with storage time and specimen pH. The ability to reconfirm original 
results was not correlated with storage time. Instead, specimen pH was far more predictive. 
The relationship between initial and final drug concentration was highly pH-dependent, 
yielding significant correlations for α-PVP, ethylone and methylone, particularly under 
acidic conditions.  
These results are in good agreement with experimental findings and highlight the 
critical importance of specimen pH, rather than conventional time dependent variables, 
when considering cathinone stability in biological samples. The potential for pre-
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analytical changes in cathinone concentrations must be carefully considered when 
interpreting their results. 
 
Key Words:  Urine, Synthetic cathinones, Stability, pH 
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CATHINONE STABILITY IN AUTHENTIC URINE SPECIMENS 
Introduction 
The escalating use of new psychoactive substances (NPS) has significantly 
impacted the global landscape of recreational drug use.  These increases have been 
documented through reports issued by the European Monitoring Center for Drugs and Drug 
Addiction (EMCDDA), the National Forensic Laboratory Information System (NFLIS), 
poison control center reports, and both ante-mortem and post-mortem forensic toxicology 
casework (1-6). Synthetic cathinones still represent a significant portion of the NPS market, 
which is significantly fueled by the Internet (7). The epidemiology of their use is 
complicated by the rapid emergence of new analogs and derivatives.  
As of 2016, the EMCDDA was monitoring as many as 103 synthetic cathinones 
(3). According to the 2017 European Drug Report, this number increased to 118, making 
it the second largest new substance group, having been identified in more than half of the 
participating European countries (8). NFLIS reported an increase from 5 cathinones in 
2009 to 35 in 2015. The five cathinones reported in 2009 were mephedrone, MDPV, 
methylone, methcathinone, and 4-MEC, with mephedrone and methcathinone being the 
most prevalent (1). By 2015, methcathinone was no longer among the top twenty 
cathinones, having been largely replaced by methylone, ethylone, and α-PVP. Although 
NPS use in the US lags behind many of the European countries, they tend to follow the 
same overall trends.While some cathinones have remained popular, others have decreased 
(e.g. buphedrone), or have been largely replaced by newer analogs such as brephedrone (4-
BMC) and other halogenated species. Despite their evolving nature, surveillance reports 
from both the United States and Europe confirm that recreational use of these novel 
psychostimulants continues to be a problem.  
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Synthetic cathinones are capable of producing stimulant and euphoric effects 
similar to methamphetamine and cocaine. Sought after effects may include increased 
sociability, energy, focus, and empathy (9-11). Synthetic cathinone toxicity has resulted in 
neurological, cardiovascular, and psychopathological symptoms including hyperthermia, 
paranoid psychosis, organ failure, and death (4, 10-13). Their physical and neurological 
effects are attributed to their interactions with the monoamine neurotransmitters dopamine, 
norepinephrine, and serotonin.  
Synthetic cathinones have been associated with impairment, intoxication, and fatal 
overdose. Quantitative determinations have been reported throughout the scientific 
literature in a variety of biological matrices. In this report, we describe changes in urinary 
drug concentrations among a population of cathinone users. Cathinone concentrations in 
antemortem urine have been reported over a very wide range, from tens of nanograms per 
milliliter to several thousand (14-18). Therefore, analytical methods must have not only 
adequate specificity to identify structurally similar drugs and regioisomers, but also high 
sensitivity. The latter becomes critically important, particularly if pre-analytical changes 
in concentration take place due to instability or degradation of the drug. 
We previously reported a comprehensive synthetic cathinone stability study in 
urine to address analyte, pH, temperature, concentration and time-dependent variables (19). 
Although no concentration dependence was observed, cathinone stability was significantly 
dependent upon urinary pH, storage temperature, and structural characteristics of the 
cathinone itself. A total of twenty-two cathinones were evaluated in pooled human urine 
(pH 4 and 8) at four temperatures (32, 20, 4, and -20°C) during six months of storage. 
Cathinones were less stable in alkaline urine, with significant changes observed within 
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hours for some drugs under certain conditions. In contrast, all drugs remained stable over 
the entire six month period in acidic urine when refrigerated or frozen. The pyrrolidine 
(tertiary amine) and methylenedioxy groups exerted significant stabilizing effects. Drugs 
containing both groups (e.g. methylenedioxypyrovalerone (MDPV) and 3,4-
methylenedioxy-α-pyrrolidinobutiophenone (MDPBP)) were the most stable of the 
twenty-two drugs investigated. Unsubstituted and ring substituted cathinones were 
considerably less stable, with 3-fluoromethcathinone (3-FMC) exhibiting the greatest 
instability. Although the approach using fortified preserved urine affords a robust 
experimental design for the evaluation of long-term stability, authentic urine specimens 
from cathinone users can also provide valuable information. In this study, we compare 
cathinone concentrations in 180 authentic unpreserved urine specimens from cathinone 
users after specified periods of storage. These findings are compared with previously 
published experimental data using fortified drug-free urine.  
Materials and Methods 
Chemicals and reagents  
Methcathinone, 3-FMC, 4-fluoromethcathinone (4-FMC, flephedrone), methylone, 
ethcathinone, ethylone, methedrone, buphedrone, butylone, mephedrone, eutylone, 4-
methylethcathinone (4-MEC), 3,4-methylenedioxy-α-pyrrolidinobutiophenone (MDPBP), 
pentedrone, pentylone, 3,4-dimethylmethcathinone (3,4-DMMC), α-
pyrrolidinopentiophenone (α-PVP), 4-ethylmethcathinone (4-EMC), 4-methyl-α-
pyrrolidinobutiophenone (MPBP), methylenedioxypyrovalerone (MDPV), pyrovalerone, 
and naphyrone were purchased from Cerilliant Corporation (Round Rock, TX, USA) in 1.0 
mg/mL methanolic solutions. Internal standards methylone-D3, ethylone-D5, butylone-
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D3, mephedrone-D3, eutylone-D5, pentylone-D3, α-PVP -D8, MDPV-D8, and naphyrone-
D5 were also purchased from Cerilliant Corporation in 0.1 mg/mL methanolic solutions. 
The internal standard solution consisted of all nine deuterated internal standards at a 
concentration of 0.25 µg/mL in methanol. Pooled drug-free urine, preserved with 1% 
sodium fluoride, was purchased from Utak Laboratories (Valencia, CA, USA).  
Dichloromethane, isopropyl alcohol, and glacial acetic acid were purchased from 
Mallinckrodt Chemicals (St. Louis, MO, USA). LC-MS grade methanol, concentrated 
hydrochloric acid, LCMS grade acetonitrile, and dibasic sodium phosphate were purchased 
from J.T. Baker (Center Valley, MA, USA). Optima® hexane and HPLC grade ethyl 
acetate were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Formic acid (>99%) 
was purchased from Sigma-Aldrich (St. Louis, MO, USA). Monobasic sodium phosphate 
was purchased from VWR (Radnor, PA, USA). Deionized water was purified in-house 
using a Millipore Direct-Q® UV Water Purification system (Billerica, MA, USA). 
PolyChrom ClinII 3 cc (35 mg) solid phase extraction (SPE) columns were purchased from 
SPEware (Baldwin Park, CA, USA). 
Instrumentation  
An Agilent Technologies 6530 LC-Q/TOF-MS (Santa Clara, CA, USA) equipped 
with an Agilent 1290 Infinity autosampler and a Series 1200 LC system was used for 
instrumental analysis. Cathinones were separated using an Agilent Poroshell 120 EC-C18 
column (2.1 x 100 mm, 2.7 µm particle size) and an Agilent Poroshell 120 EC-C18 guard 
column (2.1 x 5 mm, 2.7 µm particle size) maintained at 35°C. Mobile phase A and B 
comprised of 0.1% formic acid in deionized water and acetonitrile, respectively, and used 
the following gradient elution profile: 96% A and 4% B (0 – 0.5 mins); 90% A (0.5 – 5 
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mins); 60% A (5 – 11 mins); 0% A and 100% B (11 – 12 mins). Nitrogen was generated 
using a Genius 3040 Nitrogen Generator (Peak Scientific, Billerica, MA, USA). Solid 
phase extraction (SPE) was performed using a JT Baker vacuum manifold and extracts 
were evaporated to dryness under nitrogen using a TurboVap LV® concentration 
workstation (Caliper Life Sciences, Hopkinton, MA, USA). A FiveEasyTM FiveGoTM pH 
meter FE20/FG2 was used for pH measurement (Mettler Toledo, Columbus, OH, USA). 
The LC-Q/TOF-MS procedure used for quantification of cathinones in urine was based on 
a previously published method and was validated in accordance with generally accepted 
guidelines (20, 21).  
Authentic urine samples 
Urine specimens from cathinone users were obtained in accordance with an IRB-
approved study.  Samples were transported on ice and were reanalyzed after a specified 
period of refrigerated storage. A one milliliter aliquot of unpreserved urine was analyzed 
quantitatively and appropriate dilutions were performed for samples that exceeded the 
calibration range of the assay (500 ng/mL). Following SPE, samples were reconstituted in 
25 µL of a 50:50 mixture of Mobile Phase A:B and 1 µL was injected onto the LC-Q/TOF-
MS for analysis. Limits of quantitation for the twenty-two target compounds ranged from 
0.25 to 5 ng/mL  (20).  
Extraction of cathinones from urine 
Internal standard solution (100 µL) was added to 1 mL urine to achieve a final 
concentration of 25 ng/mL. Urine, diluted with 2 mL of pH 6 phosphate buffer (0.1 M), 
was transferred to PolyChrom ClinII SPE columns and allowed to flow through under 
gravity. Columns were rinsed successively with 1 mL deionized water and 1 M acetic acid. 
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SPE columns were dried for 5 minutes under full vacuum, followed by 1 mL hexane, ethyl 
acetate, and methanol washes. Drugs were eluted using two 0.5 mL aliquots of elution 
solvent (2% concentrated ammonium hydroxide in 95:5 dichloromethane: isopropyl 
alcohol). Extracts were salted out using acidic methanol (30 µL) prior to evaporation under 
nitrogen at 50°C. Samples were reconstituted in 25 µL Mobile Phase A:B (50:50) and 1 
µL was injected onto the LC-Q/TOF-MS for analysis.  
Data analysis  
Quantitative measurements were compared and statistically evaluated for urine 
specimens stored for a period of less than 24 months. Where possible, storage time, analyte, 
and pH dependent differences in stability were addressed. Results using authentic urine 
specimens from cathinone users were compared with experimentally determined findings 
using fortified urine (19). Storage temperature was not assessed however, because all 
specimens were refrigerated throughout.  
Results and Discussion 
The 180 urine specimens yielded a total of 164 cathinone positive results for α-PVP 
(n=92), ethylone (n=55), methylone (n=8), MDPV (n=1), pentylone (n=1), 4-FMC (n=2), 
4-MEC (n=2) and pentedrone (n=3). No quantitative comparisons were made if the original 
date of analysis was unknown, or if results were reported qualitatively during either assay. 
Correlations and statistical evaluations were performed only on urine specimens that had 
been stored for less than 24 months.  
Of the 164 positive findings, it was possible to make 156 quantitative comparisons 
involving α-PVP (n=92), ethylone (n=55), methylone (n=8), MDPV (n=1) and pentylone 
(n=1). The quantitative comparisons are summarized in Table 5.1 and the remaining 
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qualitative data is shown in Table 5.2. Results for individual cases can be found in 
Appendix G. Specimens were stored for a period of 5 to 17 months (median=14.5) at 
refrigerated temperature in the absence of preservative. Urinary pH upon reanalysis ranged 
from 4.5 to 10. Among all samples tested, the percentage of drug remaining was highly 
variable (0-119%). The median percentage of drug remaining for α-PVP, ethylone and 
methylone was 13, 2 and 61%. Synthetic cathinones bearing a pyrrolidinyl group are 
significantly more stable than their secondary amine counterparts (19, 22). However, both 
ethylone and methylone contain methylenedioxy groups, which are also known to have a 
stabilizing effect. Given the population size and the known differences in stability between 
these secondary and tertiary amines, these were further investigated.  
No correlation was observed between the percentage of drug remaining and storage 
time (Figure 5.1). This is significant because it suggests that factors other than storage 
time may play a role. When initial and final concentrations were compared, specimen pH 
was also evaluated (Figure 5.2).  
 
Figure 5.1. Percentage of cathinone remaining after specified periods of storage 
(months). 
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Figure 5.2. Correlation between initial and final cathinone concentrations (ng/mL) 
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Significance tests on correlation coefficients (R) were performed using the t-test. The 
strongest correlations were clearly observed at acidic pH. Coefficients of determination 
(R2) for α-PVP in acidic urine (<pH 7) were 0.889, compared with 0.543 in alkaline urine 
(>pH 8). Correlations were significant for each pH range tested (p<0.001). Similar results 
were observed for ethylone, with R2 values of 0.988 at pH <7, compared with 0.001 at pH 
>7. Correlations were significant in acidic and neutral urine, p<0.001 and p=0.05, 
respectively. Although the methylone positive population was limited in size and urinary 
pH (range 4.5-6.5), the correlation was highly significant at pH<6 (p<0.001).  
Consistent with experimental studies, cathinone concentrations in acidic urine 
specimens were readily confirmed following periods of storage up to 24 months. In acidic 
urine, the relationship between initial and final α-PVP concentration was strong (y = 0.998 
x + 732). Strong relationships were also observed for ethylone (y = 1.169 x + 1078) and 
methylone (y = 1.683 x + 24), although the steeper gradients reflect the overall reduced 
stability of these drugs.  Due to the profound effect of pH on cathinone stability, alkaline 
specimens often suffered dramatic losses. For example, a specimen with a pH of 8.5 
containing >37,000 ng/mL ethylone was undetectable upon reanalysis (LOD 2 ng/mL). 
Although this specimen had been stored for 17 months, studies have shown that even when 
refrigerated, ethylone can undergo significant losses within 9 days of storage (19). Under 
the same conditions, significant losses were observed for 3-FMC in < 1 day, while no 
decrease in concentration was observed for MDPV over six months. These findings 
highlight the critical importance of specimen pH and analyte dependent differences in 
stability among these arylaminoketones.  
 
   
260 
Table 5.1. Summary of quantitative cathinone determinations in urine following periods of specified storage (< 24 months). The 
percentage of drug remaining and mean pH is shown in parentheses.  
Cathinone LOQ 
(ng/mL) 




Range Median Mean Range Median Mean 
α-PVP (n=91) 2 25 - 104,111 1,100 3,560 0 - 19,926 









1 30 - 167,973 206 9,119 0 - 146,124 









0.25 32 - 1,535 86 286 2-922 





5 - 8 4.5 - 6.5 
(6) 
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5 ng/mL 2R002 Positive ND 5.5 7 
2R016 Positive <LOQ 5 5 
2R001 Positive ND 4.5 7 
4-MEC 
 
1 ng/mL 2R003 Positive <LOQ 6 8 
2R019 Positive ND 7 6 
4-FMC 
 
1 ng/mL 2R008 Positive ND 4.5 7 
2R007 Positive <LOQ 7 7 
α-PVP 2 ng/mL R042 Positive 7,947 7 15 
    ND: Not detected.  
 
Among the α-PVP positive samples (n=91) specimen pH ranged from 4.5 to 10 and 
storage time ranged from 5 to 17 months. Original α-PVP concentrations in urine were 25 
– 104,111 ng/mL, with mean and median concentrations of 3,560 and 1,100 ng/mL, 
respectively. Upon reanalysis α-PVP concentrations were in the range 0 – 19,926 ng/mL, 
with mean and median concentrations of 1,923 and 99 ng/mL, respectively. Quantitative 
reanalysis produced results between 0% and 119% of the original result. The profound 
effect of specimen pH on the percentage of drug remaining is shown in Figure 5.3. When 
considering the effect of pH, storage time was not considered. At a pH of 8.5 and above, 
amount of α-PVP that remained was significantly diminished. In contrast, most urine 
specimens with a pH of 6.5 suffered relatively minimal losses. Although not included in 
the correlation of quantitative results, no significant decrease in α-PVP was observed (94% 
remaining) in a urine specimen that was stored for as long as 40 months, attributed to the 
acidity of the specimen (pH 5.5).  
Among the ethylone positive samples (n=55), the pH of the specimen ranged from 
4.5 to 10 and storage time ranged from 6 to 17 months. Original ethylone concentrations 
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in urine were 30 – 167,973 ng/mL, with mean and median concentrations of 9,119 and 206 
ng/mL respectively. Upon reanalysis ethylone concentrations were in the range 0 – 146,124 
ng/mL, with mean and median concentrations of 4,166 and 7 ng/mL, respectively. 
Quantitative reanalysis produced results between 0% and 102% of the original results. 
Consistent with α-PVP, specimen pH exerted much greater influence than storage time 
(Figure 5.3). At a pH of 7.5 or above, virtually all of the ethylone was lost.      
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Figure 5.3. Influence of specimen pH on cathinone stability.  
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Methylone consisted of a relatively small population of samples (n=8) and 
specimen pH was more limited (4.5 to 6.5) for samples stored < 24 months. Original 
methylone concentrations in urine were 32 – 1,535 ng/mL, with mean and median 
concentrations of 286 and 86 ng/mL, respectively. Upon reanalysis methylone 
concentrations were in the range 2 – 922 ng/mL, with mean and median concentrations of 
168 and 41 ng/mL, respectively. Quantitative reanalysis produced concentrations between 
12% and 81% of the original results. Once again, Figure 5.3 depicts the importance of pH 
rather than storage time, when considering cathinone stability. The ability to reconfirm 
original results became increasingly more difficult at a pH of 6 or above.  These results for 
both ethylone and methylone are consistent with earlier experimental findings using 
fortified urine that suggest that the secondary amines are more susceptible to pH dependent 
degradation. This may be attributed to the inability of the pyrrolidine derivatives to undergo 
oxidative deamination.  
Concerns related to cathinone stability have been reported for several biological 
matrices, including urine (23-26). Tsujikawa (27) and Maskell (28) were among the first 
to highlight the importance of pH in aqueous and formalin solutions. Half-lives for 
methylone, ethylone, and α-PVP in refrigerated pH 8 urine were 1.4, 1.8, and 7.1 months, 
respectively (19). In contrast, at pH 4, drugs were relatively stable when refrigerated. 
Experimental studies using drug-fortified urine are advantageous from an experimental 
design standpoint. They may allow for more extensive sampling over extended periods, 
multiple experimental conditions, and the simultaneous evaluation of a large number of 
substances. In contrast, when authentic urine specimens are used, the number of analytes 
is dependent upon drug user preference, and sample volumes may be limited. In the 
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previous reported study, cathinone stability in urine was evaluated at pH 4 and 8 [19]. In 
this report however, urine pH reflects a much broader range (pH 4.5 to 10).  
Although normal urinary pH is generally in the range ~4 to 8, this varies with the 
time of day, diet, disease state, and many other factors (29, 30). Post-collection, urinary pH 
can increase over time. At elevated temperatures, increases of 2 pH units or more have 
been observed within 24 hours (29, 30). Although increases in pH are also possible in 
refrigerated urine, the magnitude of the increase is significantly diminished. Urine contains 
a variety nitrogenous and inorganic species including bicarbonate, phosphates, and 
ammonium salts. Elevations in urinary pH have been attributed to the chemical breakdown 
of nitrogenous analytes. Pre-analytical contamination of the sample with microorganisms 
during collection can also increase urinary pH, due to the bacterial decomposition of urea 
to ammonia (29, 30).  While the authentic unpreserved urine samples presented here have 
some uncontrolled variables, the data can be used to complement the results from a 
controlled stability study, and are more likely to represent actual cases encountered in the 
laboratory. In this report, urinary pH values exceeded the normal physiological range. This 
may be attributed to the length of storage, possible exposure to elevated temperatures 
during initial shipping of the specimens, and the absence of preservative.  
Conclusions 
These results using authentic urine specimens from cathinone users support our 
previously reported experimental findings (19). This study reinforces the importance of 
analyte and pH-dependent considerations, when interpreting forensic toxicology results 
involving cathinones. While all cathinones should be considered alkaline-labile drugs, their 
susceptibility to pH-mediated degradation is analyte-dependent. Urinary pH values within 
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the normal physiological range can result in significant degradation, and pre-analytical 
increases in pH during storage may further exacerbate the issue. Results from this study 
suggest that although conventional time-dependent interpretation is often used when 
comparing forensic toxicology results, specimen pH is a more critical variable for the 
synthetic cathinones.  
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Abstract 
Synthetic cathinones are powerful psychostimulants that have been associated with 
fatal intoxications. Due to changes that take place following death, postmortem toxicology 
results require careful interpretation. The purpose of this study was to evaluate the 
distribution of synthetic cathinones in postmortem specimens in a series of fifty cathinone-
positive fatalities.  
Liquid chromatography quadrupole time-of-flight mass spectrometry (LC-Q/TOF-
MS) was used to quantitatively identify cathinones in central blood (n=51), peripheral 
blood (n=31), urine (n=33), liver (n=22), vitreous humor (n=1) and stomach contents 
(n=1). The distribution of cathinones and the potential for postmortem redistribution was 
assessed.  
Among the fifty cases investigated, a total of nine synthetic cathinones (α-PVP, 
ethylone, methylone, butylone, MDPV, methedrone, pentylone, 4-MEC, and MDPBP) 
were identified in 139 specimens. The number of specimens per case ranged from one to 
six. In cases that included central blood or liver, together with a peripheral blood source, 
the C/P or L/P ratio was estimated (n=21 C/P; n=11 L/P). Methylone and ethylone appeared 
to exhibit the greatest potential for postmortem redistribution, producing C/P ratios of 4.0 
(1.5-6.1) and 2.9 (0.5-9.2), respectively. In contrast, the C/P ratio for α-PVP was 1.1 (0.5-
1.9). Differences in C/P ratios between methylone and α-PVP were statistically significant 
(α=0.05).  
Although synthetic cathinones may exhibit low to moderate postmortem 
redistribution, significant variability exists due to site- and time dependent factors. This, in 
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combination with their overall instability, necessitates careful interpretation of postmortem 
toxicology results.  
 
Key Words:  Synthetic cathinones, Designer drugs, LC-Q/TOF-MS, Postmortem 
redistribution 
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POSTMORTEM DISTRIBUTION AND REDISTRIBUTION OF SYNTHETIC 
CATHINONES 
Introduction 
Interpreting postmortem toxicology results can be challenging due to the changes 
that take place in the body after death. Drug movement within the body after death can 
cause significant variability in blood concentrations (1-3). Postmortem changes in drug 
concentration have been largely attributed to drug instability or postmortem redistribution 
(PMR), the latter of which has lived up to its reputation as a “toxicological nightmare” (2). 
PMR is ideally assessed by comparing postmortem blood concentrations with antemortem 
specimens, obtained shortly before death. Although this is sometimes possible in hospital 
deaths, the extent to which a drug is susceptible to PMR is more often limited to the 
comparison of central (C) and peripheral (P) blood sources. Although other approaches, 
such as liver/peripheral (L/P) ratios have also been proposed (4), the most widely used 
approach involves the use of C/P ratios. Notwithstanding this approach, standardized 
postmortem sampling protocols for toxicology testing have not yet been universally 
established. Although there is a general consensus that specimen collection should be 
performed as early as possible during the postmortem interval, the sampling procedure 
itself, quantity, and selection of specimens varies significantly by jurisdiction (5). While 
there is no standardized collection protocol, central blood, peripheral blood, and liver are 
often submitted for toxicology testing, from which C/P and L/P ratios can be determined. 
Although conclusions should not be drawn from single cases, increases in the C/P ratio 
(>1) or L/P ratio (>20) in a population of cases may indicate a tendency for the drug to 
exhibit PMR (4, 6, 7).  
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The thoracic cavity contains many organs in close proximity, including the lungs, 
liver, gastrointestinal tract, and myocardium. Depending on physico-chemical properties, 
including lipophilicity, volume of distribution (Vd), protein binding, and pKa, drugs may 
have a tendency to accumulate in these organs antemortem. Postmortem, the drug may be 
released and redistributed, resulting in elevated concentrations in central blood (1, 3, 8, 9). 
To minimize the influence of PMR, lung, liver and cardiac blood may be sampled from the 
right side (5, 8).  Nonetheless, a peripheral blood specimen is highly preferred because it 
is anatomically isolated from the thoracic compartment. Although peripheral blood drug 
concentrations are still subject to variability, they are expected to be more representative 
of the drug concentration prior to death.  
While information regarding PMR potential of synthetic cathinones is still limited, 
some inferences may be possible from structurally similar drugs that have been more 
extensively evaluated. Synthetic cathinones are beta-keto amphetamines that are 
structurally related to both methamphetamine and 3,4-methylenedioxymethamphetamine 
(MDMA, “Ecstasy”). MDMA (pKa 8.7) and methamphetamine (pKa 9.9) are basic drugs 
with volumes of distribution (Vd) of 3 - 7 L/kg (10). Both have been shown to exhibit some 
degree of PMR (6, 10). The average C/P ratios for methamphetamine and MDMA were 
2.3 (0.9-5.8, n=39) and 2.7 (0.9-4.6, n=7), respectively and average L/P ratios were 5.5 
(1.7-9.1 L/kg, n=19) and 6.5 (3.1-8.5 L/kg, n=5), respectively (7, 11-17). Although MDMA 
may have greater potential for PMR than methamphetamine, the wide range of reported 
C/P and L/P values highlight the inter-subject and sampling variations (18).  
Synthetic cathinones can be structurally differentiated by substituents on the phenyl 
ring, alkyl chain, and nitrogen terminus (particularly the introduction of a pyrrolidine 
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group). Many pharmacologic and physico-chemical properties of these relatively new 
drugs have not yet been established. Like their amphetamine counterparts, they are basic 
drugs, with pKa values ranging from 7.2 to 8.9 (10, 19, 20). It might be inferred that 
synthetic cathinones could also exhibit some degree of PMR. However, the influence of 
the various substituents, including the methylenedioxy and pyrrolidine groups, is not yet 
well understood. 
Synthetic cathinone abuse is well documented and fatalities have been reported (4, 
21-29). A compilation of C/P and L/P ratios is shown for published case reports to date 
(Table 6.1). Although C/P ratios were generally >1, synthetic cathinone L/P ratios were 
<5 L/kg (with the exception of MDPV). McIntyre proposed the use of L/P ratios, 
suggesting that the broader range of values might allow for better differentiation of drugs 
that exhibit PMR (>20 L/kg) from those that do not (<5 L/kg) (4, 30). However, liver is 
not a homogeneous specimen and drug concentrations within this complex organ are 
variable (8). Although sampling from the deep right lobe is recommended to avoid 
contamination or diffusion from the gastrointestinal compartment, sampling protocols vary 
(5). Due to inter-subject variation and sample collection variation, C/P and L/P ratios from 
single case studies or very small sample populations may not be representative and should 
be interpreted with caution.  
The purpose of this study was to further investigate the distribution and potential 
redistribution of synthetic cathinones in fifty cathinone positive fatalities; to compare 
findings with existing published case reports; and to investigate the influence of structural 
characteristics or various substituents on the potential for PMR. 
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Table 6.1. Summary of C/P and L/P ratios for synthetic cathinones from published case 
reports.  
Cathinone C/P L/P (L/kg) Reference 
Butylone N/A 1.7 (21) 
Ethylone 1.0 3.6 (4) 
MDPV 1.7 23 (22) 
1.6 2.9 (22) 
- 3.0 (22) 
1.3 2.5 (22) 
1.6 19 (22) 
- 9.5 (22) 
1.4 2.2 (31) 
0.7  N/A (23) 
Average 1.3 8.9  
Methylone - 2.9 (24) 
1.2 - (25) 
1.0 1.6 (25) 
1.0 3.2 (32) 
1.1 2.7 (26) 
2.1 - (27) 
Average 1.3 2.6  
Pentedrone - 11 (33) 




- 2.9 (33) 
Average 1.45 1.7  
Pyrovalerone 1.4 3.0 (22) 
  
Material and Methods 
Chemicals and reagents  
Reference standards for 3,4-dimethylmethcathinone (3,4-DMMC), 3-
fluoromethcathinone (3-FMC), 4-fluoromethcathinone  (4-FMC), 4-ethylmethcathinone  
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(4-EMC), 4-methyletehcathinone (4-MEC), α-PVP, buphedrone, butylone, ethcathinone, 
ethylone, eutylone, 3,4-methylenedioxy-α-pyrrolidinobutiophenone (MDPBP), MDPV, 
methcathinone, methedrone, methylone, mephedrone, 4-methyl-α-
pyrrolidinobutiophenone (MPBP), naphyrone, pentedrone, pentylone, and pyrovalerone 
were purchased as methanolic standards (1.0 mg/mL) from Cerilliant Corp. (Round Rock, 
TX, USA). Internal standards methylone-D3, ethylone-D3, butylone-D3, eutylone-D5, 
MDPV-D8, α-PVP-D8, naphyrone-D5, and mephedrone-D3 were purchased as methanolic 
0.1 mg/mL standards from Cerilliant Corp. (Round Rock, TX, USA). 
Pooled drug-free urine, preserved with 1% sodium fluoride, was purchased from 
Utak Laboratories (Valencia, CA, USA) and  bovine blood containing 1% sodium fluoride 
and 0.2% potassium oxalate was purchased from Quad Five (Ryegate, Montana, USA). 
Drug free human liver was procured from Sam Houston State University’s Southeast Texas 
Applied Forensic Science (STAFS) Facility. Postmortem samples were received from the 
LA County Department of the Medical Examiner and the North Carolina Office of the 
Chief Medical Examiner in accordance with an IRB approved study. 
Ethyl acetate (HPLC grade), hexane (Optima®), and acetonitrile (LCMS grade) 
were obtained from Fisher Scientific (Fair Lawn, NJ, USA). Formic acid (>95%) was 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Dichloromethane (LCMS grade), 
isopropyl alcohol (LCMS grade), and glacial acetic acid (ACS grade) were purchased from 
Mallinckrodt Chemicals (St. Louis, MO, USA). Methanol (LCMS grade), concentrated 
hydrochloric acid (ACS grade), and dibasic sodium phosphate (ACS grade) were obtained 
from J.T. Baker (Center Valley, MA, USA). Concentrated ammonium hydroxide 
(Optima®) was obtained from Macron Fine Chemicals (Center Valley, MA, USA). 
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Monobasic sodium phosphate (ACS grade) was obtained from VWR (Randor, PA, USA). 
Deionized water was purified in-house using a Millipore Direct-Q® UV Water Purification 
system (Billerica, MA, USA). PolyChrom Clin II 3 cc (35 mg) solid phase extraction (SPE) 
columns were obtained from Tecan SP, Inc. (Baldwin Park, CA, USA).  
Instrumentation  
An Agilent Technologies 6530 LC-Q/TOF-MS equipped with an Agilent 1290 
Infinity autosampler was used to analyze samples (Agilent Technologies, Santa Clara, CA, 
USA). An Agilent Technologies Series 1200 LC system and Agilent Poroshell 120 EC-
C18 column (2.1 x 100 mm, 2.7 µm) (equipped with guard column , 2.1 x 5 mm, 2.7 µm) 
was used for chromatographic separation at 35°C. Nitrogen for the LC-Q/TOF was 
generated with a Genius 3040 nitrogen generator (Peak Scientific, Billerica, MA, USA). 
Mobile phase A and B consisted of 0.1% formic acid in deionized water and 0.1% formic 
acid in acetonitrile, respectively. Using a flow rate of 0.4 mL/min, compounds were 
separated using gradient elution: 96% A and 4% B (0 – 0.5 mins); 10% B (0.5 – 5 mins); 
40% B (5 – 11 mins); 100% B (12 mins). The LC-Q/TOF MS was equipped with an 
electrospray ionization (ESI) source operated in positive mode under the following 
conditions: drying gas (N2), 13 L/min; drying gas temperature, 200oC; nebulizer, 20 psi; 
sheath gas temperature, 250oC; nitrogen sheath gas flow, 12 L/min; capillary voltage, 4000 
V; nozzle voltage, 0 V; fragmentor, 150 V; skimmer, 65V. Full analytical details and 
validation data was previously published (35). Agilent MassHunter software was used for 
acquisition, qualitative, and quantitative analysis.  
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Preparation of standards and reagents  
Methanolic working standards containing all twenty-two synthetic cathinones were 
prepared at 0.1 and 1.0 ng/µL for urine calibrators, and 0.2 and 2.0 ng/µL for blood 
calibrators. A total of 6 non-zero calibrators (5, 10, 250, 100, 250, 350, and 500 ng/mL) 
were prepared daily in blood and urine. A stock standard of 10 ng/µL was used to prepare 
high calibrators (>250 ng/mL) for both matrices. Tissue homogenates were fortified using 
the 0.2, 1.0, or 2.0 ng/µL working solution for the low, medium, and high control, 
respectively. The working internal standard (IS) solution consisted of all nine deuterated 
internal standards in methanol at 0.5 ng/µL. Phosphate buffer (pH 6, 0.1M) was prepared 
from 0.1M solutions of mono and dibasic sodium phosphate solutions. Acidic methanol 
was prepared using 2% (v/v) concentrated hydrochloric acid in methanol. The elution 
solvent, consisting of 2% concentrated ammonium hydroxide in 95:5 
dichloromethane/isopropyl alcohol (v/v), was prepared daily.  
Sample Preparation 
Cathinones were isolated from blood and urine using a previously published 
technique [35]. Urine (1.0 mL) was fortified with IS to achieve a final concentration of 25 
ng/mL. Samples were diluted with 2.0 mL of 0.1M phosphate buffer and transferred to SPE 
columns. A J.T. Baker vacuum manifold (Center Valley, MA, USA) was used for all 
extractions. Columns were washed with 1.0 mL deionized water and 1.0 mL 1M acetic 
acid, dried under vacuum, and then washed successively with 1.0 mL hexane, ethyl acetate 
and methanol. Cathinones were eluted using 1.0 mL of elution solvent, delivered in two 
0.5 mL volumes. Following the addition of 30 µL of 2% acidic methanol, extracts were 
evaporated to dryness under nitrogen at 50°C using a TurboVap LV® (Caliper Life 
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Sciences, Hopkinton, MA, USA). Samples were reconstituted in 25 µL of 50:50 mobile 
phase A: B and 1 µL was injected onto the LC-Q/TOF MS for analysis. Vitreous fluid was 
treated in an analogous fashion.  
Blood (2.0 mL) was fortified with IS to achieve final concentration of 25 ng/mL. 
Cold acetonitrile (4.0 mL) was added with vortex-mixing to precipitate proteins. Following 
centrifugation at 4,000 RPM (5 mins), the supernatant was transferred to a clean culture 
tube, diluted with 6.0 mL of 0.1M phosphate buffer, and transferred to an SPE column. 
Samples were washed with 1.0 mL deionized water and 1.0 mL of 1M acetic acid, dried 
under vacuum, and then washed with 1.0 mL hexane, 1.0 mL ethyl acetate, 1.0 mL 
methanol, and 1.0 mL dichloromethane. Elution, acidification, reconstitution and injection 
of extracts onto the LC-Q/TOF was performed as described above.  
Liver homogenates were prepared using one part tissue (0.5 g) with two parts 
deionized water using a Bead Ruptor 12 (OMNI International, Kennesaw, GA, USA). Full 
homogenization was achieved using two 30-second pulses (at high speed) in reinforced 
sample tubes (7 mL) pre-filled with twelve 2.8 mm ceramic beads (OMNI International, 
Kennesaw, GA, USA). Following the transfer of 0.5 mL homogenate to a clean culture 
tube, IS (25 ng total) was added. Proteins were precipitated using cold acetonitrile (2.0 mL) 
and samples were centrifuged at 4,000 RPM (5 mins). The supernatant was transferred to 
a clean culture tube, diluted with 3.0 mL of 0.1M phosphate buffer, and extracted using the 
procedure described for blood. Quantitative liver determinations were performed using 
whole blood calibrators and matrix-matched (liver) controls. Liver homogenates (0.5 mL 
of a 1:2 homogenate) were fortified with 10, 25, and 50 ng (total) drug,  reflecting final 
liver concentrations of 60, 150, and 300 ng/g. Bias and precision were evaluated using 
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three replicates over five days. Acceptable criteria for bias and precision was ±20% (34). 
In addition to whole blood controls, a matrix-matched (liver) control (150 ng/g) was 
routinely included in each assay. In order to obtain quantitative results within the 
calibration range of the assay, appropriate dilutions were used if necessary.  
Postmortem specimens 
A total of fifty cathinone positive cases were identified. A total of 139 specimens 
were included in the study, comprised of vitreous humor (n=1), urine (n=33), liver (n=22), 
stomach contents (n=1), central blood (n=51) and peripheral blood (n=31). Central blood 
was identified as aorta blood (n=33), heart blood (n=5), vena cava blood (n=11), right chest 
cavity blood (n=1) and central blood (n=1). Peripheral sources were identified as femoral 
vessel blood (n=17), iliac vein blood (n=10), subclavian vessel blood (n=3), and peripheral 
blood (n=1). The number of specimens per case (n=50) ranged from one to six. In cases 
that included central blood or liver, together with a peripheral blood source, the C/P or L/P 
ratio was estimated (n=21 C/P; n=11 L/P). 
Results and discussion 
Tissue validation 
 
Assay performance in blood and urine was previously reported, demonstrating 
limits of quantitation between 0.25 – 5 ng/mL (35). In order to establish validity of the 
quantitative assay in tissue, precision and bias were assessed using liver fortified with drug 
at three concentrations in triplicate, over five days. A low control (containing 10 ng total 
drug in homogenate) was selected to ensure reliable quantitative performance in tissue. 
Bias for all twenty-two cathinones ranged from -20 to 14.7% (Table 6.2). In all but four 
instances, precision yielded coefficients of variation (%CV) of 20% or less. Intra-assay 
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CVs for 3-FMC, ethcathinone, MDPBP and MPBP in liver were 0.3-26.4%, 0.7-20.9%, 
2.1-20.7% and 0.7-24.7%, respectively. In an abundance of caution, concentrations in liver 
below the low control (60 ng/g) were reported as <60 ng/g. Extracted ion chromatograms 
for the twenty-two target drugs are presented in Figure 6.1 and Figure 6.2 depicts an 
authentic liver sample (Case #16) containing methylone at 61 ng/g. 
 
Figure 6.3. Separation of synthetic cathinones in a representative liver extract (60 ng/g). 
Overlaid extracted ion chromatograms are shown for methcathinone (3.534), 3-FMC 
(4.096), 4-FMC (4.237), methylone (4.314), ethcathinone (4.452), ethylone (5.361), 
methedrone (5.503), buphedrone (5.618), butylone (6.432), mephedrone (6.612), eutylone 
(7.053), 4-MEC (7.307), MDPBP (7.363), pentedrone (7.597), pentylone (7.951), 3,4-
DMMC (8.182), α-PVP (8.239), 4-EMC (8.349), MPBP (8.503), MDPV (8.554), 
pyrovalerone (9.526), naphyrone (10.832).  
 
 
Figure 6.4. Representative postmortem liver extract (Case #16) containing methylone 
(122 ng/g). Extracted ion chromatograms for the nine internal standards are also shown: 
methylone-D3 (4.260), ethylone-D5 (5.256), butylone-D3 (6.404), mephedrone-D3 
(6.583), eutylone-D5 (7.021), pentylone-d3 (7.918), α-PVP-D8 (8.236), MDPV-D8 
(8.525), naphyrone-D5 (10.832).  
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Table 6.2. Summary of bias, intra- and inter-assay precision in liver. The limit of 
quantitation (LOQ) in blood is indicated in parentheses for comparison purposes. Drugs 
identified in the cathinone-positive fatalities are shown in bold.   
Cathinone  
(Blood LOQ,  
ng/mL) 
Intra-assay Precision  
(n=3, %CV) 





















Methcathinone (2) 3.9-7.6 1.2-11.1 1.2-7.5 7.6 8.9 5.1 -12.5 -3.0 1.3 
3-FMC (2) 1.7-8.7 0.3-26.4 2.8-13.5 8.7 16.9 8.5 -20.0 -11.9 -5.9 
4-FMC (5) 1.7-13.4 0.4-7.4 3.7-10.7 13.4 9.1 7.6 3.5 6.6 7.8 
Methylone* (2) 1.7-5.9 1.9-5.2 1.6-7.2 3.9 3.2 4.7 -2.8 -5.0 -1.2 
Ethcathinone (5) 1.6-9.6 0.7-20.9 0.5-9.8 9.6 14.1 8.2 -18.0 -12.0 -6.0 
Ethylone* (2) 4.3-6.0 1.1-4.2 2.2-4.2 6.0 4.5 4.3 -3.7 -1.5 3.1 
Methedrone* (2) 3.6-11.4 2.4-10.7 0.7-5.8 11.4 5.9 3.4 -12.6 1.3 7.9 
Buphedrone (5) 3.3-10.3 1.4-11.1 0.6-11.2 10.3 9.1 5.9 -15.6 -6.9 -1.0 
Butylone* (2) 1.4-6.1 2.4-5.9 2.1-6.1 5.3 5.1 4.5 -2.4 -3.2 0.2 
Mephedrone (2) 1.9-6.2 0.9-5.2 1.3-4.5 3.8 4.2 3.9 -0.7 -2.3 -0.6 
Eutylone (5) 1.3-9.9 1.2-6.3 2.2-6.1 8.1 5.4 4.1 -0.7 -0.8 3.8 
4-MEC (5) 1.9-18.5 2.1-5.4 1.5-5.5 18.5 6.3 4.7 -14.2 10.3 12.2 
MDPBP (5) 3.1-20.7 2.4-7.2 2.1-4.9 17.3 8.1 6.6 -16.2 5.1 8.9 
Pentedrone (5) 1.4-12.6 0.9-9.2 2.4-6.4 12.6 8.6 3.8 -14.5 -2.7 1.0 
Pentylone (5) 2.4-11.7 1.9-7.1 2.8-7.5 8.0 5.3 6.2 -0.7 -4.9 -1.3 
3,4-DMMC (2) 1.0-8.8 1.4-5.2 1.7-6.6 8.8 12.1 8.5 -8.7 -6.1 0.6 
α-PVP* (2) 0.8-4.6 1.5-8.0 0.9-5.7 4.6 6.4 8.4 3.1 -1.5 -1.0 
4-EMC (1) 1.6-10.3 0.7-4.8 1.3-4.4 10.3 6.1 3.4 -10.1 0.6 4.4 
MPBP (2) 1.3-24.7 1.4-8.7 0.7-18.7 15.8 6.0 10.4 4.3 4.9 14.7 
MDPV* (2) 2.0-6.2 2.5-6.1 0.8-7.1 4.1 3.7 5.0 -4.8 -11.0 -6.7 
Pyrovalerone (2)  3.0-9.3 0.7-9.5 1.4-7.2 8.4 6.5 5.0 -2.9 2.2 9.5 
Naphyrone (1) 1.5-5.0 3.1-5.4 2.2-9.7 4.6 4.4 6.5 -7.4 -4.9 -4.0 
 
Identification of Cathinones in Postmortem Specimens 
 
Of the fifty cases investigated, a total of nine synthetic cathinones were identified, 
including α-PVP (n=19), methylone (n=18), ethylone (n=15), MDPV (n=6), pentylone 
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(n=3), butylone (n=1), methedrone (n=2), 4-MEC (n=1), and MDPBP (n=1). Postmortem 
findings for all specimens are summarized in Table 6.3. Concentrations in blood ranged 
from <2 - 1,090 ng/mL (α-PVP), <2 - 202 ng/mL (methylone), 3 - 2,743 ng/mL (ethylone), 
3 - 80 ng/mL (MDPV), and <5 - 322 ng/mL (pentylone). These results highlight the wide 
range of forensic interest, and the need for sensitive analytical methods to detect low ng/mL 
concentrations.   
More than one synthetic cathinone was identified in seven cases (Case #1, 7, 8, 34, 
37, 38 and 44).  In two fatalities, α-PVP and pentylone were identified. Ethylone was also 
detected in combination with methylone, MDPV or α-PVP. As many as four cathinones 
were detected in one fatality (MDPV, methylone, MDPBP and pentylone), highlighting the 
problems associated with illicit NPS use. Overall, the most commonly identified 
cathinones were α-PVP, methylone and ethylone.   
Only one vitreous fluid was available for testing (Case #48), but the ethylone 
concentration (279 ng/mL) was in good agreement with peripheral blood (262 ng/mL). In 
previously published studies, the distribution of MDPV, methylone, ethylone and 
mephedrone in vitreous fluid relative to peripheral blood has been highly variable (4, 22, 
27, 32, 36). Time dependent variables and cathinone stability may be contributing factors. 
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Table 6.3. Cathinone-positive specimens (n=139) in a series of fifty fatalities. 
Cathinone Case # Contents  Concentration  
(ng/mL or ng/g) 
C/P L/P 
4-MEC 6 subclavian vessel blood 57   
Butylone 39 aorta blood 6 0.7 14 
iliac vein blood 8   
liver 116   
urine 934   
Ethylone 26 aorta blood 872 1.1 0.2 
  iliac vein blood 780   
  liver 170   
  urine 214   
 27 aorta blood 1,271   
  liver 857   
  urine 8,743   
 28 iliac vein blood 10 0.5  
  heart blood 5   
  urine 273   
 29 aorta blood 4   
  vena cava blood 6   
  urine 958   
 30 femoral vessel blood 19 1.0 <3.2 
  central blood 19   
  urine 150   
  liver <60   
 33 femoral vessel blood 298 9.2  
  aorta blood 2,743   
 34 aorta blood 3   
 35 aorta blood 193 2.8 1.7 
  femoral vessel blood 69   
    (continued) 
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Cathinone Case # Contents  Concentration  
(ng/mL or ng/g) 
C/P L/P 
  urine >20,000   
  liver 116   
 36 right chest cavity blood 81   
  urine 2,424   
 37 aorta blood 146 2.5  
  iliac vein blood 59   
  urine 32   
 38 urine 310   
 45 femoral blood 267   
 46 heart blood 2,156   
 48 vitreous fluid 279  20 
  femoral blood 262   
  stomach contents 6,827   
  liver 5,196   
MDPBP 1 urine  111   
MDPV 1 aorta blood 80 1.0  
  femoral blood 80   
  urine  5,210   
 2 urine 4   
 15 aorta blood 10   
  vena cava blood 35   
  liver 223   
  urine 203   
 37 liver <60   
 44 heart blood 4   
Methedrone 11 aorta blood 79 1.1 10 
  iliac vein blood 70   
  urine 1,213   
  liver 720   
    (continued) 
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Cathinone Case # Contents  Concentration  
(ng/mL or ng/g) 
C/P L/P 
Methylone 1 aorta blood 3 1.5  
  femoral blood 2   
  urine  12,100   
 13 aorta blood 23   
  vena cava blood 6   
  urine 856   
  liver 235   
 16 subclavian vessel blood 20 2.4 3.1 
  aorta blood 48   
  urine 38,064   
  liver 61   
 17 urine 5   
 18 aorta blood 10   
  vena cava blood 16   
  liver 142   
  urine >5,000   
 19 aorta blood 14 3.4  
  femoral vessel blood 4   
 20 aorta blood 20 6.1  
  femoral vessel blood 3   
  urine 756   
 21 aorta blood 14   
  vena cava blood 47   
  urine >5,000   
 22 aorta blood 202   
  vena cava blood 68   
  urine 52   
  liver 216   
    (continued) 
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Cathinone Case # Contents  Concentration  
(ng/mL or ng/g) 
C/P L/P 
 23 aorta blood 129   
  vena cava blood 46   
  liver >300   
  urine >20,000   
 24 aorta blood 62   
  urine >5,000   
  liver 594   
  vena cava blood 45   
 34 aorta blood 119 4.2 40 
  iliac vein blood 28   
  liver 1,114   
 44 heart blood 2   
 47 liver 77   
  heart blood <2   
 50 femoral blood <2   
Pentedrone 4 aorta blood <5   
Pentylone 1 urine  122   
 7 iliac vein blood <5   
  aorta blood <5   
 8 aorta blood 323 2.0  
  iliac vein blood 160   
  urine >10,000   
α-PVP 3 aorta blood 15 0.5  
  femoral vessel blood 30   
  urine >5,000   
 5 aorta blood 4   
  vena cava blood 8   
  urine 38   
    (continued) 
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Cathinone Case # Contents  Concentration  
(ng/mL or ng/g) 
C/P L/P 
 7 aorta blood 8 1.0  
  iliac vein blood 8   
 8 aorta blood 218 0.9  
  iliac vein blood 234   
  urine 7,580   
 9 subclavian vessel blood 4   
  urine 853   
  femoral vessel blood <2   
 10 aorta blood 3 1.5  
  peripheral blood 2   
  urine 52   
 12 liver 169   
  vena cava blood 3   
  urine 3,846   
 14 aorta blood 41 1.9  
  iliac vein blood 21   
  urine 3,972   
 25 aorta blood 224 1.1 <0.3 
  femoral vessel blood 208   
  liver <60   
 31 aorta blood 1,090 1.1 <0.1 
  iliac vein blood 1,019   
  liver <60   
 32 aorta blood 75   
  urine 33   
  liver 69   
 38 aorta blood 58 1.3 <1.4 
  femoral vessel blood 44   
  urine 1,731   
    (continued) 
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Cathinone Case # Contents  Concentration  
(ng/mL or ng/g) 
C/P L/P 
  liver <60   
 40 femoral vessel blood 84 0.9  
  heart blood 79   
 41 urine 598   
  femoral vessel blood <2   
 42 femoral vessel blood 7   
  aorta blood <2   
 43 aorta blood 28   
  vena cava blood 18   
  urine 1,254   
 44 femoral blood 3   
 49 heart blood <2   
 
Postmortem redistribution 
Twenty-one cases contained both a central and peripheral blood source, which 
allowed C/P ratios to be determined for seven drugs (Table 6.4). The average C/P ratio for 
α-PVP was 1.1 (0.5 - 1.9, n=9). By comparison, average C/P ratios for methylenedioxy-
substituted cathinones ethylone and methylone were 2.9 (0.5 - 9.2, n=6) and 4.0 (1.5 - 6.1, 
n=5), suggesting greater potential for postmortem redistribution. Although conclusions 
cannot be drawn form single cases, C/P ratios for butylone, MDPV, methedrone and 
pentylone were 0.7, 1.0, 1.1, and 2.0, respectively. 
In a similar fashion, L/P ratios proposed by McIntyre were also evaluated where 
possible (n=7) (Table 6.4).  Consistent with the trends observed with methylenedioxy-
substituted cathinones, the highest reported L/P ratios were observed with methylone (40), 
ethylone (20) and butylone (14). However, L/P ratios were highly variable; ethylone L/P 
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ratios varied by two orders of magnitude, demonstrating the difficulty associated with 
individual measurements. Although some measurements exceed the proposed L/P 
threshold of 20-30, average L/P ratios for all of the cathinones fell below this range, 
suggesting a lower potential for redistribution.  
There were nine instances where both a C/P and L/P ratio were determined. Among 
the three α-PVP cases, C/P ratios were 1.1 - 1.3 and L/P ratios were <1.4. However, C/P 
and L/P ratios of 1.1 and 10, respectively were observed for methedrone, and 0.7 and 14 
for butylone.  These findings further reinforce time dependent factors, postmortem interval 
and other issues that complicate quantitative comparisons.  Results were also compared 
with previously published studies (Table 6.4).  C/P ratios were in good agreement for some 
drugs (e.g. MDPV, α-PVP). Although C/P ranges generally overlapped for the remaining 
cathinones, significant variability was observed. This is perhaps not unexpected given the 
relatively small populations and limited number of case reports to date.  
Table 6.4. Comparison of C/P and L/P ratios with previously published literature. The 
mean (range) and number of specimens are summarized for cathinones. 
Methamphetamine and MDMA are shown for comparison.  
 
Drug Current Study Previously Published Literature 
C/P L/P C/P L/P Reference 
Butylone 0.7 n=1 14 n=1  1.7 n=1 (21) 
Ethylone 2.9 (0.5 – 9.2) 
n=6 
7.2 (0.2 – 20) 
n=3* 
0.97 n=1 3.6 n=1 (4) 
MDPV 1.0 n=1 - 1.3 (0.7 – 1.7) 
n=6 
 
8.8 (2.2 – 23) 
n=7 
 
(22, 23, 31) 
Methedrone 1.1 10 - - - 
Methylone 4.0 (1.5 – 6.1) 
n=5 
12.9 (3.1 – 
40) (n=2) 
1.3 (1.0 – 2.1) 
n=5 
2.6 (1.6 – 3.2) 
n=4 
(24-27, 32) 
Pentylone 2.0 n=1 -   - 
α-PVP 1.1 (0.5 – 1.9) 
n=9 
<1.4 n=3 1.4 – 1.5* n=1 1.5 (1.1 – 2.9) 
n=3 
(28, 29, 33) 
     (continued) 
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Drug Current Study Previously Published Literature 
C/P L/P C/P L/P Reference 
MDMA - - 2.7 (0.9 – 4.6) 
n=7 
6.5 (3.1 – 8.5) 
n=5 
(13-17) 
Methamphetamine - - 2.3 (0.9 – 5.8) 
n=39 
5.5 (1.7 – 9.1) 
n=19 
(7, 11, 12) 
*One case report with left and right cardiac chambers sampled. 
 
The synthetic cathinones with calculated C/P and L/P ratios comprised of secondary 
amines bearing a ring substituent (methedrone) or methylenedioxy group (methylone, 
ethylone, butylone, pentylone), and tertiary amines (pyrrolidines) with and without a 
methylenedioxy group (MDPV and α-PVP, respectively) (Figure 6.3). In general, the 
secondary amine, methylenedioxy-type cathinones had the highest C/P ratios, indicating 
that this particular sub population of cathinones may be more susceptible to postmortem 
redistribution. Butylone was the exception however, but the sample size was limited (n=1).  
The higher C/P ratios associated with the secondary amine methylenedioxy-substituted 
cathinones is consistent with MDMA (C/P = 2.7) and methamphetamine (C/P = 2.3) (Table 
6.4).  
A box plot depicting C/P ratios for α-PVP (n=9), methylone (n=5), and ethylone 
(n=6) is shown in (Figure 6.4). Statistical significance was investigated using a two-sample 
t-test assuming unequal variances.  There was no statistical difference (α=0.05) between 
methylone and ethylone, the two methylenedioxy-substituted cathinones with larger 
sample sizes (t(8)=0.44, p=0.67). The C/P ratios for both pyrrolidine derivatives (tertiary 
amines), indicated a minimal potential for redistribution. Although they are more 
lipophilic, the pyrrolidines are less basic than their secondary amine counterparts, due to 
steric hindrance and solvation of ions. Their reduced tendency to undergo PMR is 
consistent with the fact that basic drugs are believed to be more susceptible to PMR (37-
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39). Statistically, there was a significant difference between α-PVP and methylone 
(t(3)=2.99, p<0.04), but not between α-PVP and ethylone (t(5)=1.29, p=0.25).  
Synthetic Cathinone Stability  
The distribution of cathinones postmortem is complicated by the instability of these 
beta-keto amphetamines.  We previously investigated the stability of synthetic cathinones 
in blood and urine (40, 41). Cathinone stability is highly pH, temperature, and analyte 
dependent. Although all samples included in this study were refrigerated following 
collection, degradation during the postmortem interval is possible and should be 
considered. Although pyrrolidine derivatives are relatively stable, ring substituted and 
unsubstituted secondary amines are significantly less stable. Furthermore, since matrix pH 
is highly variable, it should be expected that while degradation may be minimal in acidic 
compartments (e.g. stomach), alkaline conditions will accelerate degradation. This 
becomes more complicated for biological samples with wide-ranging pH values, such as 
urine (pH 4-8) (42, 43). It is further complicated by changes in pH post-collection or 
postmortem. While increases of 2 pH units have been documented in stored urine, the pH 
of postmortem blood may decrease following death. Quantitative results must be 
interpreted with caution, and conclusions regarding the distribution of cathinones 
following death must acknowledge the added complexity that arises due to their limited 
stability.  
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Secondary Amine Cathinones Tertiary Amine Cathinones 
Non-Methylenedioxy Substituted 




























































Figure 6.3. Structures and C/P ratios of selected cathinones and non-cathinone species 
(methamphetamine and MDPV) for comparison.  
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Figure 6.4. Box plots depicting C/P ratios for α-PVP (n=9), methylone (n=5), and 




The distribution of synthetic cathinones was evaluated in a series of fifty fatalities. 
C/P and L/P ratios were also evaluated and compared with existing published literature. 
Although significant variability was observed, cathinones bearing secondary amines and 
methylenedioxy groups appeared to have the greatest potential for postmortem 
redistribution. Drugs such as methylone and ethylone may be slightly more susceptible to 
PMR than either methamphetamine or MDMA. In contrast, pyrrolidines, such as α-PVP 
and MDPV appear to be less susceptible to PMR.  
Pharmacological and physico-chemical properties of the drug can influence 
postmortem redistribution (8, 44). However, interpretation of postmortem toxicology 
results is complicated by specimen collection practices, site and time dependent issues, 
circumstances of death, postmortem interval, decomposition and environmental factors. 
* 
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While conclusions based on large sample sizes are preferable, published case reports are 
sometimes limited to single cases or small populations. This is particularly true for new 
and emerging recreational drugs. Although drug properties can provide insight into a PMR, 
the tendency of cathinones to degrade in biological evidence further complicates 
toxicological interpretation.  
Acknowledgements 
This project was supported by Award No. 2013-R2-CX-K006 awarded by the 
National Institute of Justice, Office of Justice Programs, U.S. Department of Justice. The 
opinions, findings, and conclusions or recommendations expressed in this publication are 
those of the author(s) and do not necessarily reflect those of the Department of Justice.  
  
   299 
   
References 
1. Cook, D. S., Braithwaite, R. A. and Hale, K. A. (2000) Estimating antemortem 
drug concentrations from postmortem blood samples: The influence of 
postmortem redistribution. Journal of Clinical Pathology, 53, 282-285. 
2. Pounder, D. J. and Jones, G. R. (1990) Post-mortem drug redistribution — a 
toxicological nightmare. Forensic Science International, 45, 253-263. 
3. Jones, G. R. and Pounder, D. J. (1987) Site dependence of drug concentrations in 
postmortem blood—a case study. Journal of Analytical Toxicology, 11, 186-190. 
4. McIntyre, I. M., Hamm, C. E., Sherrard, J. L., Gary, R. D., Burton, C. G. and 
Mena, O. (2014) Acute 3,4-methylenedioxy-N-ethylcathinone (ethylone) 
intoxication and related fatality: A case report with postmortem concentrations. 
Journal of Analytical Toxicology, 39, 225-228. 
5. Dinis-Oliveira, R. J., Carvalho, F., Duarte, J. A., Remião, F., Marques, A., Santos, 
A., et al. (2010) Collection of biological samples in forensic toxicology. 
Toxicology Mechanisms and Methods, 20, 363-414. 
6. Drummer, O. H. (2004) Postmortem toxicology of drugs of abuse. Forensic 
Science International, 142, 101-113. 
7. Barnhart, F. E., Fogacci, J. R. and Reed, D. W. (1999) Methamphetamine—a 
study of postmortem redistribution. Journal of Analytical Toxicology, 23, 69-70. 
8. Pélissier-Alicot, A.-L., Gaulier, J.-M., Champsaur, P. and Marquet, P. (2003) 
Mechanisms underlying postmortem redistribution of drugs: A review. Journal of 
Analytical Toxicology, 27, 533-544. 
   300 
   
9. Skopp, G. (2010) Postmortem toxicology. Forensic Science, Medicine, and 
Pathology, 6, 314-325. 
10. Baselt, R.C. (2017) Disposition of toxic drugs and chemicals in man. 11th ed. 
Biomedical Publications, Seal Beach, California. 
11. Logan, B., Weiss, E. and Harruff, R. (1996) Case report: Distribution of 
methamphetamine in a massive fatal ingestion. Journal of Forensic Science, 41, 
322-323. 
12. McIntyre, I., Hamm, C. and Bader, E. (2011) Postmortem methamphetamine 
distribution. Journal of Forensic Research, 2, 1-3. 
13. Elliott, S. P. (2005) Mdma and mda concentrations in antemortem and 
postmortem specimens in fatalities following hospital admission. Journal of 
Analytical Toxicology, 29, 296-300. 
14. Dams, R., De Letter, E. A., Mortier, K. A., Cordonnier, J. A., Lambert, W. E., 
Piette, M. H. A., et al. (2003) Fatality due to combined use of the designer drugs 
MDMA and PMA: A distribution study. Journal of Analytical Toxicology, 27, 
318-323. 
15. Rohrig, T. P. and Prouty, R. W. (1992) Tissue distribution of 
methylenedioxymethamphetamine. Journal of Analytical Toxicology, 16, 52-53. 
16. De Letter, E. A., Bouche, M.-P. L. A., Van Bocxlaer, J. F., Lambert, W. E. and 
Piette, M. H. A. (2004) Interpretation of a 3,4-methylenedioxymethamphetamine 
(MDMA) blood level: Discussion by means of a distribution study in two 
fatalities. Forensic Science International, 141, 85-90. 
   301 
   
17. De Letter, E. A., Clauwaert, K. M., Lambert, W. E., Van Bocxlaer, J. F., De 
Leenheer, A. P. and Piette, M. H. A. (2002) Distribution study of 3,4-
methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine in a fatal 
overdose. Journal of Analytical Toxicology, 26, 113-118. 
18. Kennedy, M. C. (2010) Post-mortem drug concentrations. Internal Medicine 
Journal, 40, 183-187. 
19. Zhou, M. J., Bouazzaoui, S., Jones, L. E., Goodrich, P., Bell, S. E. J., Sheldrake, 
G. N., et al. (2015) Isolation and structural determination of non-racemic tertiary 
cathinone derivatives. Organic & Biomolecular Chemistry, 13, 9629-9636. 
20. Gibbons, S. and Zloh, M. (2010) An analysis of the ‘legal high’ mephedrone. 
Bioorganic & Medicinal Chemistry Letters, 20, 4135-4139. 
21. Rojek, S., Kłys, M., Strona, M., Maciów, M. and Kula, K. (2012) “Legal highs”—
toxicity in the clinical and medico-legal aspect as exemplified by suicide with bk-
mbdb administration. Forensic Science International, 222, e1-e6. 
22. Marinetti, L. J. and Antonides, H. M. (2013) Analysis of synthetic cathinones 
commonly found in bath salts in human performance and postmortem toxicology: 
Method development, drug distribution and interpretation of results. Journal of 
Analytical Toxicology, 37, 135-146. 
23. Kesha, K., Boggs, C. L., Ripple, M. G., Allan, C. H., Levine, B., Jufer-Phipps, R., 
et al. (2013) Methylenedioxypyrovalerone ("bath salts"), related death: Case 
report and review of the literature. Journal of Forensic Sciences, 58, 1654-1659. 
24. Shimomura, E. T., Briones, A. J., Warren, W. S., Addison, J. W., Knittel, J. L., 
Shoemaker, S. A., et al. (2016) Case report of methylone, oxymorphone and 
   302 
   
ethanol in a fatality case with tissue distribution. Journal of Analytical 
Toxicology, 40, 543-545. 
25. Pearson, J. M., Hargraves, T. L., Hair, L. S., Massucci, C. J., Frazee, C. C., Garg, 
U., et al. (2012) Three fatal intoxications due to methylone. Journal of Analytical 
Toxicology, 36, 444-451. 
26. Cawrse, B. M., Levine, B., Jufer, R. A., Fowler, D. R., Vorce, S. P., Dickson, A. 
J., et al. (2012) Distribution of methylone in four postmortem cases. Journal of 
Analytical Toxicology, 36, 434-439. 
27. Barrios, L., Grison-Hernando, H., Boels, D., Bouquie, R., Monteil-Ganiere, C. 
and Clement, R. (2016) Death following ingestion of methylone. International 
Journal of Legal Medicine, 130, 381-385. 
28. Potocka-Banaś, B., Janus, T., Majdanik, S., Banaś, T., Dembińska, T. and 
Borowiak, K. (2017) Fatal intoxication with α-PVP, a synthetic cathinone 
derivative. Journal of Forensic Sciences, 62, 553-556. 
29. Hasegawa, K., Suzuki, O., Wurita, A., Minakata, K., Yamagishi, I., Nozawa, H., 
et al. (2014) Postmortem distribution of α-pyrrolidinovalerophenone and its 
metabolite in body fluids and solid tissues in a fatal poisoning case measured by 
LC-MS-MS with the standard addition method. Forensic Toxicology, 32, 225-
234. 
30. McIntyre, I. M. (2014) Liver and peripheral blood concentration ratio (L/P) as a 
marker of postmortem drug redistribution: A literature review. Forensic Science, 
Medicine, and Pathology, 10, 91-96. 
   303 
   
31. Wyman, J. F., Lavins, E. S., Engelhart, D., Armstrong, E. J., Snell, K. D., Boggs, 
P. D., et al. (2013) Postmortem tissue distribution of mdpv following lethal 
intoxication by “bath salts”. Journal of Analytical Toxicology, 37, 182-185. 
32. McIntyre, I. M., Hamm, C. E., Aldridge, L. and Nelson, C. L. (2013) Acute 
methylone intoxication in an accidental drowning - a case report. Forensic 
Science International, 231, e1-3. 
33. Sykutera, M., Cychowska, M. and Bloch-Boguslawska, E. (2015) A fatal case of 
pentedrone and α-pyrrolidinovalerophenone poisoning. Journal of Analytical 
Toxicology, 39, 324-329. 
34. Toxicology, S. W. G. f. F. (2013) Standard practices for method validation in 
forensic toxicology. Journal of  Analytical Toxicology, 37, 452-474. 
35. Glicksberg, L., Bryand, K. and Kerrigan, S. (2016) Identification and 
quantification of synthetic cathinones in blood and urine using liquid 
chromatography-quadrupole/time of flight (LC-Q/TOF) mass spectrometry. 
Journal of Chromatography B, 1035, 91-103. 
36. Adamowicz, P., Tokarczyk, B., Stanaszek, R. and Slopianka, M. (2013) Fatal 
mephedrone intoxication—a case report. Journal of Analytical Toxicology, 37, 
37-42. 
37. Dalpe-Scott, M., Degouffe, M., Garbutt, D. and Drost, M. (1995) A comparison 
of drug concentrations in postmortem cardiac and peripheral blood in 320 cases. 
Canadian Society of Forensic Science Journal, 28, 113-121. 
   304 
   
38. Roettger, J. R. (1990) The importance of blood collection site for the 
determination of basic drugs: A case with fluoxetine and diphenhydramine 
overdose. Journal of Analytical Toxicology, 14, 191-192. 
39. Moriya, F. and Hashimoto, Y. (1999) Redistribution of basic drugs into cardiac 
blood from surrounding tissues during early-stages postmortem. Journal of 
Forensic Science, 44, 10-16. 
40. Glicksberg, L. and Kerrigan, S. (2017) Synthetic cathinone stability in blood. 
Journal of Analytical Toxicology, https://doi.org/10.1093/jat/bkx071. 
41. Glicksberg, L. and Kerrigan, S. (in press) Stability of synthetic cathinones in 
urine. Journal of Analytical Toxicology.  
42. Fura, A., Harper, T. W., Zhang, H., Fung, L. and Shyu, W. C. (2003) Shift in pH 
of biological fluids during storage and processing: Effect on bioanalysis. Journal 
of Pharmaceutical and Biomedical Analysis, 32, 513-522. 
43. Cook, J. D., Strauss, K. A., Caplan, Y. H., LoDico, C. P. and Bush, D. M. (2007) 
Urine pH: The effects of time and temperature after collection. Journal of 
Analytical Toxicology, 31, 486-496. 
44. Ferner, R. E. (2008) Post-mortem clinical pharmacology. British Journal of 




   305 
   
CHAPTER VII 
CONCLUSIONS 
The synthetic cathinones are powerful psychostimulants that have been associated 
with impairment, intoxication, and fatal overdose. Forensic toxicology laboratories must 
be able to identify these new drugs as part of antemortem and postmortem toxicology 
investigations. Anecdotally, and in a small number of preliminary reports, some of the 
cathinones have been reported to be unstable. It is important to understand drug stability in 
biological evidence in order to reliably interpret analytical findings and draw valid 
conclusions. In this study a systematic and comprehensive approach to evaluate cathinone 
stability is described in terms of matrix, pH, temperature, concentration, and analyte 
dependence. This approach will not only aid in the interpretation of toxicological findings, 
but will also improve our understanding of future designer drugs within the class.  
Cathinone stability was evaluated in preserved blood (pH 7) and urine (pH 4 and 
8) at two concentrations (100 and 1,000 ng/mL) at four storage temperatures over six 
months. These were chosen to reflect frozen (-20°C) and refrigerated (4°C) long- and short-
term storage temperatures at the laboratory; exposure to ambient (20°C) or room 
temperature during routine processing and handling; and finally, potential exposure to 
elevated temperatures during shipping and transport to the laboratory (32°C). A total of 
nine deuterated internal standards were utilized. All quantitative measurements were 
performed using liquid chromatography-quadrupole/time of flight mass spectrometry 
following isolation of the drugs using solid phase extraction. The analytical procedure was 
fully validated in accordance with the Scientific Working Group for Forensic Toxicology 
Standard Practices for Method Validation. Extraction efficiencies were 84-104% and 81-
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93% in urine and blood, respectively, and limits of quantitation in both matrices were 0.25 
– 5 ng/mL. Precision, bias, and matrix effect were all within acceptable thresholds and the 
assay was free from more than fifty interferences.  
Of the twenty-two drugs selected, sixteen were secondary amines. Of these, four 
were unsubstituted at the benzene ring (methcathinone, ethcathinone, buphedrone, and 
pentedrone), seven were ring substituted (mephedrone, 4-MEC, 4-EMC, methedrone, 3,4-
DMMC, 3-FMC, and 4-FMC) and five were methylenedioxy-substituted (ethylone, 
methylone, butylone, pentylone, and eutylone). Six tertiary amines (pyrrolidines) were also 
included, and of these, two were methylenedioxy-substituted. 
Drug stability was evaluated to determine analyte, concentration, pH, matrix, and 
temperature dependence. Although no concentration dependence was observed, cathinone 
stability was highly analyte dependent. Structural features and substituents within these 
arylaminoketones exerted significant stabilizing and destabilizing effects. Notably, 3-FMC 
was the least stable of all of the drugs tested. Significant differences were observed between 
secondary and tertiary amines. Pyrrolidinyl analogs were inherently more stable, 
demonstrating far greater resilience than their secondary amine counterparts. With the 
exception of fluorine substitution, stability within the ring substituted cathinones was not 
significantly different. Both the unsubstituted and ring substituted cathinones were equally 
unstable under most conditions. In contrast, however, the methylenedioxy-substituted 
cathinones were significantly more stable. The stabilizing effect of the methylenedioxy 
group was observed for both the secondary amines and the pyrrolidines. As a result, 
cathinone species that contained both a methylenedioxy and a pyrrolidine were the most 
stable drugs tested. Stability was also highly pH dependent. Cathinones were considerably 
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more stable under acidic conditions. Degradation of the drug was accelerated dramatically 
under alkaline conditions, for even the most stable drugs. Significant temperature 
dependent stability was observed for all cathinones. Exposure to elevated temperature 
decreased estimated half-lives by several orders of magnitude for some drugs. With the 
exception of the methylenedioxy-substituted pyrrolidines, significant degradation was 
observed for all drugs within hours following exposure to elevated temperatures (32oC). 
With the exception of 3-FMC, cathinones were stable, or underwent only moderate 
degradation in blood when frozen. At refrigerated temperatures in blood, all drugs except 
3-FMC were stable or underwent moderate losses (<40%) during the first 30 days of 
storage. 
At elevated temperatures in blood, all of the cathinones demonstrated significant 
(>20%) loss within 5.5 hours (3-FMC) to 7 days (for the most stable methylenedioxy-
substituted pyrrolidines). At refrigerated temperature, significant losses were seen within 
7 days to more than five months in blood, and 1 day to more than six months in pH 8 urine. 
These results highlight the critical role of chemical structure among these complex 
arylaminoketones. Although frozen temperatures provided the greatest protection from 
loss, this is not necessarily feasible in many laboratories, except for long-term storage. 
Studies using fortified matrix show that exposure of biological evidence to elevated or 
ambient temperatures can significantly decrease concentrations over time.  
High resolution mass spectrometry was used to investigate possible decomposition 
products. Although acidic breakdown products have been proposed (particularly for 
cathinones bearing a secondary amine), identification was precluded due to the nature of 
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the (alkaline) solid phase extraction. However, N-oxide and 2”-oxo degradation products 
were identified for all tertiary amine cathinones. 
Experimental results using fortified, preserved matrix were confirmed using 
authentic urine specimens (n=180) from cathinone users in accordance with an IRB-
approved protocol. Urinary pH ranged from pH 4.5–10 following 5 to 17 months of 
refrigerated storage. The 180 specimens yielded a total of 164 cathinone positive findings. 
Of these, quantitative comparisons were made in 156 instances. Results using authentic 
urine samples from cathinone users were in good agreement with experimentally 
determined stability data using fortified matrix. This data also underscored the critical 
importance of specimen pH on overall drug stability. Moreover, the limited degradation of 
some drugs following extended periods of storage suggest that pH dependent variables 
were equally as important as conventional time dependent interpretation of drug stability.  
Cathinones were also identified in a series of fifty cathinone-positive fatalities. The 
distribution and postmortem distribution was assessed using central and peripheral blood, 
urine, vitreous humor, liver, and stomach contents. When cases included either a central 
blood or liver specimen, together with a peripheral blood sample, central to peripheral 
(C/P) and liver to peripheral (L/P) ratios were determined (n=21 C/P, n=11 L/P). These 
were used to evaluate PMR for seven synthetic cathinones, including α-PVP, MDPV, 
methedrone, butylone, ethylone, methylone, and pentylone. In general, cathinones 
appeared to exhibit low to moderate PMR (similar to methamphetamine and MDMA). 
However, cathinones bearing a secondary amine and a methylenedioxy group produced the 
highest C/P ratios, possibly suggesting greater potential for PMR. In contrast, the lowest 
C/P ratios were observed for tertiary amines bearing a pyrrolidine group. Differences in 
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C/P ratios that may arise from these structural characteristics were statistically significant 
(α = 0.05) for α-PVP and methylone.  
Forensic toxicology specimens may be subjected to a variety of conditions during 
sample transport, shipping, storage, and analysis that may cause drug concentrations to 
change considerably between the time of collection and the time of analysis. Furthermore, 
information pertaining to synthetic cathinones is still somewhat limited because not all 
forensic toxicology laboratories routinely screen for these drugs. In order for toxicological 
results to be reliably interpreted in forensic investigations, factors that influence drug 
stability must be considered.  
With the continued emergence of novel psychoactive substances, it is important to 
understand pre-analytical factors that may contribute to changes in concentration. The 
stability of a drug in biological evidence can significantly impact the detection and 
interpretation of forensic toxicology results in antemortem and postmortem investigations.  
This research provides the forensic toxicological community with a comprehensive 
understanding of synthetic cathinone stability which will aid in the interpretation of results. 
As this class of novel psychoactive substances continues to evolve and grow, the structural 
influences that impact cathinone stability provides valuable insight into new or yet to be 
discovered illicit cathinones.  
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APPENDIX A: INDIVIDUAL EXTRACTED ION CHROMATOGRAMS AND 
MS/MS SPECTRA FOR TWENTY-TWO SYNTHETIC CATHINONES 
 
Extracted ion chromatograms (EICs) for twenty-two synthetic cathinones with chemical 
structure and MS/MS spectra. Quantifier (bold) and qualifier ions identified with 
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APPENDIX B: CALIBRATION CURVES AND RESIDUAL PLOTS FOR SYNTHETIC CATHINONES IN BLOOD 
Calibration curves, quadratic, weighted (1/x), for synthetic cathinones in blood organized by sub-population. Axes expressed as 
relative concentration and relative response. Calibrator concentrations were 10, 25, 100, 250, 500, 750, and 1,000 ng/mL.  
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APPENDIX C: CALIBRATION CURVES AND RESIDUAL PLOTS FOR SYNTHETIC CATHINONES IN URINE 
Calibration curves, quadratic, weighted (1/x), for synthetic cathinones in urine organized by sub-population. Axes expressed as 
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APPENDIX D: ONE-WAY ANOVA STATISTICAL ANALYSIS FOR 
CONCENTRATION, TEMPERATURE, AND ANALYTE DEPENDENCE IN 
BLOOD 
One-way ANOVA statistical analysis for stability factors in blood. Bold p-values indicate 






Df-Between Df-Within F F crit P-value 
Methcathinone      
H 1 58 0.004 4.01 0.95 
RT 1 57 0.001 4.01 0.97 
R 1 40 1.31 4.08 0.26 
F 1 29 1.97 4.18 0.17 
3-FMC         
H 1 58 0.01 4.01 0.94 
RT 1 58 0.02 4.01 0.89 
R 1 40 0.04 4.08 0.84 
F 1 35 1.20 4.12 0.28 
4-FMC         
H 1 58 0.0001 4.01 0.99 
RT 1 57 0.01 4.01 0.90 
R 1 40 0.39 4.08 0.53 
F 1 26 0.15 4.23 0.70 
Methylone         
H 1 57 0.10 4.01 0.76 
RT 1 50 0.28 4.03 0.60 
R 1 37 0.07 4.11 0.80 
F Stable, no comparison made 
Ethcathinone      
H 1 56 0.003 4.01 0.96 
RT 1 55 0.01 4.02 0.91 
R 1 36 2.54 4.11 0.12 
F 1 33 4.00 4.14 0.05 
Ethylone         
H 1 53 0.00002 4.02 1.00 
    (continued) 
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Df-Between Df-Within F F crit P-value 
RT 1 47 0.32 4.05 0.58 
R Stable, no comparison made 
F Stable, no comparison made 
Methedrone      
H 1 55 0.01 4.02 0.92 
RT 1 53 0.01 4.02 0.91 
R 1 37 1.04 4.11 0.31 
F Stable, no comparison made 
Buphedrone       
H 1 56 0.02 4.01 0.88 
RT 1 56 0.001 4.01 0.97 
R 1 39 1.55 4.09 0.22 
F 1 29 2.48 4.18 0.13 
Butylone          
H 1 54 0.17 4.02 0.69 
RT 1 50 0.21 4.03 0.65 
R Stable, no comparison made 
F Stable, no comparison made 
Mephedrone      
H 1 56 0.02 4.01 0.89 
RT 1 55 0.0001 4.02 0.99 
R 1 41 0.41 4.08 0.53 
F 1 36 3.64 4.11 0.06 
Eutylone         
H 1 51 0.02 4.03 0.89 
RT 1 42 0.26 4.07 0.61 
R Stable, no comparison made 
F Stable, no comparison made 
4-MEC      
H 1 56 0.03 4.01 0.86 
RT 1 56 0.00002 4.01 1.00 
R 1 39 0.13 4.09 0.72 
F Stable, no comparison made 
MDPBP      
H 1 50 0.04 4.03 0.84 
RT 1 41 3.27 4.08 0.08 
R Stable, no comparison made 
F Stable, no comparison made 
 (continued) 
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Df-Between Df-Within F F crit P-value 
Pentedrone      
H 1 56 0.01 4.01 0.91 
RT 1 57 0.01 4.01 0.94 
R 1 40 2.89 4.08 0.10 
F Stable, no comparison made 
Pentylone      
H 1 55 0.003 4.02 0.96 
RT 1 49 0.003 4.04 0.95 
R Stable, no comparison made 
F Stable, no comparison made 
3,4-DMMC      
H 1 56 0.03 4.01 0.87 
RT 1 55 0.004 4.02 0.95 
R 1 41 0.02 4.08 0.88 
F Stable, no comparison made 
α-PVP      
H 1 53 0.001 4.02 0.98 
RT 1 48 0.05 4.04 0.83 
R Stable, no comparison made  
F Stable, no comparison made 
4-EMC      
H 1 56 0.003 4.01 0.96 
RT 1 57 0.003 4.01 0.96 
R 1 42 0.40 4.07 0.53 
F Stable, no comparison made 
MPBP      
H 1 47 0.002 4.047 0.965 
RT 1 49 0.002 4.038 0.969 
R Stable, no comparison made 
F Stable, no comparison made 
MDPV      
H 1 52 0.01 4.03 0.91 
RT 1 42 0.40 4.07 0.53 
R Stable, no comparison made 
F Stable, no comparison made 
Pyrovalerone      
H 1 54 0.39 4.02 0.53 
RT 1 49 0.53 4.04 0.47 
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Df-Between Df-Within F F crit P-value 
R Stable, no comparison made 
F Stable, no comparison made 
Naphyrone      
H 1 56 0.10 4.01 0.75 
RT 1 50 0.01 4.03 0.91 
R 1 41 0.29 4.08 0.59 
F Stable, no comparison made 
Df: degrees of freedom 
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Temperature Dependence 
Temperature Dependence (1,000 ng/mL) 
Synthetic 
Cathinone 
Df-Between Df-Within F F crit P-value 
Methcathinone 3 94 23.11 2.70 < .0001 
3-FMC 3 96 14.68 2.70 < .0001 
4-FMC 3 91 16.15 2.70 < .0001 
Methylone 3 93 30.51 2.70 < .0001 
Ethcathinone 3 94 26.45 2.70 < .0001 
Ethylone 3 90 24.56 2.71 < .0001 
Methedrone 3 94 32.13 2.70 < .0001 
Buphedrone  3 97 28.24 2.70 < .0001 
Butylone  3 89 24.84 2.71 < .0001 
Mephedrone 3 98 29.14 2.70 < .0001 
Eutylone 3 85 24.50 2.71 < .0001 
4-MEC 3 99 32.79 2.70 < .0001 
MDPBP 3 84 14.86 2.71 < .0001 
Pentedrone 3 98 29.34 2.70 < .0001 
Pentylone 3 97 31.93 2.70 < .0001 
3,4-DMMC 3 96 26.77 2.70 < .0001 
α-PVP 3 91 23.11 2.70 < .0001 
4-EMC 3 100 29.27 2.70 < .0001 
MPBP 3 89 27.69 2.71 < .0001 
MDPV 3 86 20.02 2.71 < .0001 
Pyrovalerone 3 89 25.80 2.71 < .0001 
Naphyrone 3 94 26.06 2.70 < .0001 
Df: degrees of freedom 
  
    393 
   
Analyte Dependence  
Within cathinone sub-population  
Within Group Significance 
Sub Group Df-Between Df-Within F F crit P-value 
Secondary amine, unsubstituted Cathinones 
H  3 116 0.03 2.68 0.99 
RT 3 114 0.17 2.68 0.91 
R 3 84 0.90 2.71 0.45 
F 3 64 1.18 2.75 0.32 
Secondary amine, substituted Cathinones 
H  6 202 0.11 2.14 0.99 
RT 6 200 0.55 2.14 0.77 
R 6 144 4.56 2.16 < .001 
F 6 116 2.65 2.18 < .05 
Secondary amine, substituted (excl. 3-FMC) cathinones 
H  Difference not significant w/ 3-FMC included 
RT Difference not significant w/ 3-FMC included 
R 5 124 1.02 2.29 0.41 
F 5 99 1.60 2.31 0.17 
Secondary amine, MD cathinones 
H  4 140 0.37 2.44 0.83 
RT 4 121 0.44 2.45 0.78 
R 4 105 3.63 2.46 < .01 
F 4 104 7.05 2.49 < .0001 
Tertiary amine, MD cathinones 
H  1 50 0.54 4.03 0.47 
RT 1 44 0.14 4.06 0.71 
R 1 41 0.40 4.08 0.53 
F 1 31 0.001 4.16 0.97 
Tertiary amine  (excl. MD/3°) cathinones 
H  3 111 0.12 2.69 0.95 
RT 3 100 0.36 2.70 0.78 
R 3 84 2.79 2.71 < 0.05 
F 3 61 3.69 2.76 < 0.05 
Secondary amine, substituted cathinones 
H  15 458 0.55 1.69 0.91 
RT 15 435 1.17 1.69 0.30 
R 15 333 5.99 1.70 < .0001 
F 15 260 2.42 1.70 < .01 
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Within Group Significance 
Sub Group Df-Between Df-Within F F crit P-value 
Secondary amine, substituted (excl. 3-FMC) cathinones 
H  Difference not significant w/ 3-FMC included 
RT Difference not significant w/ 3-FMC included 
R 14 313 3.04 1.72 < .001 
F 14 243 1.71 1.73 0.05 
Tertiary amine cathinones 
H  5 161 2.03 2.27 0.08 
RT 5 144 4.00 2.28 < .01 
R 5 125 8.01 2.29 < .0001 
F 5 92 7.67 2.31 < .0001 
Df: degrees of freedom 
Between cathinone sub-population 
Between Group Significance 
Comparison Df-Between Df-Within F F crit P-value 
Secondary amine, unsubstituted – secondary amine, substituted cathinones 
H  10 318 0.08 1.86 1.00 
RT 10 314 0.38 1.86 0.95 
R* 9 208 1.04 1.93 0.41 
F* 9 172 1.29 1.94 0.24 
Secondary amine, unsubstituted – secondary amine, MD cathinones 
H  8 256 0.65 1.97 0.73 
RT 8 235 1.23 1.98 0.28 
R Significant difference within MD/2°  
F Significant difference within MD/2°  
Secondary amine, unsubstituted – tertiary amine, MD cathinones  
H  5 166 4.04 2.27 < .01 
RT 5 158 7.73 2.27 < .0001 
R 5 125 4.68 2.29 < .001 
F 5 95 0.93 2.31 0.47 
Secondary amine, unsubstituted – tertiary amine,  (excl. MD) cathinones  
H  7 227 0.49 2.05 0.84 
RT 7 214 1.17 2.05 0.32 
R Significant difference within 3° (excl. MD)  
F Significant difference within 3° (excl. MD)  
Secondary amine, substituted – secondary amine, MD cathinones  
H  11 342 0.67 1.82 0.77 
RT 11 321 1.42 1.82 0.16 
R Significant difference within MD/2°  
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Between Group Significance 
Comparison Df-Between Df-Within F F crit P-value 
F Significant difference within MD/2°    
Secondary amine, substituted – tertiary amine, MD cathinones 
H  8 252 3.12 1.98 < .01 
RT 8 244 5.71 1.98 < .0001 
R* 7 165 3.88 2.07 < .001 
F* 7 130 1.40 2.08 0.21 
Secondary amine, substituted – tertiary amine, (excl. MD) cathinones 
H  10 313 0.51 1.86 0.88 
RT 10 300 1.33 1.86 0.21 
R Significant difference within 3° (excl. MD)  
F Significant difference within 3° (excl. MD)  
Secondary amine, MD – tertiary amine, MD cathinones 
H  6 190 1.76 2.15 0.11 
RT 6 165 2.94 2.15 0.01 
R Significant difference within MD/2°   
F Significant difference within MD/2°   
Secondary amine, MD – tertiary amine (excl. MD) cathinones  
H  8 251 0.24 1.98 0.98 
RT 8 221 0.36 1.98 0.94 
R Significant difference within MD/2° & within 3° (excl. MD)  
F Significant difference within MD/2° & within 3° (excl. MD)     
*Substituted (excluding 3-FMC) was used for statistical analysis; Df: degrees of freedom 
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APPENDIX F: ONE-WAY ANOVA STATISTICAL ANALYSIS FOR 
CONCENTRATION, TEMPERATURE, PH, AND ANALYTE DEPENDENCE IN 
URINE 
One-way ANOVA statistical analysis for stability factors in urine. Bold p-values indicate 






Df-Between Df-Within F F crit P-value 
Methcathinone      
H 1 53 0.04 4.02 0.84 
RT 1 52 0.003 4.03 0.95 
R Stable, no comparison made 
F Stable, no comparison made 
3-FMC      
H 1 45 0.01 4.06 0.91 
RT 1 42 0.08 4.07 0.77 
R Stable, no comparison made 
F Stable, no comparison made 
4-FMC      
H 1 54 0.0002 4.02 0.99 
RT 1 50 0.07 4.03 0.79 
R Stable, no comparison made 
F Stable, no comparison made 
Methylone      
H 1 49 0.28 4.04 0.60 
RT Stable, no comparison made 
R Stable, no comparison made 
F Stable, no comparison made 
Ethcathinone      
H 1 45 0.23 4.06 0.63 
RT 1 43 0.07 4.07 0.79 
R Stable, no comparison made 
F Stable, no comparison made 
Ethylone      
H 1 45 0.01 4.06 0.92 
RT Stable, no comparison made 
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Df-Between Df-Within F F crit P-value 
R Stable, no comparison made 
F Stable, no comparison made 
Methedrone      
H 1 47 0.02 4.05 0.88 
RT Stable, no comparison made 
R Stable, no comparison made 
F Stable, no comparison made 
Buphedrone       
H 1 50 0.19 4.03 0.67 
RT 1 53 0.16 4.02 0.69 
R Stable, no comparison made 
F Stable, no comparison made 
Butylone       
H 1 46 0.45 4.05 0.50 
RT Stable, no comparison made 
R Stable, no comparison made 
F Stable, no comparison made 
Mephedrone      
H 1 53 0.07 4.02 0.79 
RT 1 49 1.00 4.04 0.32 
R Stable, no comparison made 
F Stable, no comparison made 
Eutylone      
H 1 47 0.74 4.05 0.40 
RT Stable, no comparison made 
R Stable, no comparison made 
F Stable, no comparison made 
4-MEC      
H 1 50 0.02 4.03 0.88 
RT 1 48 0.10 4.04 0.75 
R Stable, no comparison made 
F Stable, no comparison made 
MDPBP      
H 1 40 0.21 4.08 0.65 
RT Stable, no comparison made 
R Stable, no comparison made 
F Stable, no comparison made 
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Df-Between Df-Within F F crit P-value 
Pentedrone      
H 1 48 0.01 4.04 0.90 
RT 1 53 0.66 4.02 0.42 
R Stable, no comparison made 
F Stable, no comparison made 
Pentylone      
H 1 68 0.17 3.98 0.68 
RT 1 68 1.23 3.98 0.27 
R Stable, no comparison made 
F Stable, no comparison made 
3,4-DMMC      
H 1 46 0.08 4.05 0.78 
RT 1 49 1.46 4.04 0.23 
R Stable, no comparison made 
F Stable, no comparison made 
α-PVP      
H Stable, no comparison made 
RT Stable, no comparison made 
R Stable, no comparison made 
F Stable, no comparison made 
4-EMC      
H 1 47 0.01 4.05 0.94 
RT 1 51 0.34 4.03 0.56 
R Stable, no comparison made 
F Stable, no comparison made 
MPBP      
H Stable, no comparison made 
RT Stable, no comparison made 
R Stable, no comparison made 
F Stable, no comparison made 
MDPV      
H Stable, no comparison made 
RT Stable, no comparison made 
R Stable, no comparison made 
F Stable, no comparison made 
Pyrovalerone      
H 1 44 0.25 4.06 0.62 
RT 1 50 0.36 4.03 0.55 
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Df-Between Df-Within F F crit P-value 
R Stable, no comparison made 
F Stable, no comparison made 
Naphyrone      
H 1 45 0.30 4.06 0.59 
RT Stable, no comparison made 
R Stable, no comparison made 
F Stable, no comparison made 





Df-Between Df-Within F F crit P-value 
Methcathinone      
H 1 65 5.07E-05 3.99 0.99 
RT 1 66 0.01 3.99 0.93 
R 1 63 0.26 3.99 0.61 
F 1 52 0.20 4.03 0.66 
3-FMC      
H 1 56 0.0 4.0 1.0 
RT 1 57 0.0 4.0 1.0 
R 1 48 0.6 4.0 0.4 
F 1 48 0.3 4.0 0.6 
4-FMC      
H 1 64 4.0E-05 3.99 0.99 
RT 1 64 0.00 3.99 0.99 
R 1 57 0.02 4.01 0.90 
F 1 52 0.07 4.03 0.80 
Methylone      
H 1 65 0.01 3.99 0.91 
RT 1 64 0.04 3.99 0.85 
R 1 60 0.19 4.00 0.67 
F 1 52 0.21 4.03 0.65 
Ethcathinone      
H 1 61 0.0003 4.00 0.99 
RT 1 63 0.03 3.99 0.86 
R 1 55 1.08 4.02 0.30 
F 1 46 0.04 4.05 0.84 
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Df-Between Df-Within F F crit P-value 
Ethylone      
H 1 65 0.001 3.99 0.98 
RT 1 66 0.002 3.99 0.97 
R 1 58 0.07 4.01 0.80 
F 1 51 0.31 4.03 0.58 
Methedrone      
H 1 63 0.01 3.99 0.94 
RT 1 64 0.01 3.99 0.91 
R 1 56 0.26 4.01 0.61 
F 1 46 0.00 4.05 0.96 
Buphedrone       
H 1 65 0.004 3.99 0.95 
RT 1 64 0.02 3.99 0.89 
R 1 55 21.17 4.02 < .0001 
F 1 55 14.73 4.02 < .001 
Butylone       
H 1 65 0.002 3.99 0.96 
RT 1 64 0.001 3.99 0.98 
R 1 55 0.001 4.02 0.97 
F 1 42 0.75 4.07 0.39 
Mephedrone      
H 1 65 0.002 3.99 0.96 
RT 1 66 0.003 3.99 0.96 
R 1 61 0.38 4.00 0.54 
F 1 52 0.01 4.03 0.91 
Eutylone      
H 1 66 0.02 3.99 0.88 
RT 1 63 0.31 3.99 0.58 
R 1 54 0.52 4.02 0.47 
F Stable, no comparison made 
4-MEC      
H 1 65 0.002 3.99 0.96 
RT 1 66 0.01 3.99 0.91 
R 1 60 0.001 4.00 0.98 
F 1 48 0.42 4.04 0.52 
MDPBP      
H 1 44 1.14 4.06 0.29 
RT 1 42 10.17 4.07 < .01 
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Df-Between Df-Within F F crit P-value 
R 1 40 0.83 4.08 0.37 
F Stable, no comparison made 
Pentedrone      
H 1 65 0.0003 3.99 0.99 
RT 1 66 0.003 3.99 0.95 
R 1 61 0.02 4.00 0.89 
F 1 50 0.002 4.03 0.97 
Pentylone      
H 1 65 0.01 3.99 0.90 
RT 1 64 0.01 3.99 0.94 
R 1 56 0.15 4.01 0.70 
F 1 47 1.55 4.05 0.22 
3,4-DMMC      
H 1 63 9E-05 3.99 0.99 
RT 1 64 0.05 3.99 0.83 
R 1 51 0.01 4.03 0.91 
F 1 48 0.44 4.04 0.51 
α-PVP      
H 1 60 0.02 4.00 0.89 
RT 1 58 0.003 4.01 0.96 
R 1 48 3.41 4.04 0.07 
F Stable, no comparison made 
4-EMC      
H 1 63 0.001 3.99 0.98 
RT 1 64 0.002 3.99 0.96 
R 1 59 0.23 4.00 0.63 
F 1 49 0.07 4.04 0.79 
MPBP      
H 1 50 1.32 4.03 0.26 
RT 1 50 6.37 4.03 0.01 
R 1 47 0.39 4.05 0.54 
F 1 41 1.65 4.08 0.21 
MDPV      
H 1 55 0.004 4.02 0.95 
RT 1 49 0.003 4.04 0.95 
R Stable, no comparison made 
F Stable, no comparison made 
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Df-Between Df-Within F F crit P-value 
Pyrovalerone      
H 1 61 0.24 4.00 0.63 
RT 1 54 0.23 4.02 0.64 
R 1 53 2.04 4.02 0.16 
F Stable, no comparison made 
Naphyrone      
H 1 66 0.05 3.99 0.82 
RT 1 63 0.002 3.99 0.96 
R 1 58 0.004 4.01 0.95 
F 1 48 3.17 4.04 0.08 




pH 4; 1,000 ng/mL 
Synthetic 
Cathinone 
Df-Between Df-Within F F crit P-value 
Methcathinone 3 103 23.72 2.69 < .0001 
3-FMC 3 86 31.75 2.71 < .0001 
4-FMC 3 97 20.48 2.70 < .0001 
Methylone 3 103 9.89 2.69 < .0001 
Ethcathinone 3 90 14.00 2.71 < .0001 
Ethylone 3 101 15.31 2.69 < .0001 
Methedrone 3 97 15.65 2.70 < .0001 
Buphedrone  3 103 12.05 2.69 < .0001 
Butylone  3 100 5.27 2.70 < .01 
Mephedrone 3 103 13.30 2.69 < .0001 
Eutylone 3 96 4.28 2.70 < .01  
4-MEC 3 88 10.27 2.71 < .0001 
MDPBP 3 80 1.33 2.72 0.27 
Pentedrone 3 100 20.27 2.70 < .0001 
Pentylone 3 99 10.60 2.70 < .0001 
3,4-DMMC 3 93 20.69 2.70 < .0001 
α-PVP 3 90 5.12 2.71 < .01 
4-EMC 3 95 15.77 2.70 < .0001 
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pH 4; 1,000 ng/mL 
Synthetic 
Cathinone 
Df-Between Df-Within F F crit P-value 
MPBP 3 90 2.45 2.71 0.07 
MDPV 3 103 46.49 2.69 < .0001 
Pyrovalerone 3 98 3.06 2.70 < .05 
Naphyrone 3 102 5.18 2.69 < .01 
Df: degrees of freedom 
 
pH 8; 1,000 ng/mL 
Synthetic 
Cathinone 
Df-Between Df-Within F F crit P-value 
Methcathinone 3 125 25.55 2.68 < .0001 
3-FMC 3 101 9.83 2.69 < .0001 
4-FMC 3 121 25.02 2.68 < .0001 
Methylone 3 123 59.82 2.68 < .0001 
Ethcathinone 3 112 35.49 2.69 < .0001 
Ethylone 3 121 68.77 2.68 < .0001 
Methedrone 3 113 46.48 2.68 < .0001 
Buphedrone  3 119 37.65 2.68 < .0001 
Butylone  3 113 57.13 2.68 < .0001 
Mephedrone 3 124 39.00 2.68 < .0001 
Eutylone 3 120 69.45 2.68 < .0001 
4-MEC 3 119 35.83 2.68 < .0001 
MDPBP 3 78 38.87 2.72 < .0001 
Pentedrone 3 121 31.29 2.68 < .0001 
Pentylone 3 119 56.15 2.68 < .0001 
3,4-DMMC 3 117 42.79 2.68 < .0001 
α-PVP 3 103 28.39 2.69 < .0001 
4-EMC 3 119 29.09 2.68 < .0001 
MPBP 3 92 37.38 2.70 < .0001 
MDPV 3 98 18.76 2.70 < .0001 
Pyrovalerone 3 106 47.37 2.69 < .0001 
Naphyrone 3 116 48.17 2.68 < .0001 
Df: degrees of freedom 
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Df-Between Df-Within F F crit P-value 
Methcathinone      
H 1 60 34.31 4.00 < .0001 
RT 1 59 177.28 4.00 < .0001 
R 1 59 151.82 4.00 < .0001 
F 1 50 50.94 4.03 < .0001 
3-FMC        
H 1 51 11.26 4.03 < .001 
RT 1 49 36.01 4.04 < .0001 
R 1 43 164.39 4.07 < .0001 
F 1 44 86.33 4.06 < .0001 
4-FMC        
H 1 59 30.40 4.00 < .0001 
RT 1 56 144.46 4.01 < .0001 
R 1 54 173.56 4.02 < .0001 
F 1 49 53.92 4.04 < .0001 
Methylone        
H 1 60 57.23 4.00 < .0001 
RT 1 59 319.88 4.00 < .0001 
R 1 57 75.64 4.01 < .0001 
F 1 50 42.24 4.03 < .0001 
Ethcathinone        
H 1 55 36.12 4.02 < .0001 
RT 1 53 186.40 4.02 < .0001 
R 1 51 153.66 4.03 < .0001 
F 1 43 32.94 4.07 < .0001 
Ethylone        
H 1 57 49.81 4.01 < .0001 
RT 1 58 286.28 4.01 < .0001 
R 1 57 70.88 4.01 < .0001 
F 1 50 38.03 4.03 < .0001 
Methedrone        
H 1 55 44.80 4.02 < .0001 
RT 1 57 277.38 4.01 < .0001 
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Df-Between Df-Within F F crit P-value 
R 1 52 78.75 4.03 < .0001 
F 1 46 29.17 4.05 < .0001 
Buphedrone         
H 1 60 53.70 4.00 < .0001 
RT 1 59 296.93 4.00 < .0001 
R 1 55 111.85 4.02 < .0001 
F 1 48 42.74 4.04 < .0001 
Butylone         
H 1 58 69.11 4.01 < .0001 
RT 1 58 182.92 4.01 < .0001 
R 1 52 48.20 4.03 < .0001 
F 1 45 13.83 4.06 < .001 
Mephedrone        
H 1 61 50.08 4.00 < .0001 
RT 1 58 263.83 4.01 < .0001 
R 1 58 128.86 4.01 < .0001 
F 1 50 48.25 4.03 < .0001 
Eutylone        
H 1 58 72.74 4.01 < .0001 
RT 1 58 120.83 4.01 < .0001 
R 1 55 47.92 4.02 < .0001 
F 1 45 9.36 4.06 < .01 
4-MEC        
H 1 58 41.93 4.01 < .0001 
RT 1 56 185.98 4.01 < .0001 
R 1 52 83.24 4.03 < .0001 
F 1 41 24.96 4.08 < .0001 
MDPBP        
H 1 39 74.09 4.09 < .0001 
RT 1 40 96.67 4.08 < .0001 
R 1 41 23.57 4.08 < .0001 
F 1 38 5.37 4.10 < 0.05 
Pentedrone        
H 1 57 40.05 4.01 < .0001 
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Df-Between Df-Within F F crit P-value 
RT 1 60 288.98 4.00 < .0001 
R 1 58 129.85 4.01 < .0001 
F 1 46 40.90 4.05 < .0001 
Pentylone        
H 1 54 49.55 4.02 < .0001 
RT 1 59 194.47 4.00 < .0001 
R 1 58 63.63 4.01 < .0001 
F 1 47 16.94 4.05 < .0001 
3,4-DMMC        
H 1 54 38.10 4.02 < .0001 
RT 1 56 227.89 4.01 < .0001 
R 1 52 115.15 4.03 < .0001 
F 1 48 49.35 4.04 < .0001 
α-PVP        
H 1 48 77.74 4.04 < .0001 
RT 1 56 76.14 4.01 < .0001 
R 1 50 58.10 4.03 < .0001 
F 1 39 5.74 4.09 < .05 
4-EMC        
H 1 55 35.15 4.02 < .0001 
RT 1 58 232.32 4.01 < .0001 
R 1 56 95.82 4.01 < .0001 
F 1 45 43.92 4.06 < .0001 
MPBP        
H 1 46 84.50 4.05 < .0001 
RT 1 50 82.03 4.03 < .0001 
R 1 46 28.81 4.05 < .0001 
F 1 40 2.20 4.08 0.14 
MDPV        
H 1 47 61.11 4.05 < .0001 
RT 1 54 26.05 4.02 < .0001 
R 1 53 26.63 4.02 < .0001 
F 1 47 1.85 4.05 0.18 
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Df-Between Df-Within F F crit P-value 
Pyrovalerone        
H 1 53 100.08 4.02 < .0001 
RT 1 50 77.72 4.03 < .0001 
R 1 54 57.82 4.02 < .0001 
F 1 47 5.02 4.05 < 0.05 
Naphyrone        
H 1 56 73.52 4.01 < .0001 
RT 1 57 140.36 4.01 < .0001 
R 1 59 65.49 4.00 < .0001 
F 1 46 15.89 4.05 < .0001 
Analyte Dependence 
Within sub-population 
Within Group Significance (pH 4) 
Sub Group Df-Between Df-Within F F crit P-value 
Secondary amine, unsubstituted cathinones 
H  3 76 1.25 2.72 0.30 
RT 3 77 1.31 2.72 0.28 
R 3 80 2.25 2.72 0.09 
F 3 69 0.19 2.74 0.90 
Secondary amine, substituted cathinones 
H  6 130 3.24 2.17 < .01 
RT 6 127 12.11 2.17 < .0001 
R 6 131 3.31 2.17 < .01 
F 6 119 5.78 2.18 < .0001 
Secondary amine, substituted (excl. 3-FMC) cathinones 
H  5 112 0.85 2.30 0.52 
RT 5 111 3.94 2.30 < .01 
R 5 113 3.53 2.29 < .01 
F 5 104 7.41 2.30 < .0001 
Secondary amine, MD cathinones 
H  4 91 2.07 2.47 0.09 
RT 4 102 0.15 2.46 0.96 
R 4 108 1.41 2.46 0.24 
F 4 84 2.73 2.48 < 0.05 
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Within Group Significance (pH 4) 
Sub Group Df-Between Df-Within F F crit P-value 
Tertiary amine, MD cathinones  
H  1 33 0.39 4.14 0.53 
RT 1 41 13.66 4.08 < .001 
R 1 40 12.68 4.08 < .001 
F 1 32 26.22 4.15 < .0001 
Tertiary amine (excl. tertiary amine, MD) cathinones 
H  3 64 4.64 2.75 < .01 
RT 3 85 1.60 2.71 0.19 
R 3 87 3.02 2.71 < .05 
F 3 66 1.03 2.74 0.38 
Secondary amine cathinones 
H  15 297 4.85 1.70 < .0001 
RT 15 306 11.22 1.70 < .0001 
R 15 319 3.39 1.70 < .0001 
F 15 272 4.29 1.70 < .0001 
Secondary amine (excl. 3-FMC) cathinones 
H  14 279 3.19 1.73 < .0001 
RT 14 290 5.86 1.73 < .0001 
R 14 301 3.78 1.72 < .0001 
F 14 257 4.66 1.73 < .0001 
Tertiary amine cathinones 
H  5 97 2.68 2.31 < .05 
RT 5 126 3.23 2.29 < .01 
R 5 127 4.74 2.29 < .001 
F 5 98 8.71 2.31 < .0001 
Df: degrees of freedom 
 
Within Group Significance (pH 8) 
Sub Group Df-Between Df-Within F F crit P-value 
Secondary amine, unsubstituted cathinones 
H  3 106 0.02 2.69 1.00 
RT 3 106 0.13 2.69 0.94 
R 3 97 0.58 2.70 0.63 
F 3 73 1.33 2.73 0.27 
Secondary amine, substituted cathinones 
H  6 182 0.04 2.15 1.00 
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Within Group Significance (pH 8) 
Sub Group Df-Between Df-Within F F crit P-value 
RT 6 182 0.41 2.15 0.87 
R 6 160 2.13 2.16 0.05 
F 6 130 7.38 2.17 < .0001 
Secondary amine, substituted (excl. 3-FMC) cathinones 
H  Difference not significant w/ 3-FMC included 
RT Difference not significant w/ 3-FMC included 
R 5 144 1.85 2.28 0.11 
F 5 111 3.17 2.30 < .01 
Secondary amine, MD cathinones 
H  4 135 0.71 2.44 0.58 
RT 4 134 2.02 2.44 0.10 
R 4 113 4.38 2.45 < .01 
F 4 96 3.70 2.47 < .01 
Tertiary amine, MD cathinones  
H  1 36 2.73 4.11 0.11 
RT 1 34 14.78 4.13 < .001 
R 1 34 0.01 4.13 0.91 
F 1 33 7.16 4.14 < .01 
Tertiary amine, (excl. tertiary amine, MD) cathinones 
H  3 98 3.04 2.70 < .05 
RT 3 88 4.35 2.71 < .01 
R 3 82 6.64 2.72 < .001 
F 3 67 4.05 2.74 < .01 
Secondary amine cathinones 
H  15 423 0.58 1.69 0.89 
RT 15 422 2.38 1.69 < .01 
R 15 370 7.74 1.69 < .0001 
F 15 314 9.54 1.70 < .0001 
Secondary amine (excl. 3-FMC) cathinones 
H  Difference not significant w/ 3-FMC included 
RT 14 399 2.33 1.72 < .01 
R 14 354 7.71 1.72 < .0001 
F 14 280 6.59 1.73 < .0001 
Tertiary amine cathinones  
H  5 134 7.50 2.28 < .0001 
RT 5 122 8.28 2.29 < .0001 
R 5 116 8.22 2.29 < .0001 
F 5 100 5.71 2.31 < .0001 
Df: degrees of freedom 
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Between Sub-population 
Between Group Significance (pH 4) 
Comparison Df-Between Df-Within F F crit P-value 
Secondary amine, unsubstituted  – secondary amine, substituted  
H * 9 188 0.90 1.93 0.53 
RT Significant difference within Sub even when 3-FMC excluded 
R Significant difference within Sub even when 3-FMC excluded 
F Significant difference within Sub even when 3-FMC excluded 
Secondary amine, unsubstituted - secondary amine, MD 
H  8 167 4.77 1.99 < .0001 
RT 8 179 8.58 1.99 < .0001 
R 8 188 2.43 1.99 < .05 
F Significant difference within MD/2° 
Secondary amine, unsubstituted - tertiary amine, MD 
H  5 109 9.34 2.30 < .0001 
RT Significant difference within MD/3°    
R Significant difference within MD/3°     
F Significant difference within MD/3°   
Secondary amine, unsubstituted - tertiary amine (excl. MD) cathinones 
H  Significant difference within 3°   
RT 7 162 11.41 2.07 < .0001 
R Significant difference within 3°   
F 7 135 0.47 2.08 0.85 
Secondary amine, substituted - secondary amine, MD cathinones  
H * 10 203 3.55 1.88 < .0001 
RT Significant difference within Sub even when 3-FMC excluded  
R Significant difference within Sub even when 3-FMC excluded   
F Significant difference within Sub even when 3-FMC excluded & 
within MD/2° 
Secondary amine, substituted - tertiary amine, MD cathinones 
H * 7 145 5.87 2.07 < .0001 
RT Significant difference within Sub even when 3-FMC excluded  & 
within MD/3°    
R Significant difference within Sub even when 3-FMC excluded  & 
within MD/3°    
F Significant difference within Sub even when 3-FMC excluded  & 
within MD/3°    
 (continued) 
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Between Group Significance (pH 4) 
Comparison Df-Between Df-Within F F crit P-value 
Secondary amine, substituted - tertiary amine, (excl. MD) cathinones 
H  Significant difference within 3° (excl. MD)    
RT Significant difference within Sub even when 3-FMC excluded    
R Significant difference within Sub even when 3-FMC excluded & 
within 3° (excl. MD)    
F Significant difference within Sub even when 3-FMC excluded   
Secondary amine, MD – tertiary amine, MD cathinones 
H  6 124 4.37 2.17 < .001 
RT Significant difference within MD/3°      
R Significant difference within MD/3°     
F Significant difference within MD/3° & within MD/2°      
Secondary amine, MD – tertiary amine (excl. MD) cathinones 
H  Significant difference within 3° (excl. MD)     
RT 8 187 1.66 1.99 0.11 
R Significant difference within 3° (excl. MD)      
F Significant difference within MD/2°  
*Substituted (excluding 3-FMC) was used for comparison; Df: degrees of freedom 
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APPENDIX G: QUANTITATION RESULTS FOR REDWOOD TOXICOLOGY 












R054 9523 4.5 7189 75% 15 
R046 11943 5 10826 91% 17 
R063 12314 5 10765 87% 17 
R079 16316 5 11921 73% 17 
R121 7435 5 446 6% 15 
R123 67 5 70 104% 15 
R135 7465 5 7580 102% 14 
R003 729 5.5 688 94% 40 
R065 500 5.5 593 119% 15 
R086 1427 5.5 1671 117% 15 
R012 1429 5.57 1301 91% 13 
2R004 100 6 110 110% 8 
R039 5480 6 5057 92% 15 
R055 18094 6 19926 110% 17 
R070 5396 6 4838 90% 15 
R111 2887 6 3261 113% 15 
R119 4328 6 4711 109% 15 
R139 540 6 72 13% 14 
2R015 68 6.5 0 0% 5 
2R020 101 6.5 103 102% 6 
2R021 87 6.5 100 115% 5 
R011 2114 6.5 2014 95% 13 
R058 7396 6.5 6734 91% 15 
R004 2347 7 2201 94% 14 
R029 7277 7 4766 65% 15 
R031 1094 7 1058 97% 15 
R033 270 7 257 95% 15 
R036 330 7 318 96% 15 
R041 93 7 99 106% 15 
R052 2948 7 2782 94% 15 
     (continued) 
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R081 11187 7 0 0% 17 
R084 2501 7 1562 62% 15 
R088 14112 7 7644 54% 17 
R094 129 7 135 105% 15 
R110 7774 7 5473 70% 15 
R113 ReExt 13292 7 7838 59% 16 
R137 3524 7 3805 108% 14 
R147 95 7 103 108% 14 
R014 4599 7.5 2866 62% 13 
R017 797 7.5 31 4% 13 
R032 2407 7.5 145 6% 15 
R059 10627 7.5 450 4% 17 
R069 13703 7.5 2206 16% 17 
R030 147 8 0 0% 15 
R051 352 8 0 0% 15 
R053 329 8 10 3% 15 
R064 7679 8 8221 107% 15 
R083 375 8 7 2% 15 
R091 26 8 0 0% 15 
R097 324 8 287 89% 15 
R115 25 8 9 35% 15 
R116 11095 8 144 1% 16 
R117 7255 8 6368 88% 15 
R120 471 8 2 0% 15 
R146 12311 8 755 6% 16 
R150 1013 8 5 0% 14 
R151 40 8 10 26% 14 
R157 23792 8 14802 62% 16 
R009 200 8.5 7 3% 13 
R034 77 8.5 0 0% 15 
R035 36 8.5 1 3% 15 
R037 1105 8.5 74 7% 15 
R038 375 8.5 18 5% 15 
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R049 1686 8.5 45 3% 15 
R050 520 8.5 5 1% 15 
R056 1770 8.5 80 5% 15 
R061 131 8.5 6 5% 15 
R062 37 8.5 5 13% 15 
R068 114 8.5 5 4% 15 
R107 703 8.5 22 3% 15 
R010 31 9 2 5% 13 
R018 2126 9 37 2% 13 
R066 1042 9 61 6% 15 
R078 4091 9 24 1% 15 
R096 85 9 2 3% 15 
R099 247 9 0 0% 15 
R101 1477 9 0 0% 15 
R102 2466 9 49 2% 15 
R109 285 9 16 6% 15 
R114 1628 9 16 1% 15 
R129 46 9 1 2% 14 
R133 6864 9 246 4% 14 
R136 392 9 58 15% 14 
R148 12333 9 231 2% 16 
R152 26 9 12 45% 14 
R159 764 9 107 14% 14 
R016 1201 9.29 45 4% 13 
R015 450 9.5 71 16% 13 
R122 27 10 1 4% 15 
R124 1348 10 65 5% 14 
R125 570 10 5 1% 14 
R138 392 10 3 1% 14 
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2R006 36 4.5 22 61% 7 
2R001 379 4.5 255 67% 8 
2R011 1542 5 1162 75% 7 
R156 252 5 171 68% 14 
R027 127 5 69 55% 15 
R104 74050 5 56418 76% 17 
2R018 189 5.5 150 79% 6 
2R002 98 5.5 66 67% 8 
R045 1312 5.5 23 2% 15 
R080 97 5.5 88 91% 15 
R085 1059 5.5 1037 98% 15 
R106 308 5.5 273 89% 15 
R077 38 6 21 56% 15 
R090 195 6 198 102% 15 
R040 131 6 132 101% 15 
R023 206 6 144 70% 15 
R025 110 6 68 61% 15 
R026 75 6 22 30% 15 
R103 ReExt 167973 6 146124 87% 17 
R105 ReExt 9584 6 9368 98% 17 
R089 32661 6 12284 38% 17 
R008 275 6.5 240 87% 13 
2R005 91 7 0 0% 7 
R140 312 7 7 2% 14 
R131 59 7 5 9% 14 
R071 433 7 3 1% 14 
R118 2788 7 153 6% 15 
R095 42 7 31 74% 15 
R092 195 7 94 48% 15 
R043 272 7 0 0% 15 
R022 2257 7 493 22% 15 
R028 6416 7.5 0 0% 15 
R087 22512 7.5 0 0% 17 
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R073 119535 7.5 0 0% 17 
R149 30 8 0 0% 14 
R154 41 8 0 0% 14 
R155 35 8 0 0% 14 
R145 105 8 0 0% 14 
R126 39 8 0 0% 14 
R072 237 8 0 0% 15 
R112 110 8 6 6% 15 
R047 1144 8 0 0% 15 
R024 62 8 0 0% 15 
R013 642 8.5 0 0% 13 
R005 487 8.5 0 0% 13 
R006 121 8.5 0 0% 13 
R075 37080 8.5 0 0% 17 
R141 123 9 0 0% 14 
R144 33 9 0 0% 14 
R100 69 9 0 0% 14 
R098 695 9 0 0% 15 
R076 8423 9 17 0% 15 
R130 102 9.5 0 0% 14 
R108 6311 9.5 0 0% 15 
R153 61 10 0 0% 14 
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2R001 87 4.5 56 64% 7.9 
2R011 175 5 110 63% 6.5 
2R016 1535 5 922 60% 5.9 
2R002 32 5.5 26 81% 7.8 
2R018 246 5.5 191 78% 5.7 
2R004 75 6 9 12% 7.5 
2R020 84 6.5 15 18% 5.6 
2R021 56 6.5 12 21% 5.4 














R049 MDPV 6626 8.5 479 7% 15 
R001 butylone 385 6.5 50 13% 59 
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 Teaching Assistant for Forensic Toxicology Lab. 
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 Obtained Top Secret Clearance. 
 Performed limit of detection studies on the following instruments: 
o Gas Chromatography-Electron Capture Detection (GC-ECD), Gas 
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Instrumentation 
 Proficient using Liquid Chromatography-Quadrupole/Time-of-Flight-Mass 
Spectrometry (LC-Q/TOF-MS), Gas Chromatography-Mass Spectrometry (GC-
MS), Liquid Chromatography-Mass Spectrometry (LC-MS), UV-Vis 
Spectrophotometer 
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